Composition and method for degrading aryl hydrocarbon receptor nuclear translocation protein
Compounds targeting ARNT degradation address the need to modulate AhR and HIF signaling, offering therapeutic benefits in treating cancer and other diseases by inhibiting ARNT activity.
Patent Information
- Application Number
- KR1020267025423
- Authority / Receiving Office
- KR · KR
- Patent Type
- Applications
- Priority Date
- 2024-01-04
- Filing Date
- 2025-01-06
- Publication Date
- 2026-11-10
AI Technical Summary
There is a need for compounds and compositions to mediate AhR and HIF signaling by degrading ARNT, as ARNT plays a central role in these pathways and is associated with various diseases and disorders, including tumors and autoimmune diseases.
Development of compounds with specific structures, such as formula (A) or (I), which can degrade ARNT, thereby modulating its activity and potentially treating or alleviating associated diseases.
The compounds effectively degrade ARNT, providing therapeutic benefits in treating cancer and other ARNT-mediated diseases by inhibiting cell growth and inducing ARNT degradation.
Smart Images

Figure PCT00216_ABST
Abstract
Description
Technology Field
[0001] Cross-reference regarding related applications
[0002] This application claims the benefit of priority to U.S. Provisional Application No. 63 / 617,634 filed January 4, 2024; the entire disclosure of which is incorporated herein by reference.
[0003] Technology field
[0004] The present invention provides a compound for use in a composition and method for degrading an aryl hydrocarbon receptor nuclear translocator protein (ARNT). Additionally, a method for treating, preventing, or alleviating diseases and disorders in which ARNT activity is undesirable is provided. Background Technology
[0005] ARNT(HIF-1β) ARNT It is a protein of approximately 86 kDa encoded by a gene. ARNT contains a basic helix-loop-helix domain and two characteristic Per-Arnt-Sim (PAS) domains along with a PAC domain. The protein binds to ligand-bound aryl hydrocarbon receptors (AhR), assists in the translocation of this complex to the nucleus, and promotes the expression of genes involved in xenobiotic metabolism in the nucleus. ARNT is also a cofactor for transcriptional regulation by hypoxia-inducible factor (HIF), for example, through heterodimers with HIF-1α, HIF-2α, and HIF-3α. The ETV6 (ets variant 6) gene on chromosome 12 and chromosomal translocations of this locus have been described in leukemia. Alternative splicing generates multiple transcript variants. ARNT also forms biologically related heterodimers with AHRR, NPAS1, NPAS3, NPAS4, SIM1, and SIM2. For example, Wu and Rastinejad, Curr. Opin. Struct. Biol. 2017 , 43 Refer to , 1-9.
[0006] AhR is a ligand-activated transcription factor that mediates many of the responses to toxic environmental chemicals such as TCDD or dioxin-like polychlorinated biphenyls (PCBs). To function as a transcription factor, AhR must form a heterodimer with ARNT. After dimerization, the AhR:ARNT heterodimer induces the transcription of genes containing xenobiotic response element (XRE) sequences in the promoter. Furthermore, the AhR pathway has been shown to be selectively active in tumors overexpressing indoleamine 2,3-dioxygenase 1 and tryptophan 2,3-dioxygenase 2 (IDO / TDO) and is associated with resistance to immune checkpoint inhibitors. Selective AhR blockade delays progression in IDO / TDO-overexpressing tumors, and its efficacy is enhanced when combined with PD-1 blockade. For example, Campesato et al. , Nat. Commun. 2020 , 11 Refer to , 4011.
[0007] HIF is a class of proteins that binds to ARNT and initiates hypoxia-induced gene expression. Elevated levels of the two isoforms, HIF-1α and HIF-2α, are commonly found in malignant tumors and are believed to play a role in tumorigenesis and poor patient prognosis. For example, Mandl et al. , Cell Death Dis. 2016 , 7 , refer to e2284. HIF-2α is a tumor-promoting factor in clear cell renal cell carcinoma and breast cancer. For example, Mazumder et al. , Cancers (Basel) 2023 , 15 , 1316; de Heer et al. , J. Clin. Invest . 2020, 130 , 5074-87; Chen et al. , Nature 2016 , 539 , 112-7; Kaelin, J. Clin. Invest. 2022 , 132 , see e162480. HIF-1 also regulates the activation of macrophages, neutrophils, and dendritic cells as a key mediator of pathogenic immune responses, such as lymphoid and myeloid immunomodulation in autoimmune diseases. For example, Islam et al. , Immunology 2021 , 164 , 31-42; Taylor and Scholz, Nat. Rev. Nephrol . 2022 , 18 See , 573-87. HIF-2α / ARNT has also been suggested to be involved in the pathogenesis of ischemic heart disease (IHD). For example, Ullah et al. , Biology (Basel) 2023 , 12 Refer to , 995.
[0008] Therefore, ARNT plays a central role in AhR and HIF signaling. For example, Vorrink and Domann, Chem. Biol. Interact . 2014 , 218 See , 82-8. There is a need for compounds and compositions to be used in a method of mediating AhR and HIF signaling by degrading ARNT.
[0009] The present invention provides a compound having the structure of the following formula (A) or its enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, or a mixture of two or more tautomers; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; or a pharmaceutically acceptable derivative thereof:
[0010]
[0011] Here:
[0012] R 1 is substituted or unsubstituted C1-C 10 Alkyl, substituted or unsubstituted C3-C 10 Cycloalkyl, substituted or unsubstituted C6-C 14 Aryl, substituted or unsubstituted C7-C 15 It is an arylalkyl, a substituted or unsubstituted heteroaryl, or a substituted or unsubstituted heterocycloalkyl;
[0013] R 2 and R 3 Each is independently H, deuterium, substituted or unsubstituted C1-C 10 Alkyl or substituted or unsubstituted C3-C 10 Cycloalkyl or; R 2 and R 3 C(O) or substituted or unsubstituted C3-C with the carbon atoms to which they are attached 10 Forming a cycloalkyl;
[0014] R 13 It is H, deuterium, or hydroxyl;
[0015] X is CR 4 R 5 or C(O), where R 4 and R 5 Each is independently H, deuterium, or substituted or unsubstituted C1-C 10 It is alkyl;
[0016] c and d are each independently integers of 0, 1, or 2.
[0017] Additionally, the present invention provides compounds and compositions for degrading ARNT, wherein the compounds have the structure of the following formula (I) or pharmaceutically acceptable derivatives thereof:
[0018]
[0019] Here:
[0020] R 1 is a cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;
[0021] R 2 and R 3 Each is independently H, alkyl, or cycloalkyl, or R 2 and R 3 It forms a spirocycloalkyl group together;
[0022] a and b are each independently integers from 1 to 3;
[0023] X is CR 4 R 5 or C(O), where R 4 and R 5 Each is independently H, alkyl, or aralkyl.
[0024] Additionally, the present invention provides a pharmaceutical composition comprising a compound provided herein, for example, a compound of formula (A) or (I) or a mirror image isomer thereof, a mixture of mirror image isomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, or a mixture of two or more tautomers; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; or a pharmaceutically acceptable derivative thereof; and a pharmaceutically acceptable excipient.
[0025] Additionally, the present invention provides a method for treating, preventing, or alleviating one or more symptoms of an ARNT-mediated disease or disorder in a subject, comprising the step of administering to a subject in need a therapeutically effective amount of a compound provided herein, for example, a compound of formula (A) or (I) or a mirror image isomer thereof, a mixture of mirror image isomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, or a mixture of two or more tautomers; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; or a pharmaceutically acceptable derivative thereof.
[0026] The present invention provides a method for treating, preventing, or alleviating one or more symptoms of cancer in a subject, comprising the step of administering to a subject in need a therapeutically effective amount of a compound provided herein, for example, a compound of formula (A) or (I) or a mirror image isomer thereof, a mixture of mirror image isomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, or a mixture of two or more tautomers; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; or a pharmaceutically acceptable derivative thereof.
[0027] The present invention provides a method for inhibiting cell growth comprising the step of contacting a cell with an effective amount of a compound provided herein, for example, a compound of formula (A) or (I) or a mirror image isomer thereof, a mixture of mirror image isomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, or a mixture of two or more tautomers; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; or a pharmaceutically acceptable derivative thereof.
[0028] The present invention provides a method for inducing degradation of ARNT, comprising the step of contacting ARNT with an effective amount of a compound provided herein, for example, a compound of formula (A) or (I) or a mirror image isomer thereof, a mixture of mirror image isomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, or a mixture of two or more tautomers; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; or a pharmaceutically acceptable derivative thereof. Brief explanation of the drawing
[0029] Figure 1 shows a compound in NCI-H929 cells A001Plots the dose-response plot for ARNT decomposition using [the method]. Figure 2 shows a dose-response plot for ARNT degradation using (3-(5-(1-benzyl-4-hydroxypiperidin-4-yl)-1-oxoisoindolin-2-yl)piperidin-2,6-dione) in NCI-H929 cells. Figure 3 shows a compound A001 Using [this], plot a dose-response plot for helios degradation in the HiBiT analysis at the 24-hour (h) time point. Figure 4 shows two dose-response plots for heliolysis in a HiBiT assay at 24 hours (h) using (3-(5-(1-benzyl-4-hydroxypiperidin-4-yl)-1-oxoisoindolin-2-yl)piperidin-2,6-dione). Figure 5 shows a compound A001 Using [this], plot the dose-response for heliolysis in Jurkat cell lines at the 6h time point. Figure 6 shows a dose-response plot for heliolysis in Jurkat cell lines at 6 h using (3-(5-(1-benzyl-4-hydroxypiperidin-4-yl)-1-oxoisoindolin-2-yl)piperidin-2,6-dione). Figure 7 shows a compound A001 Plots the dose-response plot for VEGF inhibition using [the method]. Specific details for implementing the invention
[0030] I. definition
[0031] To facilitate understanding of the disclosures presented herein, several terms are defined below.
[0032] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as generally understood by those skilled in the art. All patents, applications, publications, and other publications are incorporated herein by reference in their entirety. Where multiple definitions exist for a term in this section, the definitions in this section shall prevail unless otherwise noted.
[0033] Unless otherwise clearly indicated in the context, the singular forms "a," "an," and "the" include plural referents.
[0034] As used herein, "subject" refers to animals such as mammals, including humans such as patients.
[0035] As used herein, biological activity refers to the in vivo activity of a compound or the physiological response that occurs upon in vivo administration of a compound, composition, or other mixture. Accordingly, biological activity encompasses the therapeutic effects and pharmacokinetic behavior of such compounds, compositions, and mixtures. Biological activity may be observed in in vitro systems designed to test such activity.
[0036] As used herein, pharmaceutically acceptable derivatives of the compound include, but are not limited to, its salts, esters, enol ethers, enol esters, acetals, ketals, orthoesters, hemiacetals, hemiketals, acids, bases, clathrates, solvates, or hydrates. Such derivatives can be readily prepared by those skilled in the art using known methods for such derivatization. The resulting compound may be administered to animals or humans without substantial toxic effects and is pharmaceutically active or a prodrug. Pharmaceutically acceptable salts are N , N -Dibenzylethylenediamine, chloroprocaine, choline, ammonia, diethanolamine and other hydroxyalkylamines, ethylenediamine, N -Methylglucarmin, procaine,N - Amine salts including but not limited to benzylphenethylamine, 1-parachlorobenzyl-2-pyrrolidin-1'-ylmethylbenzimidazole, diethylamine and other alkylamines, piperazine and tris(hydroxymethyl)aminomethane; alkali metal salts including but not limited to lithium, potassium and sodium; alkaline earth metal salts including but not limited to barium, calcium and magnesium; transition metal salts including but not limited to zinc; and inorganic salts including but not limited to sodium hydrogen phosphate and disodium phosphate; and also salts of inorganic acids including but not limited to hydrochlorides and sulfates; and salts of organic acids including but not limited to acetates, lactates, malates, tartrates, citrates, ascorbs, succinates, butyrates, valerates, mesylates and fumarates. Pharmaceutically acceptable esters include, but are not limited to, alkyl, alkenyl, alkynyl, aryl, aralkyl, and cycloalkyl esters of acidic groups, including but not limited to carboxylic acids, phosphoric acids, phosphinic acids, sulfonic acids, sulfinic acids, and boronic acids. Pharmaceutically acceptable enol ethers include, but are not limited to, derivatives of the formula -C=C(OR) in which R is alkyl, alkenyl, alkynyl, aryl, aralkyl, and cycloalkyl. Pharmaceutically acceptable enol esters include, but are not limited to, derivatives of the formula -C=C(OC(O)R) in which R is hydrogen, alkyl, alkenyl, alkynyl, aryl, aralkyl, and cycloalkyl. Pharmaceutically acceptable solvates and hydrates are complexes of a compound with one or more solvent or water molecules or 1 to about 100, 1 to about 10, or 1 to about 2, 3, or 4 solvent or water molecules.
[0037] As used herein, "treatment" means any manner in which one or more symptoms of a disease or disorder are alleviated or otherwise beneficially altered. "Treatment" also encompasses any pharmaceutical use of the compositions of this invention, such as use for treating diseases or disorders associated with ARNT activity.
[0038] As used herein, relief of symptoms of a specific disorder by administration of a specific compound or pharmaceutical composition refers to any relief, whether permanent or temporary, sustained or momentary, that may be attributed to or associated with the administration of the compound or pharmaceutical composition.
[0039] Unless otherwise used herein, the terms “manage,” “managing,” and “manage” encompass preventing the recurrence of a specified disease or disorder in a subject who has already suffered from the disease or disorder and / or extending the time a subject who has suffered from the disease or disorder remains in remission. The terms also encompass controlling the threshold, onset, and / or duration of the disease or disorder, or changing the way a subject responds to the disease or disorder.
[0040] When a moiety is specified by a conventional chemical formula written from left to right, it equally encompasses chemically identical moiety obtained by writing the structure from right to left; for example, -CH2O- is equivalent to -OCH2-.
[0041] The term "alkyl" refers to having a specified number of carbon atoms (i.e., C1-C2), either alone or as part of another substituent, unless otherwise noted. 10 It refers to straight-chain (i.e., unbranched) or branched-chain saturated hydrocarbon radicals that may include 1 to 10 carbons), divalent and polyvalent radicals. Examples of alkyl groups are methyl, ethyl, n -Prop, isopropyl, n -butyl, t -Butyl, isobutyl, sec -Butyl, and for example n -pentyl, n - Hexyl, n -Heptyl and n - It includes, but is not limited to, groups such as the homologues and isomers of octyl.
[0042] The term "alkenyl" refers to having a specified number of carbon atoms (i.e., C1-C2), either alone or as part of another substituent, unless otherwise noted. 10 It means a straight-chain (i.e., unbranched) or branched-chain hydrocarbon radical having one or more carbon-carbon double bonds, which may include divalent and polyvalent radicals. Examples of alkenyl groups include, but are not limited to, vinyl (i.e., ethenyl), 2-propenyl, crotyl, 2-isopentenyl, 2-(butadienyl), 2,4-pentadienyl, 3-(1,4-pentadienyl), and their higher homologues and isomers.
[0043] The term "alkynyl" refers to having a specified number of carbon atoms (i.e., C1-C2), either alone or as part of another substituent, unless otherwise noted. 10 It means a straight-chain (i.e., unbranched) or branched-chain hydrocarbon radical having one or more carbon-carbon triple bonds, which may include divalent and polyvalent radicals. Examples of alkynyl groups include, but are not limited to, ethinyl, 1- and 3-propynyl, 3-butynyl, and their higher homologues and isomers.
[0044] The term "alkylene" means a divalent radical derived from an alkyl group, either alone or as part of another substituent, exemplified but not limited to -CH2CH2CH2CH2-. Typically, an alkyl (or alkylene) group has 1 to 24 carbon atoms and includes a group having 10 or fewer carbon atoms. "Lower alkyl" or "lower alkylene" is generally a shorter chain of alkyl or alkylene groups having 6 or fewer carbon atoms.
[0045] The terms "alkoxy," "alkylamino," and "alkylthio" (or thioalkoxy) are used in the common sense and refer to an alkyl group attached to the rest of the molecule through an oxygen atom, an amino group, or a sulfur atom, respectively.
[0046] The term “heteroalkyl” means a straight-chain or branched-chain hydrocarbon radical consisting of heteroatoms selected from the group consisting of O, N, P, Si, and S, either alone or in combination with other terms, unless otherwise noted, wherein the nitrogen and sulfur atoms may optionally be oxidized, and the nitrogen atom may have an alkyl substituent to satisfy the valence and / or may optionally be quaternized. The heteroatom(s) O, N, P, Si, and S may be placed at any internal position of the heteroalkyl group. Examples include, but are not limited to, -CH2-CH2-O-CH3, -CH2-CH2-NH-CH3, -CH2-CH2-N(CH3)-CH3, -CH2-S-CH2-CH3, -CH2-CH2-S(O)-CH3, -CH2-CH2-S(O)2-CH3, -CH=CH-O-CH3, -CH2-CH=N-OCH3, and -CH=CH-N(CH3)-CH3. For example, up to two heteroatoms may be consecutive, such as -CH2-NH-OCH3 and -CH2-O-Si(CH3)3. Similarly, the term "heteroalkylene" refers to a divalent radical derived from a heteroalkyl, exemplified but not limited to -CH2-CH2-S-CH2-CH2- and -CH2-S-CH2-CH2-NH-CH2-, either alone or as part of other substituents. For alkylene and heteroalkylene linkers, the orientation in which the linker's chemical formula is described does not imply any orientation of the linker. For example, the chemical formula -C(O)2R'- represents both -C(O)2R'- and -R'C(O)2-.
[0047] The terms “cycloalkyl” and “heterocycloalkyl”, alone or in combination with other terms, represent, unless otherwise noted, cyclic versions of “alkyl” and “heteroalkyl,” respectively, and include dicyclic, tricyclic, and bridged dicyclic groups. Additionally, in the case of heterocycloalkyl, the heteroatom may occupy a position where the heterocycle is attached to the rest of the molecule. Examples of cycloalkyl include, but are not limited to, cyclopentyl, cyclohexyl, 1-cyclohexenyl, 3-cyclohexenyl, cycloheptyl, norbornanyl, and bicyclo-[2.2.2]octanyl. Examples of heterocycloalkyls include, but are not limited to, 1-(1,2,5,6-tetrahydropyridyl), 1-piperidinyl, 2-piperidinyl, 3-piperidinyl, 4-morpholinyl, 3-morpholinyl, tetrahydrofuran-2-yl, tetrahydrofuran-3-yl, tetrahydrotiene-2-yl, tetrahydrotiene-3-yl, 1-piperazinyl, 2-piperidinyl, 1-azabicyclo[2.2.2]octanyl and 2-azabicyclo[2.2.2]octanyl.
[0048] The term "halo" means a fluorine, chlorine, bromine, or iodine atom, either alone or as part of another substituent, unless otherwise noted. Additionally, terms such as "haloalkyl" mean including monohaloalkyl and polyhaloalkyl. For example, the term "halo(C1-C4)alkyl" means including, but not limited to, trifluoromethyl, 2,2,2-trifluoroethyl, 4-chlorobutyl, and 3-bromopropyl.
[0049] The term “aryl” means a polyunsaturated aromatic hydrocarbon substituent that, unless otherwise noted, may be a single ring or a plurality of rings (1 to 3 rings in one embodiment) fused together or connected by covalent bonds. The term “heteroaryl” refers to an aryl group containing 1 to 4 heteroatoms selected from N, O, and S within the ring(s), wherein the nitrogen and sulfur atoms are optionally oxidized and the nitrogen atoms are optionally quaternized. The heteroaryl group may be attached to the rest of the molecule via carbon or heteroatoms. Non-limiting examples of aryl and heteroaryl groups include phenyl, 1-naphthyl, 2-naphthyl, 4-biphenyl, 1-pyrrolil, 2-pyrrolil, 3-pyrrolil, 3-pyrazolyl, 2-imidazolyl, 4-imidazolyl, pyrazinyl, 2-oxazolyl, 4-oxazolyl, 5-oxazolyl, 3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl, 2-thiazolyl, 4-thiazolyl, 5-thiazolyl, 2-furyl, 3-furyl, 2-thienyl, 3-thienyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidyl, 4-pyrimidyl, 5-benzothiazolyl, purinyl, Includes 2-benzimidazolyl, 5-indolyl, 1-isoquinolyl, 5-isoquinolyl, 2-quinoxalinyl, 5-quinoxalinyl, 3-quinolyl, and 6-quinolyl. Substituent moiety for aryl and heteroaryl ring systems may be selected from the group of acceptable substituent moiety described herein. The term "heteroarylium" refers to a heteroaryl group having a positive charge on one or more of the heteroatoms.
[0050] As used herein, the term "oxo" refers to an oxygen atom double-bonded to a carbon atom.
[0051] Each of the above terms (e.g., "alkyl," "heteroalkyl," "aryl," and "heteroaryl") implies including both the substituted and unsubstituted forms of the indicated radical. Non-limiting examples of substituent moiety for each type of radical are provided below.
[0052] In one embodiment, the substituent moiety for the alkyl, heteroalkyl, alkylene, alkenyl, heteroalkylene, heteroalkenyl, alkynyl, cycloalkyl, heterocycloalkyl, cycloalkenyl, and heterocycloalkenyl groups is a number ranging from 0 to the number of hydrogen atoms in these radicals, including deuterium, -OR', =O, =NR', =N-OR', -NR'R", -SR', halo, -SiR'R"R"', -OC(O)R', -C(O)R', -CO2R', -CONR'R", -OC(O)NR'R", -NR"C(O)R', -NR'-C(O)NR"R"', -NR"C(O)2R', -NR-C(NR'R"R'")=NR"", -NR-C(NR'R")=NR'", -S(O)R', Selected from -S(O)2R', -S(O)2NR'R", -NRSO2R', -NRSO2NR'R'', -CN and -NO2. In one embodiment, the substituent moiety for the cycloalkyl, heterocycloalkyl, cycloalkenyl and heterocycloalkenyl groups also comprises substituted and unsubstituted alkyl, substituted and unsubstituted alkenyl, and substituted and unsubstituted alkynyl. In one embodiment, R', R", R"' and R"" are each independently hydrogen, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl (e.g., aryl substituted with 1 to 3 halogens), substituted or unsubstituted alkyl, alkoxy or thioalkoxy group or arylalkyl group. For example, if the compounds provided herein contain more than one R group, for example, when more than one of these groups is present, each R group is selected independently, as are each R', R", R"', and R"" group. If R' and R" are attached to the same nitrogen atom, they may combine with the nitrogen atom to form a quaternary, pentary, hexavalent, or heptary ring. For example, -NR'R" means that it includes, but is not limited to, 1-pyrrolidinyl and 4-morpholinyl.From the above discussion regarding substituent moiety, those skilled in the art will understand that the term "alkyl" means a group comprising a carbon atom bonded to a group other than a hydrogen group, such as haloalkyl (e.g., -CF3 and -CH2CF3) and acyl (e.g., -C(O)CH3, -C(O)CF3 and -C(O)CH2OCH3).
[0053] In one embodiment, the substituent moiety for the aryl group and the heteroaryl group is a number ranging from 0 to the total number of hydrogens on the aromatic ring system, deuterium, halo, substituted and unsubstituted alkyl, substituted and unsubstituted alkenyl, substituted and unsubstituted alkynyl, -OR', -NR'R", -SR', -SiR'R"R"', -OC(O)R', -C(O)R', -CO2R', -CONR'R", -OC(O)NR'R", -NR"C(O)R', -NR'-C(O)NR"R"', -NR"C(O)2R', -NR-C(NR'R"R'")=NR"", -NR-C(NR'R")=NR'", -S(O)R', -S(O)2R', -S(O)2NR'R", -NRSO2R', -CN, -NO2, -R', -N3, -CH(Ph)2, fluoro(C1-C4)alkoxy and fluoro(C1-C4)alkyl are selected from; wherein in one embodiment, R', R", R"' and R"" are independently selected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl and substituted or unsubstituted heteroaryl. For example, if the compound provided herein comprises more than one R group, for example, when more than one of these groups is present, each R group is independently selected as well as each R', R", R"' and R"" group.
[0054] Two of the substituent moiety's on adjacent atoms of an aryl or heteroaryl ring are in the chemical formula -Q'-C(O) -(CRR') qA ring of -Q''- can be optionally formed, where Q' and Q'' are independently -NR-, -O-, -CRR'- or a single bond, and q is an integer from 0 to 3. Alternatively, two of the substituent moieties on adjacent atoms of the aryl or heteroaryl ring can be optionally replaced with substituents of the formula -A-(CH2)rB-, where A and B are independently -CRR'-, -O-, -NR-, -S-, -S(O)-, -S(O)2-, -S(O)2NR'- or a single bond, and r is an integer from 1 to 4. One of the single bonds of the new ring thus formed can be optionally replaced with a double bond. Alternatively, two of the substituent moieties on adjacent atoms of the aryl or heteroaryl ring are of the formula -(CRR') s -X'-(CR''R''') t - can be optionally replaced with a substituent, where s and t are independently integers from 0 to 3, and X' is -O-, -NR'-, -S-, -S(O)-, -S(O)2- or -S(O)2NR'-. In one embodiment, the substituent moiety R, R', R" and R'" are independently selected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl.
[0055] As used herein, the terms “heteroatom” or “ring heteroatom” mean that it includes oxygen (O), nitrogen (N), sulfur (S), phosphorus (P), and silicon (Si).
[0056] As used herein, a prodrug is a compound that is metabolized by one or more steps or processes upon administration in vivo, otherwise undergoes chemical changes under physiological conditions, or otherwise is converted into a biological, pharmaceutical, or therapeutically active form of the compound. Additionally, a prodrug may be converted into a biological, pharmaceutical, or therapeutically active form of the compound by chemical or biochemical methods in an in vivo environment. For example, a prodrug may be converted into the compound provided herein when placed in a transdermal patch reservoir with a suitable enzyme or chemical reagent.
[0057] The specific compounds provided herein may exist in solvated forms as well as nonsolved forms, including hydrated forms. Generally, the solvated form is equivalent to the nonsolved form and is included within the scope of this disclosure. The specific compounds provided herein may exist in polycrystalline or amorphous forms. Generally, all physical forms are intended to be equivalent for the uses considered herein and are included within the scope of this disclosure.
[0058] Certain compounds provided herein have an asymmetric carbon atom (optical center) or a double bond; racemics, diastereomers, tautomers, geometric isomers, and individual isomers are included within the scope of this disclosure. The compounds provided herein do not include compounds known in the art that are too unstable to synthesize and / or isolate.
[0059] The compounds provided herein may also contain atomic isotopes in non-natural proportions in one or more of the atoms constituting these compounds. For example, the compounds may, for example, tritium ( 3 H), iodine-125( 125 I) or carbon-14( 14It may be radiolabeled with a radioactive isotope such as C). Regardless of whether or not it is radioactive, all isotopic variations of the compounds provided herein are included within the scope of this disclosure.
[0060] II. Compounds for use in compositions and methods
[0061] In one embodiment, the present invention provides a compound having the structure of the following formula (A) or a mirror image isomer thereof, a mixture of mirror image isomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, or a mixture of two or more tautomers; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; or a pharmaceutically acceptable derivative thereof:
[0062]
[0063] Here:
[0064] R 1 is substituted or unsubstituted C1-C 10 Alkyl, substituted or unsubstituted C3-C 10 Cycloalkyl, substituted or unsubstituted C6-C 14 Aryl, substituted or unsubstituted C7-C 15 It is an arylalkyl, a substituted or unsubstituted heteroaryl, or a substituted or unsubstituted heterocycloalkyl;
[0065] R 2 and R 3 Each is independently H, deuterium, substituted or unsubstituted C1-C 10 Alkyl or substituted or unsubstituted C3-C 10 Cycloalkyl or; R 2 and R 3 C(O) or substituted or unsubstituted C3-C with the carbon atoms to which they are attached 10 Forming a cycloalkyl;
[0066] R 13 It is H, deuterium, or hydroxyl;
[0067] X is CR 4 R 5 or C(O), where R 4 and R 5 Each is independently H, deuterium, or substituted or unsubstituted C1-C 10 It is alkyl;
[0068] c and d are each independently integers of 0, 1, or 2.
[0069] In another embodiment, the present invention provides a compound having the structure of the following formula (I) or a pharmaceutically acceptable derivative thereof for use in the compositions and methods provided herein:
[0070]
[0071] Here:
[0072] R 1 is a cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;
[0073] R 2 and R 3 Each is independently H, alkyl, or cycloalkyl, or R 2 and R 3 It forms a spirocycloalkyl group together;
[0074] a and b are each independently integers from 1 to 3;
[0075] X is CR 4 R 5 or C(O), where R 4 and R 5 Each is independently H, alkyl, or aralkyl.
[0076] In another embodiment, the present invention provides a compound having the structure of the following formula (Ia) or a pharmaceutically acceptable derivative thereof for use in the compositions and methods provided herein:
[0077]
[0078] Here:
[0079] R1 is a cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;
[0080] R 2 is H, alkyl, or cycloalkyl;
[0081] X is CR 4 R 5 or C(O), where R 4 and R 5 Each is independently H, alkyl, or aralkyl.
[0082] In a specific implementation, X is CR 4 R 5 and, here R 4 and R 5 Each is as defined herein. In a specific embodiment, X is C(O).
[0083] In another embodiment, the present invention provides a compound having the structure of the following formula (II) or a mirror image isomer thereof, a mixture of mirror image isomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, or a mixture of two or more tautomers; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; or a pharmaceutically acceptable derivative thereof:
[0084]
[0085] Here, R 1 , R 2 , R 3 , R 4 , R 5 , R 13 , c and d are each as defined herein.
[0086] In another embodiment, the present invention provides a compound having the structure of the following formula (III) or a mirror image isomer thereof, a mixture of mirror image isomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, or a mixture of two or more tautomers; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; or a pharmaceutically acceptable derivative thereof:
[0087]
[0088] Here, R 1 , R 2 , R 3 , R 4 , R 5 and R 13 Each is as defined herein.
[0089] In a specific implementation, R 1 is an aryl or heteroaryl, and -OR 6 , -NR 7 R 8 , -(CH2) n -R 9 , -C(O)NR 7 R 8 , -NR 7 C(O)R 12 , -S(O) p NR 7 R 8 , -NR 7 S(O) p R 12 , -C(O)-(CH2) m -R 10 or -S(O) p -(CH2) q -R 11 It is optionally substituted as; where R 6 is H, alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; R 7 and R 8 Each is independently H, alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, or R 7 and R 8... forms a heterocycloalkyl with the atom(s) to which they are attached; R 9 , R 10 and R 11 Each is independently a monocyclic or fused, cross-linked or spiro-cyclic cycloalkyl or a monocyclic or fused, cross-linked or spiro-cyclic heterocycloalkyl; R 12 is an alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; m, n, p, and q are each independently integers from 0 to 2; or R 1 It is an aryl or heteroaryl, each of which is optionally fused to a cycloalkyl or heterocycloalkyl ring.
[0090] In a specific implementation, R 1 is an aryl or heteroaryl, and -OR 6 , -NR 7 R 8 , -(CH2) n -R 9 , -C(O)NR 7 R 8 , -NR 7 C(O)R 12 , -S(O) p NR 7 R 8 , -NR 7 S(O) p R 12 , -C(O)-(CH2) m -R 10 or -S(O) p -(CH2) q -R 11 It is optionally substituted as; where R 6 is H, alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; R 7 and R 8 Each is independently H, alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, or R 7 and R 8 ... forms a heterocycloalkyl with the atom(s) to which they are attached; R 9 , R 10and R 11 Each is independently a monocyclic or fused, cross-linked or spiro-cyclic cycloalkyl or a monocyclic or fused, cross-linked or spiro-cyclic heterocycloalkyl; R 12 is an alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; and m, n, p, and q are each independently integers from 0 to 2.
[0091] In a specific implementation, R 1 is aryl, and is -OR 6 , -NR 7 R 8 , -(CH2) n -R 9 , -C(O)NR 7 R 8 , -NR 7 C(O)R 12 , -S(O) p NR 7 R 8 , -NR 7 S(O) p R 12 , -C(O)-R 10 or -S(O)2-R 11 It is optionally substituted as; where R 6 is a cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; R 7 and R 8 Each is independently H, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, or R 7 and R 8 ... forms a heterocycloalkyl with the atom(s) to which they are attached; R 9 , R 10 and R 11 Each is independently a monocyclic or fused, cross-linked or spiro-cyclic cycloalkyl or a monocyclic or fused, cross-linked or spiro-cyclic heterocycloalkyl; R 12 is an alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; and n and p are each independently integers from 0 to 2.
[0092] In a specific implementation, R 1 is aryl, and is -OR 6 , -NR 7 R 8 , -(CH2) n -R 9 , -C(O)NR 7 R 8 , -NR 7 C(O)R 12 , -S(O) p NR 7 R 8 , -NR 7 S(O) p R 12 , -C(O)-R 10 or -S(O)2-R 11 It is optionally substituted as; where R 6 is a heterocycloalkyl or aryl; R 7 is H and; R 8 is a heterocycloalkyl or aryl; R 9 , R 10 and R 11 Each is independently a monocyclic or fused, crosslinked, or spirocyclic heterocycloalkyl; R 12 is an alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; n is an integer of 0 or 1; and p is an integer of 0 to 2, respectively, independently.
[0093] In a specific implementation, R 1 is aryl, and is -OR 6 , -NR 7 R 8 , -(CH2) n -R 9 , -C(O)-R 10 or -S(O)2-R 11 It is optionally substituted as; where R 6 is a heterocycloalkyl or aryl; R 7 is H and; R 8 is a heterocycloalkyl or aryl; R 9 , R 10 and R 11Each is independently a monocyclic or fused, cross-linked, or spirocyclic heterocycloalkyl; n is an integer of 0 or 1.
[0094] In a specific implementation, R 1 is phenyl, which is optionally substituted as described herein.
[0095] In a specific implementation, R 1 is phenyl, and this is -OR 6 , -NR 7 R 8 , -(CH2) n -R 9 , -C(O)NR 7 R 8 , -NR 7 C(O)R 8 , -C(O)-R 10 or -S(O)2-R 11 It is optionally substituted as; where R 6 is a heterocycloalkyl or aryl; R 7 is H and; R 8 is a heterocycloalkyl or aryl; R 9 , R 10 and R 11 Each is independently a monocyclic or fused, cross-linked, or spirocyclic heterocycloalkyl; n is an integer of 0 or 1.
[0096] In a specific implementation, R 1 is unsubstituted phenyl.
[0097] In a specific implementation, R 1 is an aryl and is optionally fused to a cycloalkyl or heterocycloalkyl ring. In certain embodiments, R 1 It is phenyl and is selectively fused to a heterocycloalkyl ring.
[0098] In a specific implementation, R 1 C1-C 10 Alkyl, C3-C 10 Cycloalkyl, C6-C 14 Aryl, C7-C 15It is arylalkyl, heteroaryl, or heterocycloalkyl, each optionally substituted with 1, 2, 3, or 4 substituents, each of which is independently deuterium, cyano, halo, nitro, oxo, substituted or unsubstituted C1-C 10 Alkyl, substituted or unsubstituted C1-C 10 Heteroalkyl, substituted or unsubstituted C3-C 10 Cycloalkyl, substituted or unsubstituted C6-C 14 Aryl, substituted or unsubstituted C7-C 15 arylalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocycloalkyl, -COR', -CO2R', -CONR'R", -OR', -OC(O)R', -OC(O)NR'R", -NR'R", -NR"C(O)R', -NR"C(O)2R', -NR'C(O)NR"R"', -NRSO2R', -NRSO2NR'R'', -SR', -S(O)R', -S(O)2R' or -S(O)2NR'R"; where each R', R" and R"' is independently hydrogen, substituted or unsubstituted C1-C 10 Alkyl, substituted or unsubstituted C1-C 10 Heteroalkyl, substituted or unsubstituted C1-C 10 Cycloalkyl, substituted or unsubstituted C6-C 14 Aryl, substituted or unsubstituted C7-C 15 arylalkyl, substituted or unsubstituted heteroaryl, or substituted or unsubstituted heterocycloalkyl; R' and R" are substituted or unsubstituted C3-C atoms together with the nitrogen atoms to which they are attached. 10 It forms a cycloalkyl or a substituted or unsubstituted heterocycloalkyl.
[0099] In a specific implementation, R 1 C1-C 10 Alkyl, C3-C 10 Cycloalkyl, C6-C 14 Aryl, C7-C 15It is an arylalkyl, heteroaryl, or heterocycloalkyl, each optionally substituted with one or more substituents, each of which is independently a deuterium, cyano, halo, oxo, substituted, or unsubstituted C1-C 10 Alkyl, substituted or unsubstituted C1-C 10 Heteroalkyl, substituted or unsubstituted C3-C 10 Cycloalkyl, substituted or unsubstituted C6-C 14 Aryl, substituted or unsubstituted C7-C 15 arylalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocycloalkyl, -COR', -CONR'R", -OR', -NR'R", -S(O)2R' or -S(O)2NR'R"; where each R' and R" is independently hydrogen, substituted or unsubstituted C1-C 10 Alkyl, substituted or unsubstituted C1-C 10 Heteroalkyl, substituted or unsubstituted C1-C 10 Cycloalkyl, substituted or unsubstituted C6-C 14 Aryl, substituted or unsubstituted C7-C 15 It is an arylalkyl, a substituted or unsubstituted heteroaryl, or a substituted or unsubstituted heterocycloalkyl.
[0100] In a specific implementation, R 1 is substituted or unsubstituted C1-C 10 It is an alkyl. In a specific embodiment, R 1 C1-C 10 It is an alkyl group, which is optionally substituted with one, two, or three substituents, each of which is independently a deuterium, cyano, halo, oxo, substituted, or unsubstituted C1-C 10 Alkyl, substituted or unsubstituted C1-C 10 Heteroalkyl, substituted or unsubstituted C3-C 10 Cycloalkyl, substituted or unsubstituted C6-C 14 Aryl, substituted or unsubstituted C7-C 15arylalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocycloalkyl, -COR', -CONR'R", -OR', -NR'R", -S(O)2R' or -S(O)2NR'R"; where each R' and R" is independently hydrogen, substituted or unsubstituted C1-C 10 Alkyl, substituted or unsubstituted C1-C 10 Heteroalkyl, substituted or unsubstituted C1-C 10 Cycloalkyl, substituted or unsubstituted C6-C 14 Aryl, substituted or unsubstituted C7-C 15 It is an arylalkyl, a substituted or unsubstituted heteroaryl, or a substituted or unsubstituted heterocycloalkyl. In certain embodiments, R 1 It is isopropyl.
[0101] In a specific implementation, R 1 C3-C with substituted or unsubstituted components 10 It is a cycloalkyl. In certain embodiments, R 1 C3-C 10 It is a cycloalkyl, which is optionally substituted with one, two, or three substituents, each of which is independently a deuterium, cyano, halo, oxo, substituted, or unsubstituted C1-C 10 Alkyl, substituted or unsubstituted C1-C 10 Heteroalkyl, substituted or unsubstituted C3-C 10 Cycloalkyl, substituted or unsubstituted C6-C 14 Aryl, substituted or unsubstituted C7-C 15 arylalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocycloalkyl, -COR', -CONR'R", -OR', -NR'R", -S(O)2R' or -S(O)2NR'R"; where each R' and R" is independently hydrogen, substituted or unsubstituted C1-C 10 Alkyl, substituted or unsubstituted C1-C 10 Heteroalkyl, substituted or unsubstituted C1-C 10 Cycloalkyl, substituted or unsubstituted C6-C14 Aryl, substituted or unsubstituted C7-C 15 It is an arylalkyl, a substituted or unsubstituted heteroaryl, or a substituted or unsubstituted heterocycloalkyl.
[0102] In a specific implementation, R 1 is a substituted or unsubstituted monocyclic C3-C 10 It is a cycloalkyl. In certain embodiments, R 1 is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or cycloheptyl, each optionally substituted. In certain embodiments, R 1 is a substituted or unsubstituted cyclohexyl.
[0103] In a specific implementation, R 1 is a substituted or unsubstituted cyclic formula C3-C 10 It is a cycloalkyl. In certain embodiments, R 1 Silver cross-linking, fusion, or spiro C4-C 10 It is cycloalkyl and each is optionally substituted. In certain embodiments, R 1 Silver substituted or unsubstituted cross-linked C5-C 10 It is a cycloalkyl. In certain embodiments, R 1 is a substituted or unsubstituted bicyclo[1.1.1]fentanyl. In certain embodiments, R 1 is a substituted or unsubstituted bicyclo[1.1.1]pentane-1-yl. In certain embodiments, R 1 Substituted or unsubstituted fused C4-C 10 It is a cycloalkyl. In certain embodiments, R 1 Silver substituted or unsubstituted spiro C4-C 10 It is a cycloalkyl. In certain embodiments, R 1 It is cyclohexyl, 4-aminocyclohexyl, or 3-fluorobicyclo[1.1.1]pentane-1-yl.
[0104] In a specific implementation, R 1 C6-C with substituted or unsubstituted components 14 It is Aryl. In a specific implementation, R 1C6-C 14 It is an aryl, which is optionally substituted with one, two, or three substituents, each of which is independently a deuterium, cyano, halo, substituted, or unsubstituted C1-C 10 Alkyl, substituted or unsubstituted C1-C 10 Heteroalkyl, substituted or unsubstituted C3-C 10 Cycloalkyl, substituted or unsubstituted C6-C 14 Aryl, substituted or unsubstituted C7-C 15 arylalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocycloalkyl, -COR', -CONR'R", -OR', -NR'R", -S(O)2R' or -S(O)2NR'R"; where each R' and R" is independently hydrogen, substituted or unsubstituted C1-C 10 Alkyl, substituted or unsubstituted C1-C 10 Heteroalkyl, substituted or unsubstituted C1-C 10 Cycloalkyl, substituted or unsubstituted C6-C 14 Aryl, substituted or unsubstituted C7-C 15 It is an arylalkyl, a substituted or unsubstituted heteroaryl, or a substituted or unsubstituted heterocycloalkyl.
[0105] In a specific implementation, R 1 is a substituted or unsubstituted phenyl. In certain embodiments, R 1 is phenyl, which is optionally substituted with one, two, or three substituents, each of which is independently a deuterium, cyano, halo, substituted, or unsubstituted C1-C 10 Alkyl, substituted or unsubstituted C1-C 10 Heteroalkyl, substituted or unsubstituted C3-C 10 Cycloalkyl, substituted or unsubstituted C6-C 14 Aryl, substituted or unsubstituted C7-C 15arylalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocycloalkyl, -COR', -CONR'R", -OR', -NR'R", -S(O)2R' or -S(O)2NR'R"; where each R' and R" is independently hydrogen, substituted or unsubstituted C1-C 10 Alkyl, substituted or unsubstituted C1-C 10 Heteroalkyl, substituted or unsubstituted C1-C 10 Cycloalkyl, substituted or unsubstituted C6-C 14 Aryl, substituted or unsubstituted C7-C 15 It is an arylalkyl, a substituted or unsubstituted heteroaryl, or a substituted or unsubstituted heterocycloalkyl. In certain embodiments, R 1 is phenyl, which is optionally substituted with one, two, or three substituents, each of which is independently a deuterium, cyano, halo, substituted, or unsubstituted C1-C 10 Alkyl, substituted or unsubstituted C1-C 10 Heteroalkyl, substituted or unsubstituted C6-C 14 aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocycloalkyl or -OR'; where R' is a substituted or unsubstituted C1-C 10 Alkyl or substituted or unsubstituted C6-C 14 It is Aril.
[0106] In a specific implementation, R 1... is phenyl, which is optionally substituted with one or two substituents, each of which is independently deuterium, cyano, chloro, fluoro, methyl, trifluoromethyl, ethyl, difluoroethyl, propyl, butyl, oxanylmethyl, morpholinomethyl, hydroxymethyl, methoxymethyl, phenoxymethyl, dimethylaminomethyl, cyclobutyl, cyclohexyl, phenyl, pyrazolyl, methylpyrazolyl, oxetanyl, piperidinyl, difluoropiperidinyl, (hydroxymethyl)piperidinyl, hydroxypiperidinyl, oxanyl, morpholino, 8-azabicyclo[3.2.1]octanyl, hydroxyl, methoxy, trifluoromethoxy, hydroxyethoxy, phenoxy, benzoxy, oxanyloxy, piperidinyloxy, amino, dimethylamino, phenylamino, aminocarbonyl, It is methylaminocarbonyl, dimethylaminocarbonyl, methylsulfonyl, or aminosulfonyl. In certain embodiments, R 1 phenyl is optionally substituted with one or two substituents, each of which is independently deuterium, cyano, chloro, fluoro, methyl, trifluoromethyl, ethyl, difluoroethyl, propyl, butyl, morpholinomethyl, methoxymethyl, phenoxymethyl, phenyl, pyrazolyl, methylpyrazolyl, piperidinyl, morpholino, 8-azabicyclo[3.2.1]octanyl or phenoxy.
[0107] In a specific implementation, R 1 is phenyl, which is optionally substituted with one or two substituents, each of which is independently deuterium, cyano, chloro, fluoro, methyl, trifluoromethyl, ethyl, 1,1-difluoroethyl, isopropyl, tert -Butyl, oxane-4-ylmethyl, morpholinomethyl, hydroxymethyl, methoxymethyl, phenoxymethyl, dimethylaminomethyl, cyclobutyl, cyclohexyl, phenyl, pyrazole-1-yl, 1-methylpyrazole-3-yl, 1-methylpyrazole-4-yl, 2-methylpyrazole-3-yl, oxetane-3-yl, oxane-4-yl, piperidine-1-yl, 4,4-difluoropiperidin-1-yl, 4-(hydroxymethyl)piperidin-1-yl, 4-hydroxypiperidin-1-yl, morpholino, 8-azabicyclo[3.2.1]octane-8-yl, hydroxyl, methoxy, trifluoromethoxy, 2-hydroxyethoxy, phenoxy, benzoxy, piperidine-4-yloxy, oxane-4-yloxy, It is amino, dimethylamino, phenylamino, aminocarbonyl, methylaminocarbonyl, dimethylaminocarbonyl, methylsulfonyl, or aminosulfonyl. In certain embodiments, R 1 is phenyl, which is optionally substituted with one or two substituents, each of which is independently deuterium, cyano, chloro, fluoro, methyl, trifluoromethyl, ethyl, 1,1-difluoroethyl, isopropyl, tert -butyl, morpholinomethyl, methoxymethyl, phenoxymethyl, phenyl, pyrazole-1-yl, 1-methylpyrazole-3-yl, 1-methylpyrazole-4-yl, piperidine-1-yl, morpholino, 8-azabicyclo[3.2.1]octane-8-yl or phenoxy.
[0108] In a specific implementation, R 1 phenyl, 2-cyanophenyl, 3-cyanophenyl, 4-cyanophenyl, 3-chlorophenyl, 4-chlorophenyl, 2-fluorophenyl, 3-fluorophenyl, 4-fluorophenyl, 2,4-difluorophenyl, 2-methylphenyl, 3-methylphenyl, 4-methylphenyl, 3-trifluoromethylphenyl, 4-trifluoromethylphenyl, 3-ethylphenyl, 4-ethylphenyl, 3-(1,1-difluoroethyl)phenyl, 4-(1,1-difluoroethyl)phenyl, 3-isopropylphenyl, 4-isopropylphenyl, 3- tert -butylphenyl, 4- tert -butylphenyl, 4-(oxane-4-ylmethyl)phenyl, 4-(morpholinomethyl)phenyl, 4-hydroxymethylphenyl, 4-methoxymethylphenyl, 4-phenoxymethylphenyl, 4-((dimethylamino)methyl)phenyl, 4-chloro-3-fluorophenyl, 4-chloro-3-methylphenyl, 3,4-di(trifluoromethyl)phenyl, 3-cyclobutylphenyl, 4-cyclobutylphenyl, 4-cyclohexylphenyl, 4-phenylphenyl, 4-pyrazole-1-ylphenyl, 4-(1-methylpyrazole-3-yl)phenyl, 4-(1-methylpyrazole-4-yl)phenyl, 4-(2-methylpyrazole-3-yl)phenyl, 3-(oxetane-3-yl)phenyl, 4-(oxetane-3-yl)phenyl, 3-oxane-4-ylphenyl, 4-oxane-4-ylphenyl, 3-(piperidin-1-yl)phenyl, 4-(piperidin-1-yl)phenyl, 4-(4,4-difluoropiperidin-1-yl)phenyl, 4-(4-(hydroxymethyl)piperidin-1-yl)phenyl, 4-(4-hydroxypiperidin-1-yl)phenyl, 3-morpholinophenyl, 4-morpholinophenyl, 3-(8-azabicyclo[3.2.1]octane-8-yl)phenyl, 4-(8-azabicyclo[3.2.1]octane-8-yl)phenyl, 2-hydroxyphenyl, 3-hydroxyphenyl, 4-hydroxyphenyl, 2-methoxyphenyl, 3-methoxyphenyl, 4-methoxyphenyl, 4-trifluoromethoxyphenyl, It is 4-(2-hydroxyethoxy)phenyl, 3-phenoxyphenyl, 4-phenoxyphenyl, 4-benzoxyphenyl, 4-(piperidin-4-yloxy)phenyl, 4-(oxane-4-yl)oxyphenyl, 3,4-dimethoxyphenyl, 3-aminophenyl, 3-dimethylaminophenyl, 4-dimethylaminophenyl, 4-phenylaminophenyl, 3-aminocarbonylphenyl, 4-aminocarbonylphenyl, 3-methylaminocarbonylphenyl, 4-methylaminocarbonylphenyl, 4-dimethylaminocarbonylphenyl, 4-(methylsulfonyl)phenyl or 4-aminosulfonylphenyl.
[0109] In a specific implementation, R 1phenyl, 3-cyanophenyl, 4-cyanophenyl, 3-chlorophenyl, 4-chlorophenyl, 3-fluorophenyl, 4-fluorophenyl, 4-methylphenyl, 3-trifluoromethylphenyl, 4-trifluoromethylphenyl, 4-ethylphenyl, 3-(1,1-difluoroethyl)phenyl, 4-(1,1-difluoroethyl)phenyl, 4-isopropylphenyl, 4- tert -butylphenyl, 4-(oxane-4-ylmethyl)phenyl, 4-methoxymethylphenyl, 4-phenylphenyl, 4-pyrazole-1-ylphenyl, 4-(1-methylpyrazole-3-yl)phenyl, 4-(1-methylpyrazole-4-yl)phenyl, 4-(piperidine-1-yl)phenyl, 3-morpholinophenyl, 3-(8-azabicyclo[3.2.1]octan-8-yl)phenyl, 4-(8-azabicyclo[3.2.1]octan-8-yl)phenyl, 3-phenoxyphenyl or 4-phenoxyphenyl.
[0110] In a specific implementation, R 1 is a substituted or unsubstituted cyclic formula C8-C 14 It is Aryl. In a specific implementation, R 1 Eun Hwan-sik C8-C 14 It is an aryl, which is optionally substituted with one, two, or three substituents, each of which is independently a deuterium, cyano, halo, substituted, or unsubstituted C1-C 10 Alkyl, substituted or unsubstituted C1-C 10 Heteroalkyl, substituted or unsubstituted C3-C 10 Cycloalkyl, substituted or unsubstituted C6-C 14 Aryl, substituted or unsubstituted C7-C 15 arylalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocycloalkyl, -COR', -CONR'R", -OR', -NR'R", -S(O)2R' or -S(O)2NR'R"; where each R' and R" is independently hydrogen, substituted or unsubstituted C1-C 10 Alkyl, substituted or unsubstituted C1-C 10 Heteroalkyl, substituted or unsubstituted C1-C 10 Cycloalkyl, substituted or unsubstituted C6-C 14Aryl, substituted or unsubstituted C7-C 15 It is an arylalkyl, a substituted or unsubstituted heteroaryl, or a substituted or unsubstituted heterocycloalkyl. In certain embodiments, R 1 is a substituted or unsubstituted 2,3-dihydroindennal. In certain embodiments, R 1 It is a substituted or unsubstituted 2,3-dihydroindene-2-yl.
[0111] In a specific implementation, R 1 C7-C with substituted or unsubstituted 15 It is an arylalkyl. In certain embodiments, R 1 C7-C 15 It is an arylalkyl, which is optionally substituted with one, two, or three substituents, each of which is independently a deuterium, cyano, halo, oxo, substituted or unsubstituted C1-C 10 Alkyl, substituted or unsubstituted C1-C 10 Heteroalkyl, substituted or unsubstituted C3-C 10 Cycloalkyl, substituted or unsubstituted C6-C 14 Aryl, substituted or unsubstituted C7-C 15 arylalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocycloalkyl, -COR', -CONR'R", -OR', -NR'R", -S(O)2R' or -S(O)2NR'R"; where each R' and R" is independently hydrogen, substituted or unsubstituted C1-C 10 Alkyl, substituted or unsubstituted C1-C 10 Heteroalkyl, substituted or unsubstituted C1-C 10 Cycloalkyl, substituted or unsubstituted C6-C 14 Aryl, substituted or unsubstituted C7-C 15 It is an arylalkyl, a substituted or unsubstituted heteroaryl, or a substituted or unsubstituted heterocycloalkyl. In certain embodiments, R 1 is substituted or unsubstituted benzyl. In certain embodiments, R 1 It is benzyl or 3-fluorobenzyl.
[0112] In a specific implementation, R 1 is a substituted or unsubstituted heteroaryl. In certain embodiments, R 1 It is a heteroaryl, which is optionally substituted with one, two, or three substituents, each of which is independently a deuterium, cyano, halo, substituted, or unsubstituted C1-C 10 Alkyl, substituted or unsubstituted C1-C 10 Heteroalkyl, substituted or unsubstituted C3-C 10 Cycloalkyl, substituted or unsubstituted C6-C 14 Aryl, substituted or unsubstituted C7-C 15 arylalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocycloalkyl, -COR', -CONR'R", -OR', -NR'R", -S(O)2R' or -S(O)2NR'R"; where each R' and R" is independently hydrogen, substituted or unsubstituted C1-C 10 Alkyl, substituted or unsubstituted C1-C 10 Heteroalkyl, substituted or unsubstituted C1-C 10 Cycloalkyl, substituted or unsubstituted C6-C 14 Aryl, substituted or unsubstituted C7-C 15 It is an arylalkyl, a substituted or unsubstituted heteroaryl, or a substituted or unsubstituted heterocycloalkyl.
[0113] In a specific implementation, R 1 is a substituted or unsubstituted monocyclic heteroaryl. In certain embodiments, R 1 is a pentagonal or hexaagonal heteroaryl, each optionally substituted. In certain embodiments, R 1 is a substituted or unsubstituted pentagonal heteroaryl. In certain embodiments, R 1 It is a pentomer heteroaryl, and each of these is independently a deuterium, cyano, halo, substituted, or unsubstituted C1-C 10 Alkyl, substituted or unsubstituted C1-C 10 Heteroalkyl, substituted or unsubstituted C3-C 10Cycloalkyl, substituted or unsubstituted C6-C 14 Aryl, substituted or unsubstituted C7-C 15 arylalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocycloalkyl, -COR', -CONR'R", -OR', -NR'R", -S(O)2R' or -S(O)2NR'R"; where each R' and R" is independently hydrogen, substituted or unsubstituted C1-C 10 Alkyl, substituted or unsubstituted C1-C 10 Heteroalkyl, substituted or unsubstituted C1-C 10 Cycloalkyl, substituted or unsubstituted C6-C 14 Aryl, substituted or unsubstituted C7-C 15 It is an arylalkyl, a substituted or unsubstituted heteroaryl, or a substituted or unsubstituted heterocycloalkyl. In certain embodiments, R 1 is isoxazolyl, oxazolyl, pyrazolyl, thiazolyl, 1,2,4-triazolyl, 1,3,4-thiadiazolyl, tetrazolyl, each optionally substituted with one or two substituents, each of which is independently deuterium, cyano, chloro, fluoro, methyl, trifluoromethyl, isopropyl, or phenyl. In certain embodiments, R 1 is isoxazole-4-yl, oxazole-2-yl, pyrazole-3-yl, pyrazole-4-yl, thiazole-2-yl, 1,2,4-triazole-3-yl, 1,3,4-thiadiazole-2-yl, or tetrazole-5-yl, each optionally substituted with one or two substituents, each of which is independently deuterium, cyano, chloro, fluoro, methyl, trifluoromethyl, isopropyl, or phenyl. In certain embodiments, R 1is isoxazole-4-yl, oxazole-2-yl, pyrazole-4-yl, 1-methylpyrazole-3-yl, 1-methylpyrazole-4-yl, 3-methylpyrazole-4-yl, 1-(trifluoromethyl)pyrazole-4-yl, 1-(isopropyl)pyrazole-3-yl, 1-(isopropyl)pyrazole-4-yl, 1-phenylpyrazole-4-yl, thiazole-2-yl, 5-methylthiazole-2-yl, 1,2,4-triazole-3-yl, 5-methyl-1,3,4-thiadiazole-2-yl, or tetrazole-5-yl.
[0114] In a specific implementation, R 1 is a substituted or unsubstituted 6-membered heteroaryl. In certain embodiments, R 1 It is a 6-membered heteroaryl, and each of these is independently a deuterium, cyano, halo, substituted, or unsubstituted C1-C 10 Alkyl, substituted or unsubstituted C1-C 10 Heteroalkyl, substituted or unsubstituted C3-C 10 Cycloalkyl, substituted or unsubstituted C6-C 14 Aryl, substituted or unsubstituted C7-C 15 arylalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocycloalkyl, -COR', -CONR'R", -OR', -NR'R", -S(O)2R' or -S(O)2NR'R"; where each R' and R" is independently hydrogen, substituted or unsubstituted C1-C 10 Alkyl, substituted or unsubstituted C1-C 10 Heteroalkyl, substituted or unsubstituted C1-C 10 Cycloalkyl, substituted or unsubstituted C6-C 14 Aryl, substituted or unsubstituted C7-C 15 It is an arylalkyl, a substituted or unsubstituted heteroaryl, or a substituted or unsubstituted heterocycloalkyl. In certain embodiments, R 1is pyridine-2-yl, pyridine-3-yl, or pyridine-4-yl, each optionally substituted with one or two substituents, each of which is independently deuterium, cyano, chloro, fluoro, methyl, trifluoromethyl, isopropyl, or phenyl. In certain embodiments, R 1 It is pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, 2-hydroxypyridin-4-yl, or 1-methyl-2-oxo-1,2-dihydropyridin-4-yl.
[0115] In a specific implementation, R 1 is a substituted or unsubstituted cyclic heteroaryl. In certain embodiments, R 1 is a 5,5-, 5,6-, or 6,6-fused heteroaryl, each optionally substituted. In certain embodiments, R 1 is a substituted or unsubstituted 5,5-fused heteroaryl. In certain embodiments, R 1 It is a 5,5-fused heteroaryl, which is optionally substituted with one, two, or three substituents, each of which is independently a deuterium, cyano, halo, substituted, or unsubstituted C1-C 10 Alkyl, substituted or unsubstituted C1-C 10 Heteroalkyl, substituted or unsubstituted C3-C 10 Cycloalkyl, substituted or unsubstituted C6-C 14 Aryl, substituted or unsubstituted C7-C 15 arylalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocycloalkyl, -COR', -CONR'R", -OR', -NR'R", -S(O)2R' or -S(O)2NR'R"; where each R' and R" is independently hydrogen, substituted or unsubstituted C1-C 10 Alkyl, substituted or unsubstituted C1-C 10 Heteroalkyl, substituted or unsubstituted C1-C 10 Cycloalkyl, substituted or unsubstituted C6-C 14 Aryl, substituted or unsubstituted C7-C 15It is an arylalkyl, a substituted or unsubstituted heteroaryl, or a substituted or unsubstituted heterocycloalkyl. In certain embodiments, R 1 5,6-dihydrocyclopenta[ d ]thiazolyl or 6,7-dihydropyrrolo[1,2- a ] is imidazolyl, each optionally substituted with one or two substituents, each of which is independently deuterium, cyano, chloro, fluoro, methyl, trifluoromethyl, isopropyl, or phenyl. In certain embodiments, R 1 5,6-dihydrocyclopenta[ d ]thiazole-2-yl or 6,7-dihydropyrrolo[1,2- a ] It is imidazole-2-il.
[0116] In a specific implementation, R 1 is a substituted or unsubstituted 5,6-fused heteroaryl. In certain embodiments, R 1 It is a 5,6-fused heteroaryl, which is optionally substituted with one, two, or three substituents, each of which is independently a deuterium, cyano, halo, substituted, or unsubstituted C1-C 10 Alkyl, substituted or unsubstituted C1-C 10 Heteroalkyl, substituted or unsubstituted C3-C 10 Cycloalkyl, substituted or unsubstituted C6-C 14 Aryl, substituted or unsubstituted C7-C 15 arylalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocycloalkyl, -COR', -CONR'R", -OR', -NR'R", -S(O)2R' or -S(O)2NR'R"; where each R' and R" is independently hydrogen, substituted or unsubstituted C1-C 10 Alkyl, substituted or unsubstituted C1-C 10 Heteroalkyl, substituted or unsubstituted C1-C 10 Cycloalkyl, substituted or unsubstituted C6-C 14 Aryl, substituted or unsubstituted C7-C 15It is an arylalkyl, a substituted or unsubstituted heteroaryl, or a substituted or unsubstituted heterocycloalkyl. In certain embodiments, R 1 Benzofuranil, benzimidazolil, benzoxazolil, benzothiazollil, benzo[ d ][1,2,3]Triazolyl, imidazo[1,2- a ]pyridinyl, indolyl, indazolyl, pyrazolo[1,5- a ]pyridinyl, pyrrolo[2,3- b ]pyridinyl, pyrrolo[3,2- b ]pyridinyl or [1,2,4]triazolo[1,5- a ] is pyridinyl, each optionally substituted with one or two substituents, each of which is independently deuterium, cyano, chloro, fluoro, methyl, trifluoromethyl, isopropyl, or phenyl. In certain embodiments, R 1 benzofuran-6-yl, benzimidazole-5-yl, benzoxazole-2-yl, benzothiazole-2-yl, benzo[ d ][1,2,3]triazole-5-yl, imidazo[1,2- a ]pyridin-2-yl, indole-5-yl, indole-6-yl, indazole-4-yl, indazole-5-yl, indazole-6-yl, pyrazolo[1,5- a ]pyridin-6-yl, pyrrolo[2,3- b ]pyridin-5-yl, pyrrolo[3,2- b ]pyridin-2-yl, pyrrolo[3,2- b ]pyridin-6-yl or [1,2,4]triazolo[1,5- a ]pyridine-7-yl, each optionally substituted with one or two substituents, each of which is independently deuterium, cyano, chloro, fluoro, methyl, trifluoromethyl, isopropyl, or phenyl.
[0117] In a specific implementation, R 1 2,3-dihydroisoindolyl, 2,3-dihydrobenzofuranyl, 1,3-dihydroisobenzofuranyl, benzo[ d ][1,3]dioxolyl, 5,6,7,8-tetrahydroimidazo[1,2- a]pyridinyl or 4,5,6,7-tetrahydropyrazolo[1,5- a ] is pyridinyl, each optionally substituted with one or two substituents, each of which is independently deuterium, cyano, chloro, fluoro, methyl, trifluoromethyl, isopropyl, or phenyl. In certain embodiments, R 1 2,3-dihydroisoindole-5-yl, 2,3-dihydrobenzofuran-5-yl, 2,3-dihydrobenzofuran-6-yl, 1,3-dihydroisobenzofuran-5-yl, benzo[ d ][1,3]dioxol-5-yl, 5,6,7,8-tetrahydroimidazo[1,2- a ]pyridine-2-yl or 4,5,6,7-tetrahydropyrazolo[1,5- a ]pyridine-3-yl, each optionally substituted with one or two substituents, each of which is independently oxo, cyano, chloro, fluoro, methyl, trifluoromethyl, isopropyl, or phenyl.
[0118] In a specific implementation, R 1 is benzofuran-6-yl, 1-methylbenzimidazole-5-yl, 3-methylbenzimidazole-5-yl, benzoxazole-2-yl, benzothiazole-2-yl, 1-methylbenzo[ d ][1,2,3]triazole-5-yl, imidazo[1,2- a ]pyridine-2-yl, 1-methylindole-5-yl, 1-methylindole-6-yl, indazole-5-yl, 1-methylindazole-4-yl, 1-methylindazole-5-yl, 1-methylindazole-6-yl, pyrazolo[1,5- a ]pyridine-6-yl, 2,2-difluorobenzo[ d ][1,3]dioxol-5-yl, pyrrolo[2,3- b ]pyridin-5-yl, pyrrolo[3,2- b ]pyridin-2-yl, pyrrolo[3,2- b ]pyridine-6-yl, 2,2-dimethylbenzo[ d ][1,3]dioxol-5-yl, 2,2-dimethyl-2,3-dihydrobenzofuran-6-yl, [1,2,4]triazolo[1,5- a]pyridine-7-yl, 1,3-dihydroisobenzofuran-5-yl, 2,3-dihydrobenzofuran-5-yl, 3-oxo-3,4-dihydro-1,4-benzoxazine-6-yl, 2,3-dihydroindene-2-yl, 2,3-dihydroisoindole-5-yl, 3-oxo-2,3-dihydroisoindole-5-yl, 2,3-dihydrobenzofuran-6-yl, 5,6,7,8-tetrahydroimidazo[1,2- a ]pyridine-2-yl, 4,5,6,7-tetrahydropyrazolo[1,5- a ] It is pyridin-3-day.
[0119] In a specific implementation, R 1 is a substituted or unsubstituted 6,6-fused heteroaryl. In certain embodiments, R 1 It is a 6,6-fused heteroaryl, which is optionally substituted with one, two, or three substituents, each of which is independently a deuterium, cyano, halo, substituted, or unsubstituted C1-C 10 Alkyl, substituted or unsubstituted C1-C 10 Heteroalkyl, substituted or unsubstituted C3-C 10 Cycloalkyl, substituted or unsubstituted C6-C 14 Aryl, substituted or unsubstituted C7-C 15 arylalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocycloalkyl, -COR', -CONR'R", -OR', -NR'R", -S(O)2R' or -S(O)2NR'R"; where each R' and R" is independently hydrogen, substituted or unsubstituted C1-C 10 Alkyl, substituted or unsubstituted C1-C 10 Heteroalkyl, substituted or unsubstituted C1-C 10 Cycloalkyl, substituted or unsubstituted C6-C 14 Aryl, substituted or unsubstituted C7-C 15 It is an arylalkyl, a substituted or unsubstituted heteroaryl, or a substituted or unsubstituted heterocycloalkyl. In certain embodiments, R 1 It is quinolinyl, chromanyl, 3,4-dihydropyrido[3,2-b ][1,4]oxazinyl or 3,4-dihydro-1,4-benzoxazinyl, each optionally substituted with one or two substituents, each of which is independently deuterium, cyano, chloro, fluoro, methyl, trifluoromethyl, isopropyl, or phenyl. In certain embodiments, R 1 quinoline-2-yl, quinoline-3-yl, quinoline-6-yl, chroman-6-yl, chroman-7-yl, 3,4-dihydropyrido[3,2- b ][1,4]oxazine-7-yl or 3,4-dihydro-1,4-benzoxazine-6-yl, each optionally substituted with one or two substituents, each of which is independently deuterium, cyano, chloro, fluoro, methyl, trifluoromethyl, isopropyl, or phenyl. In certain embodiments, R 1 quinoline-2-yl, quinoline-3-yl, quinoline-6-yl, chroman-6-yl, chroman-7-yl, 4-methyl-3,4-dihydropyrido[3,2- b ][1,4]oxazine-7-yl or 3-oxo-3,4-dihydro-1,4-benzoxazine-6-yl.
[0120] In a specific implementation, R 1 is a substituted or unsubstituted heterocycloalkyl. In certain embodiments, R 1 It is a heterocycloalkyl, which is optionally substituted with one, two, or three substituents, each of which is independently a deuterium, cyano, halo, oxo, substituted, or unsubstituted C1-C 10 Alkyl, substituted or unsubstituted C1-C 10 Heteroalkyl, substituted or unsubstituted C3-C 10 Cycloalkyl, substituted or unsubstituted C6-C 14 Aryl, substituted or unsubstituted C7-C 15arylalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocycloalkyl, -COR', -CONR'R", -OR', -NR'R", -S(O)2R' or -S(O)2NR'R"; where each R' and R" is independently hydrogen, substituted or unsubstituted C1-C 10 Alkyl, substituted or unsubstituted C1-C 10 Heteroalkyl, substituted or unsubstituted C1-C 10 Cycloalkyl, substituted or unsubstituted C6-C 14 Aryl, substituted or unsubstituted C7-C 15 It is an arylalkyl, a substituted or unsubstituted heteroaryl, or a substituted or unsubstituted heterocycloalkyl.
[0121] In a specific implementation, R 1 is a substituted or unsubstituted monocyclic heterocycloalkyl. In certain embodiments, R 1 is a ternary, quaternary, pentary, hexavalent, or heptary heterocycloalkyl, each optionally substituted. In certain embodiments, R 1 is a ternary, quaternary, pentary, hexavalent, or heptary heterocycloalkyl, each optionally substituted with one, two, or three substituents, each of which is independently a deuterium, cyano, halo, oxo, substituted, or unsubstituted C1-C 10 Alkyl, substituted or unsubstituted C1-C 10 Heteroalkyl, substituted or unsubstituted C3-C 10 Cycloalkyl, substituted or unsubstituted C6-C 14 Aryl, substituted or unsubstituted C7-C 15 arylalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocycloalkyl, -COR', -CONR'R", -OR', -NR'R", -S(O)2R' or -S(O)2NR'R"; where each R' and R" is independently hydrogen, substituted or unsubstituted C1-C 10 Alkyl, substituted or unsubstituted C1-C 10 Heteroalkyl, substituted or unsubstituted C1-C10 Cycloalkyl, substituted or unsubstituted C6-C 14 Aryl, substituted or unsubstituted C7-C 15 It is an arylalkyl, a substituted or unsubstituted heteroaryl, or a substituted or unsubstituted heterocycloalkyl.
[0122] In a specific implementation, R 1 is a substituted or unsubstituted 6-membered heterocycloalkyl. In certain embodiments, R 1 is a hexavalent heterocycloalkyl, optionally substituted with one, two, or three substituents, each of which is independently a deuterium, cyano, halo, oxo, substituted, or unsubstituted C1-C 10 Alkyl, substituted or unsubstituted C1-C 10 Heteroalkyl, substituted or unsubstituted C3-C 10 Cycloalkyl, substituted or unsubstituted C6-C 14 Aryl, substituted or unsubstituted C7-C 15 arylalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocycloalkyl, -COR', -CONR'R", -OR', -NR'R", -S(O)2R' or -S(O)2NR'R"; where each R' and R" is independently hydrogen, substituted or unsubstituted C1-C 10 Alkyl, substituted or unsubstituted C1-C 10 Heteroalkyl, substituted or unsubstituted C1-C 10 Cycloalkyl, substituted or unsubstituted C6-C 14 Aryl, substituted or unsubstituted C7-C 15 It is an arylalkyl, a substituted or unsubstituted heteroaryl, or a substituted or unsubstituted heterocycloalkyl.
[0123] In a specific implementation, R 1is azatidinyl, oxanyl, piperidinyl, tetrahydrothiopyranill, 2-azaspiro[3.3]heptanyl, 2-azaspiro[3.5]nonanyl, 3-azaspiro[5.5]undecanyl, or 8-azabicyclo[3.2.1]octanyl, each optionally substituted with one or two substituents, each of which is independently oxo, cyano, chloro, fluoro, methyl, trifluoromethyl, isopropyl, phenyl, or pyridinyl. In certain embodiments, R 1 is azetidin-3-yl, oxane-2-yl, oxane-3-yl, piperidin-3-yl, piperidin-4-yl, tetrahydrothiopyran-4-yl, 2-azaspiro[3.3]heptane-6-yl, 2-azaspiro[3.5]nonane-7-yl, 3-azaspiro[5.5]undecane-9-yl, or 8-azabicyclo[3.2.1]octane-3-yl, each optionally substituted with one or two substituents, each of which is independently oxo, cyano, chloro, fluoro, methyl, trifluoromethyl, isopropyl, phenyl, pyridin-2-yl, pyridin-3-yl, or pyridin-4-yl. In certain embodiments, R 1 1-phenylazetidin-3-yl, oxane-2-yl, oxane-3-yl, piperidin-4-yl, 1-(isopropyl)piperidin-4-yl, 1-phenylpiperidin-3-yl, 1-phenylpiperidin-4-yl, 1-(2-chlorophenyl)piperidin-4-yl, 1-(3-chlorophenyl)piperidin-4-yl, 1-(4-chlorophenyl)piperidin-4-yl, 1-benzylpiperidin-4-yl, 1-(pyridin-3-yl)piperidin-4-yl, 1-(pyridin-2-yl)piperidin-4-yl, 1-acetylpiperidin-4-yl, 1,1-deoxydotetrahydrothiopyran-4-yl, It is 2-azaspiro[3.3]heptane-6-yl, 2-azaspiro[3.5]nonane-7-yl, 8-phenyl-8-azabicyclo[3.2.1]octane-3-yl, or 3-azaspiro[5.5]undecane-9-yl. In certain embodiments, R 1 It is 1-phenylpiperidin-3-yl, 1-phenylpiperidin-4-yl, 1-(3-chlorophenyl)piperidin-4-yl, or 1-(4-chlorophenyl)piperidin-4-yl.
[0124] In another embodiment, the present invention provides a compound having the structure of the following formula (IV) or a mirror image isomer thereof, a mixture of mirror image isomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, or a mixture of two or more tautomers; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; or a pharmaceutically acceptable derivative thereof:
[0125]
[0126] Here:
[0127] R 1a , R 1b , R 1c , R 1d and R 1e Each is independently H, deuterium, cyano, halo, substituted, or unsubstituted C1-C 10 Alkyl, substituted or unsubstituted C1-C 10 Heteroalkyl, substituted or unsubstituted C3-C 10 Cycloalkyl, substituted or unsubstituted C6-C 14 Aryl, substituted or unsubstituted C7-C 15 arylalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocycloalkyl, -COR', -CONR'R", -OR', -NR'R", -S(O)2R' or -S(O)2NR'R"; where each R' and R" is independently hydrogen, substituted or unsubstituted C1-C 10 Alkyl, substituted or unsubstituted C1-C 10 Heteroalkyl, substituted or unsubstituted C1-C 10 Cycloalkyl, substituted or unsubstituted C6-C 14 Aryl, substituted or unsubstituted C7-C 15 arylalkyl, substituted or unsubstituted heteroaryl, or substituted or unsubstituted heterocycloalkyl; R 1a and R 1bis formed with the carbon atoms to which they are attached a substituted or unsubstituted heteroaryl or a substituted or unsubstituted heterocycloalkyl; R 1b and R 1c , together with the carbon atoms to which they are attached, form a substituted or unsubstituted heteroaryl or a substituted or unsubstituted heterocycloalkyl;
[0128] R 2 , R 3 , R 4 , R 5 , R 13 , c and d are each as defined herein.
[0129] In another embodiment, the present invention provides a compound having the structure of the following formula (V) or a mirror image isomer thereof, a mixture of mirror image isomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, or a mixture of two or more tautomers; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; or a pharmaceutically acceptable derivative thereof:
[0130]
[0131] Here, R 2 , R 3 , R 4 , R 5 , R 13 , R 1a , R 1b , R 1c , R 1d and R 1e Each is as defined herein.
[0132] In another embodiment, the present invention provides a compound having the structure of the following formula (VI) or a mirror image isomer thereof, a mixture of mirror image isomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, or a mixture of two or more tautomers; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; or a pharmaceutically acceptable derivative thereof:
[0133]
[0134] Here, R 2 , R 3 , R 4 , R 5 , R 13 , R 1a , R 1b , R 1c , R 1d and R 1e Each is as defined herein.
[0135] In another embodiment, the present invention provides a compound having the structure of the following formula (VII) or a mirror image isomer thereof, a mixture of mirror image isomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, or a mixture of two or more tautomers; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; or a pharmaceutically acceptable derivative thereof:
[0136]
[0137] Here, R 2 , R 3 , R 4 , R 5 , R 13 , R 1a , R 1b , R 1c , R 1d and R 1e Each is as defined herein.
[0138] In a specific implementation, R 1a , R 1b , R1c , R 1d and R 1e Each is independently H, deuterium, cyano, halo, substituted, or unsubstituted C1-C 10 Alkyl, substituted or unsubstituted C1-C 10 Heteroalkyl, substituted or unsubstituted C3-C 10 Cycloalkyl, substituted or unsubstituted C6-C 14 Aryl, substituted or unsubstituted C7-C 15 arylalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocycloalkyl, -COR', -CONR'R", -OR', -NR'R", -S(O)2R' or -S(O)2NR'R"; where each R' and R" is independently hydrogen, substituted or unsubstituted C1-C 10 Alkyl, substituted or unsubstituted C1-C 10 Heteroalkyl, substituted or unsubstituted C1-C 10 Cycloalkyl, substituted or unsubstituted C6-C 14 Aryl, substituted or unsubstituted C7-C 15 It is an arylalkyl, a substituted or unsubstituted heteroaryl, or a substituted or unsubstituted heterocycloalkyl.
[0139] In a specific implementation, R 1a is H, deuterium, cyano, halo, substituted or unsubstituted C1-C 10 Alkyl, substituted or unsubstituted C1-C 10 Heteroalkyl, substituted or unsubstituted C3-C 10 Cycloalkyl, substituted or unsubstituted C6-C 14 Aryl, substituted or unsubstituted C7-C 15 arylalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocycloalkyl, -COR', -CONR'R", -OR', -NR'R", -S(O)2R' or -S(O)2NR'R"; where each R' and R" is independently hydrogen, substituted or unsubstituted C1-C 10 Alkyl, substituted or unsubstituted C1-C 10Heteroalkyl, substituted or unsubstituted C1-C 10 Cycloalkyl, substituted or unsubstituted C6-C 14 Aryl, substituted or unsubstituted C7-C 15 It is an arylalkyl, a substituted or unsubstituted heteroaryl, or a substituted or unsubstituted heterocycloalkyl.
[0140] In a specific implementation, R 1a is H. In a specific embodiment, R 1a is deuterium. In a specific embodiment, R 1a is cyano. In a specific embodiment, R 1a is a halo. In a specific implementation, R 1a is fluoro or chloro. In certain embodiments, R 1a is a fluoro. In a specific embodiment, R 1a is chloro. In certain embodiments, R 1a is substituted or unsubstituted C1-C 10 It is an alkyl. In a specific embodiment, R 1a is methyl, ethyl, propyl, or butyl, each optionally substituted. In certain embodiments, R 1a is methyl, trifluoromethyl, ethyl, 1,1-difluoroethyl, isopropyl, tert -butyl, oxane-4-ylmethyl, morpholinomethyl, hydroxymethyl, methoxymethyl, phenoxymethyl, or dimethylaminomethyl. In certain embodiments, R 1a is methyl, trifluoromethyl, ethyl, difluoroethyl, propyl, butyl, oxanylmethyl, morpholinomethyl, hydroxymethyl, methoxymethyl, phenoxymethyl, or dimethylaminomethyl. In certain embodiments, R 1a is substituted or unsubstituted C1-C 10 It is a heteroalkyl.
[0141] In a specific implementation, R 1a is substituted or unsubstituted C3-C 10 It is a cycloalkyl. In certain embodiments, R 1ais cyclobutyl or cyclohexyl, each optionally substituted. In certain embodiments, R 1a is substituted or unsubstituted C6-C 14 It is Aryl. In a specific implementation, R 1a is a substituted or unsubstituted phenyl. In certain embodiments, R 1a is substituted or unsubstituted C7-C 15 It is an arylalkyl. In certain embodiments, R 1a is a substituted or unsubstituted heteroaryl. In certain embodiments, R 1a is a substituted or unsubstituted monocyclic heteroaryl. In certain embodiments, R 1a is a pentagonal or hexaagonal heteroaryl, each optionally substituted. In certain embodiments, R 1a is a substituted or unsubstituted 5-membered heteroaryl. In certain embodiments, R 1a is a substituted or unsubstituted pyrazolyl. In certain embodiments, R 1a is pyrazole-1-yl, pyrazole-3-yl, or pyrazole-4-yl, each optionally substituted. In a specific embodiment, R 1a is pyrazole-1-yl, pyrazole-3-yl, or pyrazole-4-yl, and each is a substituted or unsubstituted C1-C 10 It is optionally substituted with an alkyl group. In certain embodiments, R 1a is pyrazole-1-yl, 1-methylpyrazole-3-yl, 2-methylpyrazole-3-yl, or 1-methylpyrazole-4-yl. In certain embodiments, R 1a is pyrazole-1-yl, 1-methylpyrazole-3-yl, or 1-methylpyrazole-4-yl. In certain embodiments, R 1a is a substituted or unsubstituted 6-membered heteroaryl.
[0142] In a specific implementation, R 1a is a substituted or unsubstituted heterocycloalkyl. In certain embodiments, R 1a is a substituted or unsubstituted monocyclic heterocycloalkyl. In certain embodiments, R 1ais a ternary, quaternary, pentary, hexavalent, or heptary heterocycloalkyl, each optionally substituted. In certain embodiments, R 1a is a substituted or unsubstituted ternary heterocycloalkyl. In certain embodiments, R 1a is a substituted or unsubstituted quaternary heterocycloalkyl. In certain embodiments, R 1a is a substituted or unsubstituted pentomer heterocycloalkyl. In certain embodiments, R 1a is a substituted or unsubstituted 6-membered heterocycloalkyl. In certain embodiments, R 1a is a substituted or unsubstituted 7-membered heterocycloalkyl. In certain embodiments, R 1a is oxetanyl, oxanyl, piperidinyl, or morpholino, each optionally substituted. In certain embodiments, R 1a is oxetane-3-yl, oxane-4-yl, piperidine-1-yl, or morpholino, each optionally substituted. In certain embodiments, R 1a is oxetane-3-yl, oxane-4-yl, piperidin-1-yl, 4,4-difluoropiperidin-1-yl, 4-(hydroxymethyl)piperidin-1-yl, 4-hydroxypiperidin-1-yl, or morpholino. In certain embodiments, R 1a is piperidin-1-yl or morpholino.
[0143] In a specific implementation, R 1a is a substituted or unsubstituted heterocycloalkyl. In certain embodiments, R 1a is a crosslinked, fused, or spiro heterocycloalkyl, each optionally substituted. In certain embodiments, R 1a is a substituted or unsubstituted crosslinked heterocycloalkyl. In certain embodiments, R 1a is a substituted or unsubstituted 8-azabicyclo[3.2.1]octanyl. In certain embodiments, R 1a is a substituted or unsubstituted 8-azabicyclo[3.2.1]octane-8-yl. In certain embodiments, R 1ais a substituted or unsubstituted fused heterocycloalkyl. In certain embodiments, R 1a is a substituted or unsubstituted heterocycloalkyl.
[0144] In a specific implementation, R 1a is -COR', where R' is as defined herein. In certain embodiments, R 1a is -COR', where R' is the substituted or unsubstituted C1-C 10 It is an alkyl. In a specific embodiment, R 1a is -CONR'R", where R' and R" are each as defined herein. In certain embodiments, R 1a is -CONR'R", where R' and R" are independently H or substituted or unsubstituted C1-C 10 It is an alkyl. In a specific embodiment, R 1a is -OR', where R' is as defined herein. In certain embodiments, R 1a is -OR', where R' is independently H, substituted or unsubstituted C1-C 10 Alkyl or substituted or unsubstituted C6-C 14 It is Aryl. In a specific implementation, R 1a is -NR'R", where R' and R" are each as defined herein. In certain embodiments, R 1a is -NR'R", where R' and R" are independently H or substituted or unsubstituted C1-C 10 It is an alkyl. In a specific embodiment, R 1a is -S(O)2R', where R' is as defined herein. In certain embodiments, R 1a is -S(O)2R', where R' is the substituted or unsubstituted C1-C 10 It is an alkyl. In a specific embodiment, R 1a is -S(O)2NR'R"; where R' and R" are each as defined herein. In a specific embodiment, R 1ais -S(O)2NR'R"; where R' and R" are each independently H or substituted or unsubstituted C1-C 10 It is an alkyl.
[0145] In a specific implementation, R 1a is H, cyano, chloro, fluoro, methyl, trifluoromethyl, ethyl, difluoroethyl, propyl, butyl, oxanylmethyl, morpholinomethyl, hydroxymethyl, methoxymethyl, phenoxymethyl, dimethylaminomethyl, cyclobutyl, cyclohexyl, phenyl, pyrazolyl, methylpyrazolyl, oxetanyl, piperidinyl, difluoropiperidinyl, (hydroxymethyl)piperidinyl, hydroxypiperidinyl, oxanyl, morpholino, 8-azabicyclo[3.2.1]octanyl, hydroxyl, methoxy, trifluoromethoxy, hydroxyethoxy, phenoxy, benzoxy, oxanyloxy, piperidinyloxy, amino, dimethylamino, phenylamino, aminocarbonyl, methylaminocarbonyl, dimethylaminocarbonyl, methylsulfonyl or aminosulfonyl. In a specific implementation, R 1a is H, cyano, chloro, fluoro, methyl, trifluoromethyl, ethyl, difluoroethyl, propyl, butyl, oxanylmethyl, methoxymethyl, phenoxymethyl, phenyl, pyrazolyl, methylpyrazolyl, piperidinyl, morpholino, 8-azabicyclo[3.2.1]octanyl or phenoxy.
[0146] In a specific implementation, R 1a is H, cyano, chloro, fluoro, methyl, trifluoromethyl, ethyl, 1,1-difluoroethyl, isopropyl, tert -Butyl, oxane-4-ylmethyl, morpholinomethyl, hydroxymethyl, methoxymethyl, phenoxymethyl, dimethylaminomethyl, cyclobutyl, cyclohexyl, phenyl, pyrazole-1-yl, 1-methylpyrazole-3-yl, 1-methylpyrazole-4-yl, 2-methylpyrazole-3-yl, oxetane-3-yl, oxane-4-yl, piperidine-1-yl, 4,4-difluoropiperidin-1-yl, 4-(hydroxymethyl)piperidin-1-yl, 4-hydroxypiperidin-1-yl, morpholino, 8-azabicyclo[3.2.1]octane-8-yl, hydroxyl, methoxy, trifluoromethoxy, 2-hydroxyethoxy, phenoxy, benzoxy, piperidine-4-yloxy, oxane-4-yloxy, It is amino, dimethylamino, phenylamino, aminocarbonyl, methylaminocarbonyl, dimethylaminocarbonyl, methylsulfonyl, or aminosulfonyl. In certain embodiments, R 1a is H, cyano, chloro, fluoro, methyl, trifluoromethyl, ethyl, 1,1-difluoroethyl, isopropyl, tert -butyl, oxane-4-ylmethyl, methoxymethyl, phenyl, pyrazole-1-yl, 1-methylpyrazole-3-yl, 1-methylpyrazole-4-yl, piperidine-1-yl, morpholino, 8-azabicyclo[3.2.1]octane-8-yl or phenoxy.
[0147] In a specific implementation, R 1b is H, deuterium, cyano, halo, substituted or unsubstituted C1-C 10 Alkyl, substituted or unsubstituted C1-C 10 Heteroalkyl, substituted or unsubstituted C3-C 10 Cycloalkyl, substituted or unsubstituted C6-C 14 Aryl, substituted or unsubstituted C7-C 15 arylalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocycloalkyl, -COR', -CONR'R", -OR', -NR'R", -S(O)2R' or -S(O)2NR'R"; where each R' and R" is independently hydrogen, substituted or unsubstituted C1-C 10 Alkyl, substituted or unsubstituted C1-C10 Heteroalkyl, substituted or unsubstituted C1-C 10 Cycloalkyl, substituted or unsubstituted C6-C 14 Aryl, substituted or unsubstituted C7-C 15 It is an arylalkyl, a substituted or unsubstituted heteroaryl, or a substituted or unsubstituted heterocycloalkyl.
[0148] In a specific implementation, R 1b is H. In a specific embodiment, R 1b is deuterium. In a specific embodiment, R 1b is cyano. In a specific embodiment, R 1b is a halo. In a specific implementation, R 1b is fluoro or chloro. In certain embodiments, R 1b is a fluoro. In a specific embodiment, R 1b is chloro. In certain embodiments, R 1b is substituted or unsubstituted C1-C 10 It is an alkyl. In a specific embodiment, R 1b is methyl, ethyl, propyl, or butyl, each optionally substituted. In certain embodiments, R 1b is methyl, trifluoromethyl, ethyl, 1,1-difluoroethyl, isopropyl, tert -butyl, oxane-4-ylmethyl, morpholinomethyl, hydroxymethyl, methoxymethyl, phenoxymethyl, or dimethylaminomethyl. In certain embodiments, R 1b is methyl, trifluoromethyl, ethyl, difluoroethyl, propyl, butyl, oxanylmethyl, morpholinomethyl, hydroxymethyl, methoxymethyl, phenoxymethyl, or dimethylaminomethyl. In certain embodiments, R 1b is substituted or unsubstituted C1-C 10 It is a heteroalkyl.
[0149] In a specific implementation, R 1b is substituted or unsubstituted C3-C 10 It is a cycloalkyl. In certain embodiments, R 1bis cyclobutyl or cyclohexyl, each optionally substituted. In certain embodiments, R 1b is substituted or unsubstituted C6-C 14 It is Aryl. In a specific implementation, R 1b is a substituted or unsubstituted phenyl. In certain embodiments, R 1b is substituted or unsubstituted C7-C 15 It is an arylalkyl. In certain embodiments, R 1b is a substituted or unsubstituted heteroaryl. In certain embodiments, R 1b is a substituted or unsubstituted monocyclic heteroaryl. In certain embodiments, R 1b is a pentagonal or hexaagonal heteroaryl, each optionally substituted. In certain embodiments, R 1b is a substituted or unsubstituted 5-membered heteroaryl. In certain embodiments, R 1b is a substituted or unsubstituted pyrazolyl. In certain embodiments, R 1b is pyrazole-1-yl, pyrazole-3-yl, or pyrazole-4-yl, each optionally substituted. In a specific embodiment, R 1b is pyrazole-1-yl, pyrazole-3-yl, or pyrazole-4-yl, and each is a substituted or unsubstituted C1-C 10 It is optionally substituted with an alkyl group. In certain embodiments, R 1b is pyrazole-1-yl, 1-methylpyrazole-3-yl, 2-methylpyrazole-3-yl, or 1-methylpyrazole-4-yl. In certain embodiments, R 1b is pyrazole-1-yl, 1-methylpyrazole-3-yl, or 1-methylpyrazole-4-yl. In certain embodiments, R 1b is a substituted or unsubstituted 6-membered heteroaryl.
[0150] In a specific implementation, R 1b is a substituted or unsubstituted heterocycloalkyl. In certain embodiments, R 1b is a substituted or unsubstituted monocyclic heterocycloalkyl. In certain embodiments, R 1bis a ternary, quaternary, pentary, hexavalent, or heptary heterocycloalkyl, each optionally substituted. In certain embodiments, R 1b is a substituted or unsubstituted ternary heterocycloalkyl. In certain embodiments, R 1b is a substituted or unsubstituted quaternary heterocycloalkyl. In certain embodiments, R 1b is a substituted or unsubstituted pentomer heterocycloalkyl. In certain embodiments, R 1b is a substituted or unsubstituted 6-membered heterocycloalkyl. In certain embodiments, R 1b is a substituted or unsubstituted 7-membered heterocycloalkyl. In certain embodiments, R 1b is oxetanyl, oxanyl, piperidinyl, or morpholino, each optionally substituted. In certain embodiments, R 1b is oxetane-3-yl, oxane-4-yl, piperidine-1-yl, or morpholino, each optionally substituted. In certain embodiments, R 1b is oxetane-3-yl, oxane-4-yl, piperidin-1-yl, 4,4-difluoropiperidin-1-yl, 4-(hydroxymethyl)piperidin-1-yl, 4-hydroxypiperidin-1-yl, or morpholino. In certain embodiments, R 1b is piperidin-1-yl or morpholino.
[0151] In a specific implementation, R 1b is a substituted or unsubstituted heterocycloalkyl. In certain embodiments, R 1b is a crosslinked, fused, or spiro heterocycloalkyl, each optionally substituted. In certain embodiments, R 1b is a substituted or unsubstituted crosslinked heterocycloalkyl. In certain embodiments, R 1b is a substituted or unsubstituted 8-azabicyclo[3.2.1]octanyl. In certain embodiments, R 1b is a substituted or unsubstituted 8-azabicyclo[3.2.1]octane-8-yl. In certain embodiments, R 1bis a substituted or unsubstituted fused heterocycloalkyl. In certain embodiments, R 1b is a substituted or unsubstituted heterocycloalkyl.
[0152] In a specific implementation, R 1b is -COR', where R' is as defined herein. In certain embodiments, R 1b is -COR', where R' is the substituted or unsubstituted C1-C 10 It is an alkyl. In a specific embodiment, R 1b is -CONR'R", where R' and R" are each as defined herein. In certain embodiments, R 1b is -CONR'R", where R' and R" are independently H or substituted or unsubstituted C1-C 10 It is an alkyl. In a specific embodiment, R 1b is -OR', where R' is as defined herein. In certain embodiments, R 1b is -OR', where R' is independently H, substituted or unsubstituted C1-C 10 Alkyl or substituted or unsubstituted C6-C 14 It is Aryl. In a specific implementation, R 1b is -NR'R", where R' and R" are each as defined herein. In certain embodiments, R 1b is -NR'R", where R' and R" are independently H or substituted or unsubstituted C1-C 10 It is an alkyl. In a specific embodiment, R 1b is -S(O)2R', where R' is as defined herein. In certain embodiments, R 1b is -S(O)2R', where R' is the substituted or unsubstituted C1-C 10 It is an alkyl. In a specific embodiment, R 1b is -S(O)2NR'R"; where R' and R" are each as defined herein. In a specific embodiment, R 1bis -S(O)2NR'R"; where R' and R" are each independently H or substituted or unsubstituted C1-C 10 It is an alkyl.
[0153] In a specific implementation, R 1b is H, cyano, chloro, fluoro, methyl, trifluoromethyl, ethyl, difluoroethyl, propyl, butyl, oxanylmethyl, morpholinomethyl, hydroxymethyl, methoxymethyl, phenoxymethyl, dimethylaminomethyl, cyclobutyl, cyclohexyl, phenyl, pyrazolyl, methylpyrazolyl, oxetanyl, piperidinyl, difluoropiperidinyl, (hydroxymethyl)piperidinyl, hydroxypiperidinyl, oxanyl, morpholino, 8-azabicyclo[3.2.1]octanyl, hydroxyl, methoxy, trifluoromethoxy, hydroxyethoxy, phenoxy, benzoxy, oxanyloxy, piperidinyloxy, amino, dimethylamino, phenylamino, aminocarbonyl, methylaminocarbonyl, dimethylaminocarbonyl, methylsulfonyl or aminosulfonyl. In a specific implementation, R 1b is H, cyano, chloro, fluoro, methyl, trifluoromethyl, ethyl, difluoroethyl, propyl, butyl, oxanylmethyl, methoxymethyl, phenoxymethyl, phenyl, pyrazolyl, methylpyrazolyl, piperidinyl, morpholino, 8-azabicyclo[3.2.1]octanyl or phenoxy.
[0154] In a specific implementation, R 1b is H, cyano, chloro, fluoro, methyl, trifluoromethyl, ethyl, 1,1-difluoroethyl, isopropyl, tert -Butyl, oxane-4-ylmethyl, morpholinomethyl, hydroxymethyl, methoxymethyl, phenoxymethyl, dimethylaminomethyl, cyclobutyl, cyclohexyl, phenyl, pyrazole-1-yl, 1-methylpyrazole-3-yl, 1-methylpyrazole-4-yl, 2-methylpyrazole-3-yl, oxetane-3-yl, oxane-4-yl, piperidine-1-yl, 4,4-difluoropiperidin-1-yl, 4-(hydroxymethyl)piperidin-1-yl, 4-hydroxypiperidin-1-yl, morpholino, 8-azabicyclo[3.2.1]octane-8-yl, hydroxyl, methoxy, trifluoromethoxy, 2-hydroxyethoxy, phenoxy, benzoxy, piperidine-4-yloxy, oxane-4-yloxy, It is amino, dimethylamino, phenylamino, aminocarbonyl, methylaminocarbonyl, dimethylaminocarbonyl, methylsulfonyl, or aminosulfonyl. In certain embodiments, R 1b is H, cyano, chloro, fluoro, methyl, trifluoromethyl, ethyl, 1,1-difluoroethyl, isopropyl, tert -butyl, oxane-4-ylmethyl, methoxymethyl, phenyl, pyrazole-1-yl, 1-methylpyrazole-3-yl, 1-methylpyrazole-4-yl, piperidine-1-yl, morpholino, 8-azabicyclo[3.2.1]octane-8-yl or phenoxy.
[0155] In a specific implementation, R 1c is H, deuterium, cyano, halo, substituted or unsubstituted C1-C 10 Alkyl, substituted or unsubstituted C1-C 10 Heteroalkyl, substituted or unsubstituted C3-C 10 Cycloalkyl, substituted or unsubstituted C6-C 14 Aryl, substituted or unsubstituted C7-C 15 arylalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocycloalkyl, -COR', -CONR'R", -OR', -NR'R", -S(O)2R' or -S(O)2NR'R"; where each R' and R" is independently hydrogen, substituted or unsubstituted C1-C 10 Alkyl, substituted or unsubstituted C1-C10 Heteroalkyl, substituted or unsubstituted C1-C 10 Cycloalkyl, substituted or unsubstituted C6-C 14 Aryl, substituted or unsubstituted C7-C 15 It is an arylalkyl, a substituted or unsubstituted heteroaryl, or a substituted or unsubstituted heterocycloalkyl.
[0156] In a specific implementation, R 1c is H. In a specific embodiment, R 1c is deuterium. In a specific embodiment, R 1c is cyano. In a specific embodiment, R 1c is a halo. In a specific implementation, R 1c is fluoro or chloro. In certain embodiments, R 1c is a fluoro. In a specific embodiment, R 1c is chloro. In certain embodiments, R 1c is substituted or unsubstituted C1-C 10 It is an alkyl. In a specific embodiment, R 1c is methyl, ethyl, propyl, or butyl, each optionally substituted. In certain embodiments, R 1c is methyl, trifluoromethyl, ethyl, 1,1-difluoroethyl, isopropyl, tert -butyl, oxane-4-ylmethyl, morpholinomethyl, hydroxymethyl, methoxymethyl, phenoxymethyl, or dimethylaminomethyl. In certain embodiments, R 1c is methyl, trifluoromethyl, ethyl, difluoroethyl, propyl, butyl, oxanylmethyl, morpholinomethyl, hydroxymethyl, methoxymethyl, phenoxymethyl, or dimethylaminomethyl. In certain embodiments, R 1c is substituted or unsubstituted C1-C 10 It is a heteroalkyl.
[0157] In a specific implementation, R 1c is substituted or unsubstituted C3-C 10 It is a cycloalkyl. In certain embodiments, R 1cis cyclobutyl or cyclohexyl, each optionally substituted. In certain embodiments, R 1c is substituted or unsubstituted C6-C 14 It is Aryl. In a specific implementation, R 1c is a substituted or unsubstituted phenyl. In certain embodiments, R 1c is substituted or unsubstituted C7-C 15 It is an arylalkyl. In certain embodiments, R 1c is a substituted or unsubstituted heteroaryl. In certain embodiments, R 1c is a substituted or unsubstituted monocyclic heteroaryl. In certain embodiments, R 1c is a pentagonal or hexaagonal heteroaryl, each optionally substituted. In certain embodiments, R 1c is a substituted or unsubstituted 5-membered heteroaryl. In certain embodiments, R 1c is a substituted or unsubstituted pyrazolyl. In certain embodiments, R 1c is pyrazole-1-yl, pyrazole-3-yl, or pyrazole-4-yl, each optionally substituted. In a specific embodiment, R 1c is pyrazole-1-yl, pyrazole-3-yl, or pyrazole-4-yl, and each is a substituted or unsubstituted C1-C 10 It is optionally substituted with an alkyl group. In certain embodiments, R 1c is pyrazole-1-yl, 1-methylpyrazole-3-yl, 2-methylpyrazole-3-yl, or 1-methylpyrazole-4-yl. In certain embodiments, R 1c is pyrazole-1-yl, 1-methylpyrazole-3-yl, or 1-methylpyrazole-4-yl. In certain embodiments, R 1c is a substituted or unsubstituted 6-membered heteroaryl.
[0158] In a specific implementation, R 1c is a substituted or unsubstituted heterocycloalkyl. In certain embodiments, R 1c is a substituted or unsubstituted monocyclic heterocycloalkyl. In certain embodiments, R 1cis a ternary, quaternary, pentary, hexavalent, or heptary heterocycloalkyl, each optionally substituted. In certain embodiments, R 1c is a substituted or unsubstituted ternary heterocycloalkyl. In certain embodiments, R 1c is a substituted or unsubstituted quaternary heterocycloalkyl. In certain embodiments, R 1c is a substituted or unsubstituted pentomer heterocycloalkyl. In certain embodiments, R 1c is a substituted or unsubstituted 6-membered heterocycloalkyl. In certain embodiments, R 1c is a substituted or unsubstituted 7-membered heterocycloalkyl. In certain embodiments, R 1c is oxetanyl, oxanyl, piperidinyl, or morpholino, each optionally substituted. In certain embodiments, R 1c is oxetane-3-yl, oxane-4-yl, piperidine-1-yl, or morpholino, each optionally substituted. In certain embodiments, R 1c is oxetane-3-yl, oxane-4-yl, piperidin-1-yl, 4,4-difluoropiperidin-1-yl, 4-(hydroxymethyl)piperidin-1-yl, 4-hydroxypiperidin-1-yl, or morpholino. In certain embodiments, R 1c is piperidin-1-yl or morpholino.
[0159] In a specific implementation, R 1c is a substituted or unsubstituted heterocycloalkyl. In certain embodiments, R 1c is a crosslinked, fused, or spiro heterocycloalkyl, each optionally substituted. In certain embodiments, R 1c is a substituted or unsubstituted crosslinked heterocycloalkyl. In certain embodiments, R 1c is a substituted or unsubstituted 8-azabicyclo[3.2.1]octanyl. In certain embodiments, R 1c is a substituted or unsubstituted 8-azabicyclo[3.2.1]octane-8-yl. In certain embodiments, R 1cis a substituted or unsubstituted fused heterocycloalkyl. In certain embodiments, R 1c is a substituted or unsubstituted heterocycloalkyl.
[0160] In a specific implementation, R 1c is -COR', where R' is as defined herein. In certain embodiments, R 1c is -COR', where R' is the substituted or unsubstituted C1-C 10 It is an alkyl. In a specific embodiment, R 1c is -CONR'R", where R' and R" are each as defined herein. In certain embodiments, R 1c is -CONR'R", where R' and R" are independently H or substituted or unsubstituted C1-C 10 It is an alkyl. In a specific embodiment, R 1c is -OR', where R' is as defined herein. In certain embodiments, R 1c is -OR', where R' is independently H, substituted or unsubstituted C1-C 10 Alkyl or substituted or unsubstituted C6-C 14 It is Aryl. In a specific implementation, R 1c is -NR'R", where R' and R" are each as defined herein. In certain embodiments, R 1c is -NR'R", where R' and R" are independently H or substituted or unsubstituted C1-C 10 It is an alkyl. In a specific embodiment, R 1c is -S(O)2R', where R' is as defined herein. In certain embodiments, R 1c is -S(O)2R', where R' is the substituted or unsubstituted C1-C 10 It is an alkyl. In a specific embodiment, R 1c is -S(O)2NR'R"; where R' and R" are each as defined herein. In a specific embodiment, R 1cis -S(O)2NR'R"; where R' and R" are each independently H or substituted or unsubstituted C1-C 10 It is an alkyl.
[0161] In a specific implementation, R 1c is H, cyano, chloro, fluoro, methyl, trifluoromethyl, ethyl, difluoroethyl, propyl, butyl, oxanylmethyl, morpholinomethyl, hydroxymethyl, methoxymethyl, phenoxymethyl, dimethylaminomethyl, cyclobutyl, cyclohexyl, phenyl, pyrazolyl, methylpyrazolyl, oxetanyl, piperidinyl, difluoropiperidinyl, (hydroxymethyl)piperidinyl, hydroxypiperidinyl, oxanyl, morpholino, 8-azabicyclo[3.2.1]octanyl, hydroxyl, methoxy, trifluoromethoxy, hydroxyethoxy, phenoxy, benzoxy, oxanyloxy, piperidinyloxy, amino, dimethylamino, phenylamino, aminocarbonyl, methylaminocarbonyl, dimethylaminocarbonyl, methylsulfonyl or aminosulfonyl. In a specific implementation, R 1c is H, cyano, chloro, fluoro, methyl, trifluoromethyl, ethyl, difluoroethyl, propyl, butyl, oxanylmethyl, methoxymethyl, phenoxymethyl, phenyl, pyrazolyl, methylpyrazolyl, piperidinyl, morpholino, 8-azabicyclo[3.2.1]octanyl or phenoxy.
[0162] In a specific implementation, R 1c is H, cyano, chloro, fluoro, methyl, trifluoromethyl, ethyl, 1,1-difluoroethyl, isopropyl, tert -Butyl, oxane-4-ylmethyl, morpholinomethyl, hydroxymethyl, methoxymethyl, phenoxymethyl, dimethylaminomethyl, cyclobutyl, cyclohexyl, phenyl, pyrazole-1-yl, 1-methylpyrazole-3-yl, 1-methylpyrazole-4-yl, 2-methylpyrazole-3-yl, oxetane-3-yl, oxane-4-yl, piperidine-1-yl, 4,4-difluoropiperidin-1-yl, 4-(hydroxymethyl)piperidin-1-yl, 4-hydroxypiperidin-1-yl, morpholino, 8-azabicyclo[3.2.1]octane-8-yl, hydroxyl, methoxy, trifluoromethoxy, 2-hydroxyethoxy, phenoxy, benzoxy, piperidine-4-yloxy, oxane-4-yloxy, It is amino, dimethylamino, phenylamino, aminocarbonyl, methylaminocarbonyl, dimethylaminocarbonyl, methylsulfonyl, or aminosulfonyl. In certain embodiments, R 1c is H, cyano, chloro, fluoro, methyl, trifluoromethyl, ethyl, 1,1-difluoroethyl, isopropyl, tert -butyl, oxane-4-ylmethyl, methoxymethyl, phenyl, pyrazole-1-yl, 1-methylpyrazole-3-yl, 1-methylpyrazole-4-yl, piperidine-1-yl, morpholino, 8-azabicyclo[3.2.1]octane-8-yl or phenoxy.
[0163] In a specific implementation, R 1d is H, deuterium, cyano, halo, substituted or unsubstituted C1-C 10 Alkyl, substituted or unsubstituted C1-C 10 Heteroalkyl, substituted or unsubstituted C3-C 10 Cycloalkyl, substituted or unsubstituted C6-C 14 Aryl, substituted or unsubstituted C7-C 15 arylalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocycloalkyl, -COR', -CONR'R", -OR', -NR'R", -S(O)2R' or -S(O)2NR'R"; where each R' and R" is independently hydrogen, substituted or unsubstituted C1-C 10 Alkyl, substituted or unsubstituted C1-C10 Heteroalkyl, substituted or unsubstituted C1-C 10 Cycloalkyl, substituted or unsubstituted C6-C 14 Aryl, substituted or unsubstituted C7-C 15 It is an arylalkyl, a substituted or unsubstituted heteroaryl, or a substituted or unsubstituted heterocycloalkyl.
[0164] In a specific implementation, R 1d is H. In a specific embodiment, R 1d is deuterium. In a specific embodiment, R 1d is cyano. In a specific embodiment, R 1d is a halo. In a specific implementation, R 1d is fluoro or chloro. In certain embodiments, R 1d is a fluoro. In a specific embodiment, R 1d is chloro. In certain embodiments, R 1d is substituted or unsubstituted C1-C 10 It is an alkyl. In a specific embodiment, R 1d is methyl, ethyl, propyl, or butyl, each optionally substituted. In certain embodiments, R 1d is methyl, trifluoromethyl, ethyl, 1,1-difluoroethyl, isopropyl, tert -butyl, oxane-4-ylmethyl, morpholinomethyl, hydroxymethyl, methoxymethyl, phenoxymethyl, or dimethylaminomethyl. In certain embodiments, R 1d is methyl, trifluoromethyl, ethyl, difluoroethyl, propyl, butyl, oxanylmethyl, morpholinomethyl, hydroxymethyl, methoxymethyl, phenoxymethyl, or dimethylaminomethyl. In certain embodiments, R 1d is substituted or unsubstituted C1-C 10 It is a heteroalkyl.
[0165] In a specific implementation, R 1d is substituted or unsubstituted C3-C 10 It is a cycloalkyl. In certain embodiments, R 1dis cyclobutyl or cyclohexyl, each optionally substituted. In certain embodiments, R 1d is substituted or unsubstituted C6-C 14 It is Aryl. In a specific implementation, R 1d is a substituted or unsubstituted phenyl. In certain embodiments, R 1d is substituted or unsubstituted C7-C 15 It is an arylalkyl. In certain embodiments, R 1d is a substituted or unsubstituted heteroaryl. In certain embodiments, R 1d is a substituted or unsubstituted monocyclic heteroaryl. In certain embodiments, R 1d is a pentagonal or hexaagonal heteroaryl, each optionally substituted. In certain embodiments, R 1d is a substituted or unsubstituted 5-membered heteroaryl. In certain embodiments, R 1d is a substituted or unsubstituted pyrazolyl. In certain embodiments, R 1d is pyrazole-1-yl, pyrazole-3-yl, or pyrazole-4-yl, each optionally substituted. In a specific embodiment, R 1d is pyrazole-1-yl, pyrazole-3-yl, or pyrazole-4-yl, and each is a substituted or unsubstituted C1-C 10 It is optionally substituted with an alkyl group. In certain embodiments, R 1d is pyrazole-1-yl, 1-methylpyrazole-3-yl, 2-methylpyrazole-3-yl, or 1-methylpyrazole-4-yl. In certain embodiments, R 1d is pyrazole-1-yl, 1-methylpyrazole-3-yl, or 1-methylpyrazole-4-yl. In certain embodiments, R 1d is a substituted or unsubstituted 6-membered heteroaryl.
[0166] In a specific implementation, R 1d is a substituted or unsubstituted heterocycloalkyl. In certain embodiments, R 1d is a substituted or unsubstituted monocyclic heterocycloalkyl. In certain embodiments, R 1dis a ternary, quaternary, pentary, hexavalent, or heptary heterocycloalkyl, each optionally substituted. In certain embodiments, R 1d is a substituted or unsubstituted ternary heterocycloalkyl. In certain embodiments, R 1d is a substituted or unsubstituted quaternary heterocycloalkyl. In certain embodiments, R 1d is a substituted or unsubstituted pentomer heterocycloalkyl. In certain embodiments, R 1d is a substituted or unsubstituted 6-membered heterocycloalkyl. In certain embodiments, R 1d is a substituted or unsubstituted 7-membered heterocycloalkyl. In certain embodiments, R 1d is oxetanyl, oxanyl, piperidinyl, or morpholino, each optionally substituted. In certain embodiments, R 1d is oxetane-3-yl, oxane-4-yl, piperidine-1-yl, or morpholino, each optionally substituted. In certain embodiments, R 1d is oxetane-3-yl, oxane-4-yl, piperidin-1-yl, 4,4-difluoropiperidin-1-yl, 4-(hydroxymethyl)piperidin-1-yl, 4-hydroxypiperidin-1-yl, or morpholino. In certain embodiments, R 1d is piperidin-1-yl or morpholino.
[0167] In a specific implementation, R 1d is a substituted or unsubstituted heterocycloalkyl. In certain embodiments, R 1d is a crosslinked, fused, or spiro heterocycloalkyl, each optionally substituted. In certain embodiments, R 1d is a substituted or unsubstituted crosslinked heterocycloalkyl. In certain embodiments, R 1d is a substituted or unsubstituted 8-azabicyclo[3.2.1]octanyl. In certain embodiments, R 1d is a substituted or unsubstituted 8-azabicyclo[3.2.1]octane-8-yl. In certain embodiments, R 1dis a substituted or unsubstituted fused heterocycloalkyl. In certain embodiments, R 1d is a substituted or unsubstituted heterocycloalkyl.
[0168] In a specific implementation, R 1d is -COR', where R' is as defined herein. In certain embodiments, R 1d is -COR', where R' is the substituted or unsubstituted C1-C 10 It is an alkyl. In a specific embodiment, R 1d is -CONR'R", where R' and R" are each as defined herein. In certain embodiments, R 1d is -CONR'R", where R' and R" are independently H or substituted or unsubstituted C1-C 10 It is an alkyl. In a specific embodiment, R 1d is -OR', where R' is as defined herein. In certain embodiments, R 1d is -OR', where R' is independently H, substituted or unsubstituted C1-C 10 Alkyl or substituted or unsubstituted C6-C 14 It is Aryl. In a specific implementation, R 1d is -NR'R", where R' and R" are each as defined herein. In certain embodiments, R 1d is -NR'R", where R' and R" are independently H or substituted or unsubstituted C1-C 10 It is an alkyl. In a specific embodiment, R 1d is -S(O)2R', where R' is as defined herein. In certain embodiments, R 1d is -S(O)2R', where R' is the substituted or unsubstituted C1-C 10 It is an alkyl. In a specific embodiment, R 1d is -S(O)2NR'R"; where R' and R" are each as defined herein. In a specific embodiment, R 1dis -S(O)2NR'R"; where R' and R" are each independently H or substituted or unsubstituted C1-C 10 It is an alkyl.
[0169] In a specific implementation, R 1d is H, cyano, chloro, fluoro, methyl, trifluoromethyl, ethyl, difluoroethyl, propyl, butyl, oxanylmethyl, morpholinomethyl, hydroxymethyl, methoxymethyl, phenoxymethyl, dimethylaminomethyl, cyclobutyl, cyclohexyl, phenyl, pyrazolyl, methylpyrazolyl, oxetanyl, piperidinyl, difluoropiperidinyl, (hydroxymethyl)piperidinyl, hydroxypiperidinyl, oxanyl, morpholino, 8-azabicyclo[3.2.1]octanyl, hydroxyl, methoxy, trifluoromethoxy, hydroxyethoxy, phenoxy, benzoxy, oxanyloxy, piperidinyloxy, amino, dimethylamino, phenylamino, aminocarbonyl, methylaminocarbonyl, dimethylaminocarbonyl, methylsulfonyl or aminosulfonyl. In a specific implementation, R 1d is H, cyano, chloro, fluoro, methyl, trifluoromethyl, ethyl, difluoroethyl, propyl, butyl, oxanylmethyl, methoxymethyl, phenoxymethyl, phenyl, pyrazolyl, methylpyrazolyl, piperidinyl, morpholino, 8-azabicyclo[3.2.1]octanyl or phenoxy.
[0170] In a specific implementation, R 1d is H, cyano, chloro, fluoro, methyl, trifluoromethyl, ethyl, 1,1-difluoroethyl, isopropyl, tert -Butyl, oxane-4-ylmethyl, morpholinomethyl, hydroxymethyl, methoxymethyl, phenoxymethyl, dimethylaminomethyl, cyclobutyl, cyclohexyl, phenyl, pyrazole-1-yl, 1-methylpyrazole-3-yl, 1-methylpyrazole-4-yl, 2-methylpyrazole-3-yl, oxetane-3-yl, oxane-4-yl, piperidine-1-yl, 4,4-difluoropiperidin-1-yl, 4-(hydroxymethyl)piperidin-1-yl, 4-hydroxypiperidin-1-yl, morpholino, 8-azabicyclo[3.2.1]octane-8-yl, hydroxyl, methoxy, trifluoromethoxy, 2-hydroxyethoxy, phenoxy, benzoxy, piperidine-4-yloxy, oxane-4-yloxy, It is amino, dimethylamino, phenylamino, aminocarbonyl, methylaminocarbonyl, dimethylaminocarbonyl, methylsulfonyl, or aminosulfonyl. In certain embodiments, R 1d is H, cyano, chloro, fluoro, methyl, trifluoromethyl, ethyl, 1,1-difluoroethyl, isopropyl, tert -butyl, oxane-4-ylmethyl, methoxymethyl, phenyl, pyrazole-1-yl, 1-methylpyrazole-3-yl, 1-methylpyrazole-4-yl, piperidine-1-yl, morpholino, 8-azabicyclo[3.2.1]octane-8-yl or phenoxy.
[0171] In a specific implementation, R 1e is H, deuterium, cyano, halo, substituted or unsubstituted C1-C 10 Alkyl, substituted or unsubstituted C1-C 10 Heteroalkyl, substituted or unsubstituted C3-C 10 Cycloalkyl, substituted or unsubstituted C6-C 14 Aryl, substituted or unsubstituted C7-C 15 arylalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocycloalkyl, -COR', -CONR'R", -OR', -NR'R", -S(O)2R' or -S(O)2NR'R"; where each R' and R" is independently hydrogen, substituted or unsubstituted C1-C 10 Alkyl, substituted or unsubstituted C1-C10 Heteroalkyl, substituted or unsubstituted C1-C 10 Cycloalkyl, substituted or unsubstituted C6-C 14 Aryl, substituted or unsubstituted C7-C 15 It is an arylalkyl, a substituted or unsubstituted heteroaryl, or a substituted or unsubstituted heterocycloalkyl.
[0172] In a specific implementation, R 1e is H. In a specific embodiment, R 1e is deuterium. In a specific embodiment, R 1e is cyano. In a specific embodiment, R 1e is a halo. In a specific implementation, R 1e is fluoro or chloro. In certain embodiments, R 1e is a fluoro. In a specific embodiment, R 1e is chloro. In certain embodiments, R 1e is substituted or unsubstituted C1-C 10 It is an alkyl. In a specific embodiment, R 1e is methyl, ethyl, propyl, or butyl, each optionally substituted. In certain embodiments, R 1e is methyl, trifluoromethyl, ethyl, 1,1-difluoroethyl, isopropyl, tert -butyl, oxane-4-ylmethyl, morpholinomethyl, hydroxymethyl, methoxymethyl, phenoxymethyl, or dimethylaminomethyl. In certain embodiments, R 1e is methyl, trifluoromethyl, ethyl, difluoroethyl, propyl, butyl, oxanylmethyl, morpholinomethyl, hydroxymethyl, methoxymethyl, phenoxymethyl, or dimethylaminomethyl. In certain embodiments, R 1e is substituted or unsubstituted C1-C 10 It is a heteroalkyl.
[0173] In a specific implementation, R 1e is substituted or unsubstituted C3-C 10 It is a cycloalkyl. In certain embodiments, R 1eis cyclobutyl or cyclohexyl, each optionally substituted. In certain embodiments, R 1e is substituted or unsubstituted C6-C 14 It is Aryl. In a specific implementation, R 1e is a substituted or unsubstituted phenyl. In certain embodiments, R 1e is substituted or unsubstituted C7-C 15 It is an arylalkyl. In certain embodiments, R 1e is a substituted or unsubstituted heteroaryl. In certain embodiments, R 1e is a substituted or unsubstituted monocyclic heteroaryl. In certain embodiments, R 1e is a pentagonal or hexaagonal heteroaryl, each optionally substituted. In certain embodiments, R 1e is a substituted or unsubstituted 5-membered heteroaryl. In certain embodiments, R 1e is a substituted or unsubstituted pyrazolyl. In certain embodiments, R 1e is pyrazole-1-yl, pyrazole-3-yl, or pyrazole-4-yl, each optionally substituted. In a specific embodiment, R 1e is pyrazole-1-yl, pyrazole-3-yl, or pyrazole-4-yl, and each is a substituted or unsubstituted C1-C 10 It is optionally substituted with an alkyl group. In certain embodiments, R 1e is pyrazole-1-yl, 1-methylpyrazole-3-yl, 2-methylpyrazole-3-yl, or 1-methylpyrazole-4-yl. In certain embodiments, R 1e is pyrazole-1-yl, 1-methylpyrazole-3-yl, or 1-methylpyrazole-4-yl. In certain embodiments, R 1e is a substituted or unsubstituted 6-membered heteroaryl.
[0174] In a specific implementation, R 1e is a substituted or unsubstituted heterocycloalkyl. In certain embodiments, R 1e is a substituted or unsubstituted monocyclic heterocycloalkyl. In certain embodiments, R 1eis a ternary, quaternary, pentary, hexavalent, or heptary heterocycloalkyl, each optionally substituted. In certain embodiments, R 1e is a substituted or unsubstituted ternary heterocycloalkyl. In certain embodiments, R 1e is a substituted or unsubstituted quaternary heterocycloalkyl. In certain embodiments, R 1e is a substituted or unsubstituted pentomer heterocycloalkyl. In certain embodiments, R 1e is a substituted or unsubstituted 6-membered heterocycloalkyl. In certain embodiments, R 1e is a substituted or unsubstituted 7-membered heterocycloalkyl. In certain embodiments, R 1e is oxetanyl, oxanyl, piperidinyl, or morpholino, each optionally substituted. In certain embodiments, R 1e is oxetane-3-yl, oxane-4-yl, piperidine-1-yl, or morpholino, each optionally substituted. In certain embodiments, R 1e is oxetane-3-yl, oxane-4-yl, piperidin-1-yl, 4,4-difluoropiperidin-1-yl, 4-(hydroxymethyl)piperidin-1-yl, 4-hydroxypiperidin-1-yl, or morpholino. In certain embodiments, R 1e is piperidin-1-yl or morpholino.
[0175] In a specific implementation, R 1e is a substituted or unsubstituted heterocycloalkyl. In certain embodiments, R 1e is a crosslinked, fused, or spiro heterocycloalkyl, each optionally substituted. In certain embodiments, R 1e is a substituted or unsubstituted crosslinked heterocycloalkyl. In certain embodiments, R 1e is a substituted or unsubstituted 8-azabicyclo[3.2.1]octanyl. In certain embodiments, R 1e is a substituted or unsubstituted 8-azabicyclo[3.2.1]octane-8-yl. In certain embodiments, R 1eis a substituted or unsubstituted fused heterocycloalkyl. In certain embodiments, R 1e is a substituted or unsubstituted heterocycloalkyl.
[0176] In a specific implementation, R 1e is -COR', where R' is as defined herein. In certain embodiments, R 1e is -COR', where R' is the substituted or unsubstituted C1-C 10 It is an alkyl. In a specific embodiment, R 1e is -CONR'R", where R' and R" are each as defined herein. In certain embodiments, R 1e is -CONR'R", where R' and R" are independently H or substituted or unsubstituted C1-C 10 It is an alkyl. In a specific embodiment, R 1e is -OR', where R' is as defined herein. In certain embodiments, R 1e is -OR', where R' is independently H, substituted or unsubstituted C1-C 10 Alkyl or substituted or unsubstituted C6-C 14 It is Aryl. In a specific implementation, R 1e is -NR'R", where R' and R" are each as defined herein. In certain embodiments, R 1e is -NR'R", where R' and R" are independently H or substituted or unsubstituted C1-C 10 It is an alkyl. In a specific embodiment, R 1e is -S(O)2R', where R' is as defined herein. In certain embodiments, R 1e is -S(O)2R', where R' is the substituted or unsubstituted C1-C 10 It is an alkyl. In a specific embodiment, R 1e is -S(O)2NR'R"; where R' and R" are each as defined herein. In a specific embodiment, R 1eis -S(O)2NR'R"; where R' and R" are each independently H or substituted or unsubstituted C1-C 10 It is an alkyl.
[0177] In a specific implementation, R 1e is H, cyano, chloro, fluoro, methyl, trifluoromethyl, ethyl, difluoroethyl, propyl, butyl, oxanylmethyl, morpholinomethyl, hydroxymethyl, methoxymethyl, phenoxymethyl, dimethylaminomethyl, cyclobutyl, cyclohexyl, phenyl, pyrazolyl, methylpyrazolyl, oxetanyl, piperidinyl, difluoropiperidinyl, (hydroxymethyl)piperidinyl, hydroxypiperidinyl, oxanyl, morpholino, 8-azabicyclo[3.2.1]octanyl, hydroxyl, methoxy, trifluoromethoxy, hydroxyethoxy, phenoxy, benzoxy, oxanyloxy, piperidinyloxy, amino, dimethylamino, phenylamino, aminocarbonyl, methylaminocarbonyl, dimethylaminocarbonyl, methylsulfonyl or aminosulfonyl. In a specific implementation, R 1e is H, cyano, chloro, fluoro, methyl, trifluoromethyl, ethyl, difluoroethyl, propyl, butyl, oxanylmethyl, methoxymethyl, phenoxymethyl, phenyl, pyrazolyl, methylpyrazolyl, piperidinyl, morpholino, 8-azabicyclo[3.2.1]octanyl or phenoxy.
[0178] In a specific implementation, R 1e is H, cyano, chloro, fluoro, methyl, trifluoromethyl, ethyl, 1,1-difluoroethyl, isopropyl, tert -Butyl, oxane-4-ylmethyl, morpholinomethyl, hydroxymethyl, methoxymethyl, phenoxymethyl, dimethylaminomethyl, cyclobutyl, cyclohexyl, phenyl, pyrazole-1-yl, 1-methylpyrazole-3-yl, 1-methylpyrazole-4-yl, 2-methylpyrazole-3-yl, oxetane-3-yl, oxane-4-yl, piperidine-1-yl, 4,4-difluoropiperidin-1-yl, 4-(hydroxymethyl)piperidin-1-yl, 4-hydroxypiperidin-1-yl, morpholino, 8-azabicyclo[3.2.1]octane-8-yl, hydroxyl, methoxy, trifluoromethoxy, 2-hydroxyethoxy, phenoxy, benzoxy, piperidine-4-yloxy, oxane-4-yloxy, It is amino, dimethylamino, phenylamino, aminocarbonyl, methylaminocarbonyl, dimethylaminocarbonyl, methylsulfonyl, or aminosulfonyl. In certain embodiments, R 1e is H, cyano, chloro, fluoro, methyl, trifluoromethyl, ethyl, 1,1-difluoroethyl, isopropyl, tert -butyl, oxane-4-ylmethyl, methoxymethyl, phenyl, pyrazole-1-yl, 1-methylpyrazole-3-yl, 1-methylpyrazole-4-yl, piperidine-1-yl, morpholino, 8-azabicyclo[3.2.1]octane-8-yl or phenoxy.
[0179] In a specific implementation, R 1a and R 1b forms a substituted or unsubstituted heteroaryl or a substituted or unsubstituted heterocycloalkyl together with the carbon atoms to which they are attached. In certain embodiments, R 1a and R 1b forms a substituted or unsubstituted heteroaryl together with the carbon atoms to which they are attached. In a specific embodiment, R 1a and R 1b They form heteroaryls with the carbon atoms to which they are attached, which are optionally substituted with one, two, or three substituents, each of which is independently a deuterium, cyano, halo, substituted, or unsubstituted C1-C 10 Alkyl, substituted or unsubstituted C1-C 10Heteroalkyl, substituted or unsubstituted C3-C 10 Cycloalkyl, substituted or unsubstituted C6-C 14 Aryl, substituted or unsubstituted C7-C 15 arylalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocycloalkyl, -COR', -CONR'R", -OR', -NR'R", -S(O)2R' or -S(O)2NR'R"; where each R' and R" is independently hydrogen, substituted or unsubstituted C1-C 10 Alkyl, substituted or unsubstituted C1-C 10 Heteroalkyl, substituted or unsubstituted C1-C 10 Cycloalkyl, substituted or unsubstituted C6-C 14 Aryl, substituted or unsubstituted C7-C 15 It is an arylalkyl, a substituted or unsubstituted heteroaryl, or a substituted or unsubstituted heterocycloalkyl.
[0180] In a specific implementation, R 1a and R 1b forms a substituted or unsubstituted monocyclic heteroaryl together with the carbon atoms to which they are attached. In a specific embodiment, R 1a and R 1b They form substituted or unsubstituted pentagonal or hexaagonal heteroaryls together with the carbon atoms to which they are attached. In certain embodiments, R 1a and R 1b forms a substituted or unsubstituted pentagonal heteroaryl together with the carbon atoms to which they are attached. In a specific embodiment, R 1a and R 1b forms a substituted or unsubstituted 6-membered heteroaryl together with the carbon atoms to which they are attached. In a specific embodiment, R 1a and R 1bThey form furandyl, imidazolediyl, pyrroldyl, pyrazoldyl, 1,2,3-triazolediyl, or pyridindiyl together with the carbon atoms to which they are attached, each optionally substituted with one or two substituents, each of which is independently deuterium, cyano, halo, or substituted or unsubstituted C1-C 10 It is an alkyl. In a specific embodiment, R 1a and R 1b is formed with the carbon atoms to which they are attached to furan-2,3-diyl, imidazole-4,5-diyl, pyrrole-2,3-diyl, pyrazol-4,5-diyl, 1,2,3-triazole-4,5-diyl, or pyridine-2,3-diyl, each optionally substituted with one or two substituents, each of which is independently deuterium, cyano, fluoro, or methyl. In certain embodiments, R 1a and R 1b It forms furan-2,3-diyl, 1-methylimidazole-4,5-diyl, pyrrole-2,3-diyl, 1-methylpyrrole-2,3-diyl, pyrazole-4,5-diyl, 1-methylpyrazole-4,5-diyl, 1-methyl-1,2,3-triazole-4,5-diyl, or pyridine-2,3-diyl together with the carbon atoms to which they are attached.
[0181] In a specific implementation, R 1a and R 1b forms a substituted or unsubstituted heterocycloalkyl with the carbon atoms to which they are attached. In a specific embodiment, R 1a and R 1b They form heterocycloalkyl groups with the carbon atoms to which they are attached, which are optionally substituted with one, two, or three substituents, each of which is independently a deuterium, oxo, cyano, halo, substituted, or unsubstituted C1-C 10 Alkyl, substituted or unsubstituted C1-C 10 Heteroalkyl, substituted or unsubstituted C3-C 10 Cycloalkyl, substituted or unsubstituted C6-C 14 Aryl, substituted or unsubstituted C7-C 15arylalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocycloalkyl, -COR', -CONR'R", -OR', -NR'R", -S(O)2R' or -S(O)2NR'R"; where each R' and R" is independently hydrogen, substituted or unsubstituted C1-C 10 Alkyl, substituted or unsubstituted C1-C 10 Heteroalkyl, substituted or unsubstituted C1-C 10 Cycloalkyl, substituted or unsubstituted C6-C 14 Aryl, substituted or unsubstituted C7-C 15 It is an arylalkyl, a substituted or unsubstituted heteroaryl, or a substituted or unsubstituted heterocycloalkyl.
[0182] In a specific implementation, R 1a and R 1b forms a substituted or unsubstituted monocyclic heterocycloalkyl group together with the carbon atoms to which they are attached. In a specific embodiment, R 1a and R 1b forms a substituted or unsubstituted pentary or hexavalent heterocycloalkyl group together with the carbon atoms to which they are attached. In certain embodiments, R 1a and R 1b forms a substituted or unsubstituted pentoecycloalkyl with the carbon atoms to which they are attached. In certain embodiments, R 1a and R 1b forms a substituted or unsubstituted hexacycloalkyl group together with the carbon atoms to which they are attached. In certain embodiments, R 1a and R 1b They form tetrahydrofurandyl, pyrrolidindiyl, 1,3-dioxolandiyl, oxandyl, or morpholinediyl together with the carbon atoms to which they are attached, each optionally substituted with one or two substituents, each of which is independently an oxo, cyano, halo, or substituted or unsubstituted C1-C 10 It is an alkyl. In a specific embodiment, R 1a and R 1bThey form tetrahydrofuran-2,3-diyl, tetrahydrofuran-3,4-diyl, pyrrolidine-3,4-diyl, 1,3-dioxolane-4,5-diyl, oxane-2,3-diyl, or morpholine-2,3-diyl together with the carbon atoms to which they are attached, each optionally substituted with one or two substituents, each of which is independently oxo, fluoro, or methyl. In certain embodiments, R 1a and R 1b They form tetrahydrofuran-2,3-diyl, 5,5-dimethyltetrahydrofuran-2,3-diyl, tetrahydrofuran-3,4-diyl, pyrrolidine-3,4-diyl, 2-oxopyrrolidine-3,4-diyl, 2,2-difluoro-1,3-dioxolane-4,5-diyl, 2,2-dimethyl-1,3-dioxolane-4,5-diyl, oxane-2,3-diyl, 4-methylmorpholine-2,3-diyl, or 5-oxomorpholine-2,3-diyl together with the carbon atoms to which they are attached.
[0183] In a specific implementation, R 1b and R 1c forms a substituted or unsubstituted heteroaryl or a substituted or unsubstituted heterocycloalkyl together with the carbon atoms to which they are attached. In certain embodiments, R 1b and R 1c forms a substituted or unsubstituted heteroaryl together with the carbon atoms to which they are attached. In a specific embodiment, R 1b and R 1c They form heteroaryls with the carbon atoms to which they are attached, which are optionally substituted with one, two, or three substituents, each of which is independently a deuterium, cyano, halo, substituted, or unsubstituted C1-C 10 Alkyl, substituted or unsubstituted C1-C 10 Heteroalkyl, substituted or unsubstituted C3-C 10 Cycloalkyl, substituted or unsubstituted C6-C 14 Aryl, substituted or unsubstituted C7-C 15arylalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocycloalkyl, -COR', -CONR'R", -OR', -NR'R", -S(O)2R' or -S(O)2NR'R"; where each R' and R" is independently hydrogen, substituted or unsubstituted C1-C 10 Alkyl, substituted or unsubstituted C1-C 10 Heteroalkyl, substituted or unsubstituted C1-C 10 Cycloalkyl, substituted or unsubstituted C6-C 14 Aryl, substituted or unsubstituted C7-C 15 It is an arylalkyl, a substituted or unsubstituted heteroaryl, or a substituted or unsubstituted heterocycloalkyl.
[0184] In a specific implementation, R 1b and R 1c forms a substituted or unsubstituted monocyclic heteroaryl together with the carbon atoms to which they are attached. In a specific embodiment, R 1b and R 1c They form substituted or unsubstituted pentagonal or hexaagonal heteroaryls together with the carbon atoms to which they are attached. In certain embodiments, R 1b and R 1c forms a substituted or unsubstituted pentagonal heteroaryl together with the carbon atoms to which they are attached. In a specific embodiment, R 1b and R 1c forms a substituted or unsubstituted 6-membered heteroaryl together with the carbon atoms to which they are attached. In a specific embodiment, R 1b and R 1c They form furandyl, imidazolediyl, pyrroldyl, pyrazoldyl, 1,2,3-triazolediyl, or pyridindiyl together with the carbon atoms to which they are attached, each optionally substituted with one or two substituents, each of which is independently deuterium, cyano, halo, or substituted or unsubstituted C1-C 10 It is an alkyl. In a specific embodiment, R 1b and R 1cis formed with the carbon atoms to which they are attached to furan-2,3-diyl, imidazole-4,5-diyl, pyrrole-2,3-diyl, pyrazol-4,5-diyl, 1,2,3-triazole-4,5-diyl, or pyridine-2,3-diyl, each optionally substituted with one or two substituents, each of which is independently deuterium, cyano, fluoro, or methyl. In certain embodiments, R 1b and R 1c It forms furan-2,3-diyl, 1-methylimidazole-4,5-diyl, pyrrole-2,3-diyl, 1-methylpyrrole-2,3-diyl, pyrazole-4,5-diyl, 1-methylpyrazole-4,5-diyl, 1-methyl-1,2,3-triazole-4,5-diyl, or pyridine-2,3-diyl together with the carbon atoms to which they are attached.
[0185] In a specific implementation, R 1b and R 1c forms a substituted or unsubstituted heterocycloalkyl with the carbon atoms to which they are attached. In a specific embodiment, R 1b and R 1c They form heterocycloalkyl groups with the carbon atoms to which they are attached, which are optionally substituted with one, two, or three substituents, each of which is independently a deuterium, oxo, cyano, halo, substituted, or unsubstituted C1-C 10 Alkyl, substituted or unsubstituted C1-C 10 Heteroalkyl, substituted or unsubstituted C3-C 10 Cycloalkyl, substituted or unsubstituted C6-C 14 Aryl, substituted or unsubstituted C7-C 15 arylalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocycloalkyl, -COR', -CONR'R", -OR', -NR'R", -S(O)2R' or -S(O)2NR'R"; where each R' and R" is independently hydrogen, substituted or unsubstituted C1-C 10 Alkyl, substituted or unsubstituted C1-C 10 Heteroalkyl, substituted or unsubstituted C1-C10 Cycloalkyl, substituted or unsubstituted C6-C 14 Aryl, substituted or unsubstituted C7-C 15 It is an arylalkyl, a substituted or unsubstituted heteroaryl, or a substituted or unsubstituted heterocycloalkyl.
[0186] In a specific implementation, R 1b and R 1c forms a substituted or unsubstituted monocyclic heterocycloalkyl group together with the carbon atoms to which they are attached. In a specific embodiment, R 1b and R 1c forms a substituted or unsubstituted pentary or hexavalent heterocycloalkyl group together with the carbon atoms to which they are attached. In certain embodiments, R 1b and R 1c forms a substituted or unsubstituted pentoecycloalkyl with the carbon atoms to which they are attached. In certain embodiments, R 1b and R 1c forms a substituted or unsubstituted hexacycloalkyl group together with the carbon atoms to which they are attached. In certain embodiments, R 1b and R 1c They form tetrahydrofurandyl, pyrrolidindiyl, 1,3-dioxolandiyl, oxandyl, or morpholinediyl together with the carbon atoms to which they are attached, each optionally substituted with one or two substituents, each of which is independently an oxo, cyano, halo, or substituted or unsubstituted C1-C 10 It is an alkyl. In a specific embodiment, R 1b and R 1c They form tetrahydrofuran-2,3-diyl, tetrahydrofuran-3,4-diyl, pyrrolidine-3,4-diyl, 1,3-dioxolane-4,5-diyl, oxane-2,3-diyl, or morpholine-2,3-diyl together with the carbon atoms to which they are attached, each optionally substituted with one or two substituents, each of which is independently oxo, fluoro, or methyl. In certain embodiments, R 1b and R 1cThey form tetrahydrofuran-2,3-diyl, 5,5-dimethyltetrahydrofuran-2,3-diyl, tetrahydrofuran-3,4-diyl, pyrrolidine-3,4-diyl, 2-oxopyrrolidine-3,4-diyl, 2,2-difluoro-1,3-dioxolane-4,5-diyl, 2,2-dimethyl-1,3-dioxolane-4,5-diyl, oxane-2,3-diyl, 4-methylmorpholine-2,3-diyl, or 5-oxomorpholine-2,3-diyl together with the carbon atoms to which they are attached.
[0187] In another embodiment, the present invention provides a compound having the structure of the following formula (VIII) or a mirror image isomer thereof, a mixture of mirror image isomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, or a mixture of two or more tautomers; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; or a pharmaceutically acceptable derivative thereof:
[0188]
[0189] Here:
[0190] R 2a , R 2b , R 2c , R 2d and R 2e Each is independently H, deuterium, cyano, halo, substituted, or unsubstituted C1-C 10 Alkyl, substituted or unsubstituted C1-C 10 Heteroalkyl, substituted or unsubstituted C3-C 10 Cycloalkyl, substituted or unsubstituted C6-C 14 Aryl, substituted or unsubstituted C7-C 15 arylalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocycloalkyl, -COR', -CONR'R", -OR', -NR'R", -S(O)2R' or -S(O)2NR'R"; where each R' and R" is independently hydrogen, substituted or unsubstituted C1-C 10 Alkyl, substituted or unsubstituted C1-C10 Heteroalkyl, substituted or unsubstituted C1-C 10 Cycloalkyl, substituted or unsubstituted C6-C 14 Aryl, substituted or unsubstituted C7-C 15 arylalkyl, substituted or unsubstituted heteroaryl, or substituted or unsubstituted heterocycloalkyl; R 2a and R 2b is formed with the carbon atoms to which they are attached a substituted or unsubstituted heteroaryl or a substituted or unsubstituted heterocycloalkyl; R 2b and R 2c , together with the carbon atoms to which they are attached, form a substituted or unsubstituted heteroaryl or a substituted or unsubstituted heterocycloalkyl;
[0191] R 2 , R 3 , R 4 , R 5 , R 13 , c and d are each as defined herein.
[0192] In another embodiment, the present invention provides a compound having the structure of the following formula (IX) or a mirror image isomer thereof, a mixture of mirror image isomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, or a mixture of two or more tautomers; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; or a pharmaceutically acceptable derivative thereof:
[0193]
[0194] Here, R 2 , R 3 , R 4 , R 5 , R 13 , R 2a , R 2b , R 2c , R 2d and R 2e Each is as defined herein.
[0195] In another embodiment, the present invention provides a compound having the structure of the following formula (X) or a mirror image isomer thereof, a mixture of mirror image isomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, or a mixture of two or more tautomers; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; or a pharmaceutically acceptable derivative thereof:
[0196]
[0197] Here, R 2 , R 3 , R 4 , R 5 , R 13 , R 2a , R 2b , R 2c , R 2d and R 2e Each is as defined herein.
[0198] In another embodiment, the present invention provides a compound having the structure of the following formula (XI) or a mirror image isomer thereof, a mixture of mirror image isomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, or a mixture of two or more tautomers; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; or a pharmaceutically acceptable derivative thereof:
[0199]
[0200] Here, R 2 , R 3 , R 4 , R 5 , R 13 , R 2a , R 2b , R 2c , R 2d and R 2e Each is as defined herein.
[0201] In a specific implementation, R 2a , R 2b , R2c , R 2d and R 2e Each is independently H, deuterium, cyano, halo, substituted, or unsubstituted C1-C 10 Alkyl, substituted or unsubstituted C1-C 10 Heteroalkyl, substituted or unsubstituted C3-C 10 Cycloalkyl, substituted or unsubstituted C6-C 14 Aryl, substituted or unsubstituted C7-C 15 arylalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocycloalkyl, -COR', -CONR'R", -OR', -NR'R", -S(O)2R' or -S(O)2NR'R"; where each R' and R" is independently hydrogen, substituted or unsubstituted C1-C 10 Alkyl, substituted or unsubstituted C1-C 10 Heteroalkyl, substituted or unsubstituted C1-C 10 Cycloalkyl, substituted or unsubstituted C6-C 14 Aryl, substituted or unsubstituted C7-C 15 It is an arylalkyl, a substituted or unsubstituted heteroaryl, or a substituted or unsubstituted heterocycloalkyl.
[0202] In a specific implementation, R 2a is H, deuterium, cyano, halo, substituted or unsubstituted C1-C 10 Alkyl, substituted or unsubstituted C1-C 10 Heteroalkyl, substituted or unsubstituted C3-C 10 Cycloalkyl, substituted or unsubstituted C6-C 14 Aryl, substituted or unsubstituted C7-C 15 arylalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocycloalkyl, -COR', -CONR'R", -OR', -NR'R", -S(O)2R' or -S(O)2NR'R"; where each R' and R" is independently hydrogen, substituted or unsubstituted C1-C 10 Alkyl, substituted or unsubstituted C1-C 10Heteroalkyl, substituted or unsubstituted C1-C 10 Cycloalkyl, substituted or unsubstituted C6-C 14 Aryl, substituted or unsubstituted C7-C 15 It is an arylalkyl, a substituted or unsubstituted heteroaryl, or a substituted or unsubstituted heterocycloalkyl.
[0203] In a specific implementation, R 2a is H. In a specific embodiment, R 2a is deuterium. In a specific embodiment, R 2a is cyano. In a specific embodiment, R 2a is a halo. In a specific implementation, R 2a is fluoro or chloro. In certain embodiments, R 2a is a fluoro. In a specific embodiment, R 2a is chloro. In certain embodiments, R 2a is substituted or unsubstituted C1-C 10 It is an alkyl. In a specific embodiment, R 2a is methyl, ethyl, propyl, or butyl, each optionally substituted. In certain embodiments, R 2a is methyl, trifluoromethyl, ethyl, 1,1-difluoroethyl, isopropyl, tert -butyl, oxane-4-ylmethyl, morpholinomethyl, hydroxymethyl, methoxymethyl, phenoxymethyl, or dimethylaminomethyl. In certain embodiments, R 2a is methyl, trifluoromethyl, ethyl, difluoroethyl, propyl, butyl, oxanylmethyl, morpholinomethyl, hydroxymethyl, methoxymethyl, phenoxymethyl, or dimethylaminomethyl. In certain embodiments, R 2a is substituted or unsubstituted C1-C 10 It is a heteroalkyl.
[0204] In a specific implementation, R 2a is substituted or unsubstituted C3-C 10 It is a cycloalkyl. In certain embodiments, R 2ais cyclobutyl or cyclohexyl, each optionally substituted. In certain embodiments, R 2a is substituted or unsubstituted C6-C 14 It is Aryl. In a specific implementation, R 2a is a substituted or unsubstituted phenyl. In certain embodiments, R 2a is substituted or unsubstituted C7-C 15 It is an arylalkyl. In certain embodiments, R 2a is a substituted or unsubstituted heteroaryl. In certain embodiments, R 2a is a substituted or unsubstituted monocyclic heteroaryl. In certain embodiments, R 2a is a pentagonal or hexaagonal heteroaryl, each optionally substituted. In certain embodiments, R 2a is a substituted or unsubstituted 5-membered heteroaryl. In certain embodiments, R 2a is a substituted or unsubstituted pyrazolyl. In certain embodiments, R 2a is pyrazole-1-yl, pyrazole-3-yl, or pyrazole-4-yl, each optionally substituted. In a specific embodiment, R 2a is pyrazole-1-yl, pyrazole-3-yl, or pyrazole-4-yl, and each is a substituted or unsubstituted C1-C 10 It is optionally substituted with an alkyl group. In certain embodiments, R 2a is pyrazole-1-yl, 1-methylpyrazole-3-yl, 2-methylpyrazole-3-yl, or 1-methylpyrazole-4-yl. In certain embodiments, R 2a is pyrazole-1-yl, 1-methylpyrazole-3-yl, or 1-methylpyrazole-4-yl. In certain embodiments, R 2a is a substituted or unsubstituted 6-membered heteroaryl.
[0205] In a specific implementation, R 2a is a substituted or unsubstituted heterocycloalkyl. In certain embodiments, R 2a is a substituted or unsubstituted monocyclic heterocycloalkyl. In certain embodiments, R 2ais a ternary, quaternary, pentary, hexavalent, or heptary heterocycloalkyl, each optionally substituted. In certain embodiments, R 2a is a substituted or unsubstituted ternary heterocycloalkyl. In certain embodiments, R 2a is a substituted or unsubstituted quaternary heterocycloalkyl. In certain embodiments, R 2a is a substituted or unsubstituted pentomer heterocycloalkyl. In certain embodiments, R 2a is a substituted or unsubstituted 6-membered heterocycloalkyl. In certain embodiments, R 2a is a substituted or unsubstituted 7-membered heterocycloalkyl. In certain embodiments, R 2a is oxetanyl, oxanyl, piperidinyl, or morpholino, each optionally substituted. In certain embodiments, R 2a is oxetane-3-yl, oxane-4-yl, piperidine-1-yl, or morpholino, each optionally substituted. In certain embodiments, R 2a is oxetane-3-yl, oxane-4-yl, piperidin-1-yl, 4,4-difluoropiperidin-1-yl, 4-(hydroxymethyl)piperidin-1-yl, 4-hydroxypiperidin-1-yl, or morpholino. In certain embodiments, R 2a is piperidin-1-yl or morpholino.
[0206] In a specific implementation, R 2a is a substituted or unsubstituted heterocycloalkyl. In certain embodiments, R 2a is a crosslinked, fused, or spiro heterocycloalkyl, each optionally substituted. In certain embodiments, R 2a is a substituted or unsubstituted crosslinked heterocycloalkyl. In certain embodiments, R 2a is a substituted or unsubstituted 8-azabicyclo[3.2.1]octanyl. In certain embodiments, R 2a is a substituted or unsubstituted 8-azabicyclo[3.2.1]octane-8-yl. In certain embodiments, R 2ais a substituted or unsubstituted fused heterocycloalkyl. In certain embodiments, R 2a is a substituted or unsubstituted heterocycloalkyl.
[0207] In a specific implementation, R 2a is -COR', where R' is as defined herein. In certain embodiments, R 2a is -COR', where R' is the substituted or unsubstituted C1-C 10 It is an alkyl. In a specific embodiment, R 2a is -CONR'R", where R' and R" are each as defined herein. In certain embodiments, R 2a is -CONR'R", where R' and R" are independently H or substituted or unsubstituted C1-C 10 It is an alkyl. In a specific embodiment, R 2a is -OR', where R' is as defined herein. In certain embodiments, R 2a is -OR', where R' is independently H, substituted or unsubstituted C1-C 10 Alkyl or substituted or unsubstituted C6-C 14 It is Aryl. In a specific implementation, R 2a is -NR'R", where R' and R" are each as defined herein. In certain embodiments, R 2a is -NR'R", where R' and R" are independently H or substituted or unsubstituted C1-C 10 It is an alkyl. In a specific embodiment, R 2a is -S(O)2R', where R' is as defined herein. In certain embodiments, R 2a is -S(O)2R', where R' is the substituted or unsubstituted C1-C 10 It is an alkyl. In a specific embodiment, R 2a is -S(O)2NR'R"; where R' and R" are each as defined herein. In a specific embodiment, R 2ais -S(O)2NR'R"; where R' and R" are each independently H or substituted or unsubstituted C1-C 10 It is an alkyl.
[0208] In a specific implementation, R 2a is H, cyano, chloro, fluoro, methyl, trifluoromethyl, ethyl, difluoroethyl, propyl, butyl, oxanylmethyl, morpholinomethyl, hydroxymethyl, methoxymethyl, phenoxymethyl, dimethylaminomethyl, cyclobutyl, cyclohexyl, phenyl, pyrazolyl, methylpyrazolyl, oxetanyl, piperidinyl, difluoropiperidinyl, (hydroxymethyl)piperidinyl, hydroxypiperidinyl, oxanyl, morpholino, 8-azabicyclo[3.2.1]octanyl, hydroxyl, methoxy, trifluoromethoxy, hydroxyethoxy, phenoxy, benzoxy, oxanyloxy, piperidinyloxy, amino, dimethylamino, phenylamino, aminocarbonyl, methylaminocarbonyl, dimethylaminocarbonyl, methylsulfonyl or aminosulfonyl. In a specific implementation, R 2a is H, cyano, chloro, fluoro, methyl, trifluoromethyl, ethyl, difluoroethyl, propyl, butyl, oxanylmethyl, methoxymethyl, phenoxymethyl, phenyl, pyrazolyl, methylpyrazolyl, piperidinyl, morpholino, 8-azabicyclo[3.2.1]octanyl or phenoxy.
[0209] In a specific implementation, R 2a is H, cyano, chloro, fluoro, methyl, trifluoromethyl, ethyl, 1,1-difluoroethyl, isopropyl, tert -Butyl, oxane-4-ylmethyl, morpholinomethyl, hydroxymethyl, methoxymethyl, phenoxymethyl, dimethylaminomethyl, cyclobutyl, cyclohexyl, phenyl, pyrazole-1-yl, 1-methylpyrazole-3-yl, 1-methylpyrazole-4-yl, 2-methylpyrazole-3-yl, oxetane-3-yl, oxane-4-yl, piperidine-1-yl, 4,4-difluoropiperidin-1-yl, 4-(hydroxymethyl)piperidin-1-yl, 4-hydroxypiperidin-1-yl, morpholino, 8-azabicyclo[3.2.1]octane-8-yl, hydroxyl, methoxy, trifluoromethoxy, 2-hydroxyethoxy, phenoxy, benzoxy, piperidine-4-yloxy, oxane-4-yloxy, It is amino, dimethylamino, phenylamino, aminocarbonyl, methylaminocarbonyl, dimethylaminocarbonyl, methylsulfonyl, or aminosulfonyl. In certain embodiments, R 2a is H, cyano, chloro, fluoro, methyl, trifluoromethyl, ethyl, 1,1-difluoroethyl, isopropyl, tert -butyl, oxane-4-ylmethyl, methoxymethyl, phenyl, pyrazole-1-yl, 1-methylpyrazole-3-yl, 1-methylpyrazole-4-yl, piperidine-1-yl, morpholino, 8-azabicyclo[3.2.1]octane-8-yl or phenoxy.
[0210] In a specific implementation, R 2b is H, deuterium, cyano, halo, substituted or unsubstituted C1-C 10 Alkyl, substituted or unsubstituted C1-C 10 Heteroalkyl, substituted or unsubstituted C3-C 10 Cycloalkyl, substituted or unsubstituted C6-C 14 Aryl, substituted or unsubstituted C7-C 15 arylalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocycloalkyl, -COR', -CONR'R", -OR', -NR'R", -S(O)2R' or -S(O)2NR'R"; where each R' and R" is independently hydrogen, substituted or unsubstituted C1-C 10 Alkyl, substituted or unsubstituted C1-C10 Heteroalkyl, substituted or unsubstituted C1-C 10 Cycloalkyl, substituted or unsubstituted C6-C 14 Aryl, substituted or unsubstituted C7-C 15 It is an arylalkyl, a substituted or unsubstituted heteroaryl, or a substituted or unsubstituted heterocycloalkyl.
[0211] In a specific implementation, R 2b is H. In a specific embodiment, R 2b is deuterium. In a specific embodiment, R 2b is cyano. In a specific embodiment, R 2b is a halo. In a specific implementation, R 2b is fluoro or chloro. In certain embodiments, R 2b is a fluoro. In a specific embodiment, R 2b is chloro. In certain embodiments, R 2b is substituted or unsubstituted C1-C 10 It is an alkyl. In a specific embodiment, R 2b is methyl, ethyl, propyl, or butyl, each optionally substituted. In certain embodiments, R 2b is methyl, trifluoromethyl, ethyl, 1,1-difluoroethyl, isopropyl, tert -butyl, oxane-4-ylmethyl, morpholinomethyl, hydroxymethyl, methoxymethyl, phenoxymethyl, or dimethylaminomethyl. In certain embodiments, R 2b is methyl, trifluoromethyl, ethyl, difluoroethyl, propyl, butyl, oxanylmethyl, morpholinomethyl, hydroxymethyl, methoxymethyl, phenoxymethyl, or dimethylaminomethyl. In certain embodiments, R 2b is substituted or unsubstituted C1-C 10 It is a heteroalkyl.
[0212] In a specific implementation, R 2b is substituted or unsubstituted C3-C 10 It is a cycloalkyl. In certain embodiments, R 2bis cyclobutyl or cyclohexyl, each optionally substituted. In certain embodiments, R 2b is substituted or unsubstituted C6-C 14 It is Aryl. In a specific implementation, R 2b is a substituted or unsubstituted phenyl. In certain embodiments, R 2b is substituted or unsubstituted C7-C 15 It is an arylalkyl. In certain embodiments, R 2b is a substituted or unsubstituted heteroaryl. In certain embodiments, R 2b is a substituted or unsubstituted monocyclic heteroaryl. In certain embodiments, R 2b is a pentagonal or hexaagonal heteroaryl, each optionally substituted. In certain embodiments, R 2b is a substituted or unsubstituted 5-membered heteroaryl. In certain embodiments, R 2b is a substituted or unsubstituted pyrazolyl. In certain embodiments, R 2b is pyrazole-1-yl, pyrazole-3-yl, or pyrazole-4-yl, each optionally substituted. In a specific embodiment, R 2b is pyrazole-1-yl, pyrazole-3-yl, or pyrazole-4-yl, and each is a substituted or unsubstituted C1-C 10 It is optionally substituted with an alkyl group. In certain embodiments, R 2b is pyrazole-1-yl, 1-methylpyrazole-3-yl, 2-methylpyrazole-3-yl, or 1-methylpyrazole-4-yl. In certain embodiments, R 2b is pyrazole-1-yl, 1-methylpyrazole-3-yl, or 1-methylpyrazole-4-yl. In certain embodiments, R 2b is a substituted or unsubstituted 6-membered heteroaryl.
[0213] In a specific implementation, R 2b is a substituted or unsubstituted heterocycloalkyl. In certain embodiments, R 2b is a substituted or unsubstituted monocyclic heterocycloalkyl. In certain embodiments, R 2bis a ternary, quaternary, pentary, hexavalent, or heptary heterocycloalkyl, each optionally substituted. In certain embodiments, R 2b is a substituted or unsubstituted ternary heterocycloalkyl. In certain embodiments, R 2b is a substituted or unsubstituted quaternary heterocycloalkyl. In certain embodiments, R 2b is a substituted or unsubstituted pentomer heterocycloalkyl. In certain embodiments, R 2b is a substituted or unsubstituted 6-membered heterocycloalkyl. In certain embodiments, R 2b is a substituted or unsubstituted 7-membered heterocycloalkyl. In certain embodiments, R 2b is oxetanyl, oxanyl, piperidinyl, or morpholino, each optionally substituted. In certain embodiments, R 2b is oxetane-3-yl, oxane-4-yl, piperidine-1-yl, or morpholino, each optionally substituted. In certain embodiments, R 2b is oxetane-3-yl, oxane-4-yl, piperidin-1-yl, 4,4-difluoropiperidin-1-yl, 4-(hydroxymethyl)piperidin-1-yl, 4-hydroxypiperidin-1-yl, or morpholino. In certain embodiments, R 2b is piperidin-1-yl or morpholino.
[0214] In a specific implementation, R 2b is a substituted or unsubstituted heterocycloalkyl. In certain embodiments, R 2b is a crosslinked, fused, or spiro heterocycloalkyl, each optionally substituted. In certain embodiments, R 2b is a substituted or unsubstituted crosslinked heterocycloalkyl. In certain embodiments, R 2b is a substituted or unsubstituted 8-azabicyclo[3.2.1]octanyl. In certain embodiments, R 2b is a substituted or unsubstituted 8-azabicyclo[3.2.1]octane-8-yl. In certain embodiments, R 2bis a substituted or unsubstituted fused heterocycloalkyl. In certain embodiments, R 2b is a substituted or unsubstituted heterocycloalkyl.
[0215] In a specific implementation, R 2b is -COR', where R' is as defined herein. In certain embodiments, R 2b is -COR', where R' is the substituted or unsubstituted C1-C 10 It is an alkyl. In a specific embodiment, R 2b is -CONR'R", where R' and R" are each as defined herein. In certain embodiments, R 2b is -CONR'R", where R' and R" are independently H or substituted or unsubstituted C1-C 10 It is an alkyl. In a specific embodiment, R 2b is -OR', where R' is as defined herein. In certain embodiments, R 2b is -OR', where R' is independently H, substituted or unsubstituted C1-C 10 Alkyl or substituted or unsubstituted C6-C 14 It is Aryl. In a specific implementation, R 2b is -NR'R", where R' and R" are each as defined herein. In certain embodiments, R 2b is -NR'R", where R' and R" are independently H or substituted or unsubstituted C1-C 10 It is an alkyl. In a specific embodiment, R 2b is -S(O)2R', where R' is as defined herein. In certain embodiments, R 2b is -S(O)2R', where R' is the substituted or unsubstituted C1-C 10 It is an alkyl. In a specific embodiment, R 2b is -S(O)2NR'R"; where R' and R" are each as defined herein. In a specific embodiment, R 2bis -S(O)2NR'R"; where R' and R" are each independently H or substituted or unsubstituted C1-C 10 It is an alkyl.
[0216] In a specific implementation, R 2b is H, cyano, chloro, fluoro, methyl, trifluoromethyl, ethyl, difluoroethyl, propyl, butyl, oxanylmethyl, morpholinomethyl, hydroxymethyl, methoxymethyl, phenoxymethyl, dimethylaminomethyl, cyclobutyl, cyclohexyl, phenyl, pyrazolyl, methylpyrazolyl, oxetanyl, piperidinyl, difluoropiperidinyl, (hydroxymethyl)piperidinyl, hydroxypiperidinyl, oxanyl, morpholino, 8-azabicyclo[3.2.1]octanyl, hydroxyl, methoxy, trifluoromethoxy, hydroxyethoxy, phenoxy, benzoxy, oxanyloxy, piperidinyloxy, amino, dimethylamino, phenylamino, aminocarbonyl, methylaminocarbonyl, dimethylaminocarbonyl, methylsulfonyl or aminosulfonyl. In a specific implementation, R 2b is H, cyano, chloro, fluoro, methyl, trifluoromethyl, ethyl, difluoroethyl, propyl, butyl, oxanylmethyl, methoxymethyl, phenoxymethyl, phenyl, pyrazolyl, methylpyrazolyl, piperidinyl, morpholino, 8-azabicyclo[3.2.1]octanyl or phenoxy.
[0217] In a specific implementation, R 2b is H, cyano, chloro, fluoro, methyl, trifluoromethyl, ethyl, 1,1-difluoroethyl, isopropyl, tert -Butyl, oxane-4-ylmethyl, morpholinomethyl, hydroxymethyl, methoxymethyl, phenoxymethyl, dimethylaminomethyl, cyclobutyl, cyclohexyl, phenyl, pyrazole-1-yl, 1-methylpyrazole-3-yl, 1-methylpyrazole-4-yl, 2-methylpyrazole-3-yl, oxetane-3-yl, oxane-4-yl, piperidine-1-yl, 4,4-difluoropiperidin-1-yl, 4-(hydroxymethyl)piperidin-1-yl, 4-hydroxypiperidin-1-yl, morpholino, 8-azabicyclo[3.2.1]octane-8-yl, hydroxyl, methoxy, trifluoromethoxy, 2-hydroxyethoxy, phenoxy, benzoxy, piperidine-4-yloxy, oxane-4-yloxy, It is amino, dimethylamino, phenylamino, aminocarbonyl, methylaminocarbonyl, dimethylaminocarbonyl, methylsulfonyl, or aminosulfonyl. In certain embodiments, R 2b is H, cyano, chloro, fluoro, methyl, trifluoromethyl, ethyl, 1,1-difluoroethyl, isopropyl, tert -butyl, oxane-4-ylmethyl, methoxymethyl, phenyl, pyrazole-1-yl, 1-methylpyrazole-3-yl, 1-methylpyrazole-4-yl, piperidine-1-yl, morpholino, 8-azabicyclo[3.2.1]octane-8-yl or phenoxy.
[0218] In a specific implementation, R 2c is H, deuterium, cyano, halo, substituted or unsubstituted C1-C 10 Alkyl, substituted or unsubstituted C1-C 10 Heteroalkyl, substituted or unsubstituted C3-C 10 Cycloalkyl, substituted or unsubstituted C6-C 14 Aryl, substituted or unsubstituted C7-C 15 arylalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocycloalkyl, -COR', -CONR'R", -OR', -NR'R", -S(O)2R' or -S(O)2NR'R"; where each R' and R" is independently hydrogen, substituted or unsubstituted C1-C 10 Alkyl, substituted or unsubstituted C1-C10 Heteroalkyl, substituted or unsubstituted C1-C 10 Cycloalkyl, substituted or unsubstituted C6-C 14 Aryl, substituted or unsubstituted C7-C 15 It is an arylalkyl, a substituted or unsubstituted heteroaryl, or a substituted or unsubstituted heterocycloalkyl.
[0219] In a specific implementation, R 2c is H. In a specific embodiment, R 2c is deuterium. In a specific embodiment, R 2c is cyano. In a specific embodiment, R 2c is a halo. In a specific implementation, R 2c is fluoro or chloro. In certain embodiments, R 2c is a fluoro. In a specific embodiment, R 2c is chloro. In certain embodiments, R 2c is substituted or unsubstituted C1-C 10 It is an alkyl. In a specific embodiment, R 2c is methyl, ethyl, propyl, or butyl, each optionally substituted. In certain embodiments, R 2c is methyl, trifluoromethyl, ethyl, 1,1-difluoroethyl, isopropyl, tert -butyl, oxane-4-ylmethyl, morpholinomethyl, hydroxymethyl, methoxymethyl, phenoxymethyl, or dimethylaminomethyl. In certain embodiments, R 2c is methyl, trifluoromethyl, ethyl, difluoroethyl, propyl, butyl, oxanylmethyl, morpholinomethyl, hydroxymethyl, methoxymethyl, phenoxymethyl, or dimethylaminomethyl. In certain embodiments, R 2c is substituted or unsubstituted C1-C 10 It is a heteroalkyl.
[0220] In a specific implementation, R 2c is substituted or unsubstituted C3-C 10 It is a cycloalkyl. In certain embodiments, R 2cis cyclobutyl or cyclohexyl, each optionally substituted. In certain embodiments, R 2c is substituted or unsubstituted C6-C 14 It is Aryl. In a specific implementation, R 2c is a substituted or unsubstituted phenyl. In certain embodiments, R 2c is substituted or unsubstituted C7-C 15 It is an arylalkyl. In certain embodiments, R 2c is a substituted or unsubstituted heteroaryl. In certain embodiments, R 2c is a substituted or unsubstituted monocyclic heteroaryl. In certain embodiments, R 2c is a pentagonal or hexaagonal heteroaryl, each optionally substituted. In certain embodiments, R 2c is a substituted or unsubstituted 5-membered heteroaryl. In certain embodiments, R 2c is a substituted or unsubstituted pyrazolyl. In certain embodiments, R 2c is pyrazole-1-yl, pyrazole-3-yl, or pyrazole-4-yl, each optionally substituted. In a specific embodiment, R 2c is pyrazole-1-yl, pyrazole-3-yl, or pyrazole-4-yl, and each is a substituted or unsubstituted C1-C 10 It is optionally substituted with an alkyl group. In certain embodiments, R 2c is pyrazole-1-yl, 1-methylpyrazole-3-yl, 2-methylpyrazole-3-yl, or 1-methylpyrazole-4-yl. In certain embodiments, R 2c is pyrazole-1-yl, 1-methylpyrazole-3-yl, or 1-methylpyrazole-4-yl. In certain embodiments, R 2c is a substituted or unsubstituted 6-membered heteroaryl.
[0221] In a specific implementation, R 2c is a substituted or unsubstituted heterocycloalkyl. In certain embodiments, R 2c is a substituted or unsubstituted monocyclic heterocycloalkyl. In certain embodiments, R 2cis a ternary, quaternary, pentary, hexavalent, or heptary heterocycloalkyl, each optionally substituted. In certain embodiments, R 2c is a substituted or unsubstituted ternary heterocycloalkyl. In certain embodiments, R 2c is a substituted or unsubstituted quaternary heterocycloalkyl. In certain embodiments, R 2c is a substituted or unsubstituted pentomer heterocycloalkyl. In certain embodiments, R 2c is a substituted or unsubstituted 6-membered heterocycloalkyl. In certain embodiments, R 2c is a substituted or unsubstituted 7-membered heterocycloalkyl. In certain embodiments, R 2c is oxetanyl, oxanyl, piperidinyl, or morpholino, each optionally substituted. In certain embodiments, R 2c is oxetane-3-yl, oxane-4-yl, piperidine-1-yl, or morpholino, each optionally substituted. In certain embodiments, R 2c is oxetane-3-yl, oxane-4-yl, piperidin-1-yl, 4,4-difluoropiperidin-1-yl, 4-(hydroxymethyl)piperidin-1-yl, 4-hydroxypiperidin-1-yl, or morpholino. In certain embodiments, R 2c is piperidin-1-yl or morpholino.
[0222] In a specific implementation, R 2c is a substituted or unsubstituted heterocycloalkyl. In certain embodiments, R 2c is a crosslinked, fused, or spiro heterocycloalkyl, each optionally substituted. In certain embodiments, R 2c is a substituted or unsubstituted crosslinked heterocycloalkyl. In certain embodiments, R 2c is a substituted or unsubstituted 8-azabicyclo[3.2.1]octanyl. In certain embodiments, R 2c is a substituted or unsubstituted 8-azabicyclo[3.2.1]octane-8-yl. In certain embodiments, R 2cis a substituted or unsubstituted fused heterocycloalkyl. In certain embodiments, R 2c is a substituted or unsubstituted heterocycloalkyl.
[0223] In a specific implementation, R 2c is -COR', where R' is as defined herein. In certain embodiments, R 2c is -COR', where R' is the substituted or unsubstituted C1-C 10 It is an alkyl. In a specific embodiment, R 2c is -CONR'R", where R' and R" are each as defined herein. In certain embodiments, R 2c is -CONR'R", where R' and R" are independently H or substituted or unsubstituted C1-C 10 It is an alkyl. In a specific embodiment, R 2c is -OR', where R' is as defined herein. In certain embodiments, R 2c is -OR', where R' is independently H, substituted or unsubstituted C1-C 10 Alkyl or substituted or unsubstituted C6-C 14 It is Aryl. In a specific implementation, R 2c is -NR'R", where R' and R" are each as defined herein. In certain embodiments, R 2c is -NR'R", where R' and R" are independently H or substituted or unsubstituted C1-C 10 It is an alkyl. In a specific embodiment, R 2c is -S(O)2R', where R' is as defined herein. In certain embodiments, R 2c is -S(O)2R', where R' is the substituted or unsubstituted C1-C 10 It is an alkyl. In a specific embodiment, R 2c is -S(O)2NR'R"; where R' and R" are each as defined herein. In a specific embodiment, R 2cis -S(O)2NR'R"; where R' and R" are each independently H or substituted or unsubstituted C1-C 10 It is an alkyl.
[0224] In a specific implementation, R 2c is H, cyano, chloro, fluoro, methyl, trifluoromethyl, ethyl, difluoroethyl, propyl, butyl, oxanylmethyl, morpholinomethyl, hydroxymethyl, methoxymethyl, phenoxymethyl, dimethylaminomethyl, cyclobutyl, cyclohexyl, phenyl, pyrazolyl, methylpyrazolyl, oxetanyl, piperidinyl, difluoropiperidinyl, (hydroxymethyl)piperidinyl, hydroxypiperidinyl, oxanyl, morpholino, 8-azabicyclo[3.2.1]octanyl, hydroxyl, methoxy, trifluoromethoxy, hydroxyethoxy, phenoxy, benzoxy, oxanyloxy, piperidinyloxy, amino, dimethylamino, phenylamino, aminocarbonyl, methylaminocarbonyl, dimethylaminocarbonyl, methylsulfonyl or aminosulfonyl. In a specific implementation, R 2c is H, cyano, chloro, fluoro, methyl, trifluoromethyl, ethyl, difluoroethyl, propyl, butyl, oxanylmethyl, methoxymethyl, phenoxymethyl, phenyl, pyrazolyl, methylpyrazolyl, piperidinyl, morpholino, 8-azabicyclo[3.2.1]octanyl or phenoxy.
[0225] In a specific implementation, R 2c is H, cyano, chloro, fluoro, methyl, trifluoromethyl, ethyl, 1,1-difluoroethyl, isopropyl, tert -Butyl, oxane-4-ylmethyl, morpholinomethyl, hydroxymethyl, methoxymethyl, phenoxymethyl, dimethylaminomethyl, cyclobutyl, cyclohexyl, phenyl, pyrazole-1-yl, 1-methylpyrazole-3-yl, 1-methylpyrazole-4-yl, 2-methylpyrazole-3-yl, oxetane-3-yl, oxane-4-yl, piperidine-1-yl, 4,4-difluoropiperidin-1-yl, 4-(hydroxymethyl)piperidin-1-yl, 4-hydroxypiperidin-1-yl, morpholino, 8-azabicyclo[3.2.1]octane-8-yl, hydroxyl, methoxy, trifluoromethoxy, 2-hydroxyethoxy, phenoxy, benzoxy, piperidine-4-yloxy, oxane-4-yloxy, It is amino, dimethylamino, phenylamino, aminocarbonyl, methylaminocarbonyl, dimethylaminocarbonyl, methylsulfonyl, or aminosulfonyl. In certain embodiments, R 2c is H, cyano, chloro, fluoro, methyl, trifluoromethyl, ethyl, 1,1-difluoroethyl, isopropyl, tert -butyl, oxane-4-ylmethyl, methoxymethyl, phenyl, pyrazole-1-yl, 1-methylpyrazole-3-yl, 1-methylpyrazole-4-yl, piperidine-1-yl, morpholino, 8-azabicyclo[3.2.1]octane-8-yl or phenoxy.
[0226] In a specific implementation, R 2d is H, deuterium, cyano, halo, substituted or unsubstituted C1-C 10 Alkyl, substituted or unsubstituted C1-C 10 Heteroalkyl, substituted or unsubstituted C3-C 10 Cycloalkyl, substituted or unsubstituted C6-C 14 Aryl, substituted or unsubstituted C7-C 15 arylalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocycloalkyl, -COR', -CONR'R", -OR', -NR'R", -S(O)2R' or -S(O)2NR'R"; where each R' and R" is independently hydrogen, substituted or unsubstituted C1-C 10 Alkyl, substituted or unsubstituted C1-C10 Heteroalkyl, substituted or unsubstituted C1-C 10 Cycloalkyl, substituted or unsubstituted C6-C 14 Aryl, substituted or unsubstituted C7-C 15 It is an arylalkyl, a substituted or unsubstituted heteroaryl, or a substituted or unsubstituted heterocycloalkyl.
[0227] In a specific implementation, R 2d is H. In a specific embodiment, R 2d is deuterium. In a specific embodiment, R 2d is cyano. In a specific embodiment, R 2d is a halo. In a specific implementation, R 2d is fluoro or chloro. In certain embodiments, R 2d is a fluoro. In a specific embodiment, R 2d is chloro. In certain embodiments, R 2d is substituted or unsubstituted C1-C 10 It is an alkyl. In a specific embodiment, R 2d is methyl, ethyl, propyl, or butyl, each optionally substituted. In certain embodiments, R 2d is methyl, trifluoromethyl, ethyl, 1,1-difluoroethyl, isopropyl, tert -butyl, oxane-4-ylmethyl, morpholinomethyl, hydroxymethyl, methoxymethyl, phenoxymethyl, or dimethylaminomethyl. In certain embodiments, R 2d is methyl, trifluoromethyl, ethyl, difluoroethyl, propyl, butyl, oxanylmethyl, morpholinomethyl, hydroxymethyl, methoxymethyl, phenoxymethyl, or dimethylaminomethyl. In certain embodiments, R 2d is substituted or unsubstituted C1-C 10 It is a heteroalkyl.
[0228] In a specific implementation, R 2d is substituted or unsubstituted C3-C 10 It is a cycloalkyl. In certain embodiments, R 2dis cyclobutyl or cyclohexyl, each optionally substituted. In certain embodiments, R 2d is substituted or unsubstituted C6-C 14 It is Aryl. In a specific implementation, R 2d is a substituted or unsubstituted phenyl. In certain embodiments, R 2d is substituted or unsubstituted C7-C 15 It is an arylalkyl. In certain embodiments, R 2d is a substituted or unsubstituted heteroaryl. In certain embodiments, R 2d is a substituted or unsubstituted monocyclic heteroaryl. In certain embodiments, R 2d is a pentagonal or hexaagonal heteroaryl, each optionally substituted. In certain embodiments, R 2d is a substituted or unsubstituted 5-membered heteroaryl. In certain embodiments, R 2d is a substituted or unsubstituted pyrazolyl. In certain embodiments, R 2d is pyrazole-1-yl, pyrazole-3-yl, or pyrazole-4-yl, each optionally substituted. In a specific embodiment, R 2d is pyrazole-1-yl, pyrazole-3-yl, or pyrazole-4-yl, and each is a substituted or unsubstituted C1-C 10 It is optionally substituted with an alkyl group. In certain embodiments, R 2d is pyrazole-1-yl, 1-methylpyrazole-3-yl, 2-methylpyrazole-3-yl, or 1-methylpyrazole-4-yl. In certain embodiments, R 2d is pyrazole-1-yl, 1-methylpyrazole-3-yl, or 1-methylpyrazole-4-yl. In certain embodiments, R 2d is a substituted or unsubstituted 6-membered heteroaryl.
[0229] In a specific implementation, R 2d is a substituted or unsubstituted heterocycloalkyl. In certain embodiments, R 2d is a substituted or unsubstituted monocyclic heterocycloalkyl. In certain embodiments, R 2dis a ternary, quaternary, pentary, hexavalent, or heptary heterocycloalkyl, each optionally substituted. In certain embodiments, R 2d is a substituted or unsubstituted ternary heterocycloalkyl. In certain embodiments, R 2d is a substituted or unsubstituted quaternary heterocycloalkyl. In certain embodiments, R 2d is a substituted or unsubstituted pentomer heterocycloalkyl. In certain embodiments, R 2d is a substituted or unsubstituted 6-membered heterocycloalkyl. In certain embodiments, R 2d is a substituted or unsubstituted 7-membered heterocycloalkyl. In certain embodiments, R 2d is oxetanyl, oxanyl, piperidinyl, or morpholino, each optionally substituted. In certain embodiments, R 2d is oxetane-3-yl, oxane-4-yl, piperidine-1-yl, or morpholino, each optionally substituted. In certain embodiments, R 2d is oxetane-3-yl, oxane-4-yl, piperidin-1-yl, 4,4-difluoropiperidin-1-yl, 4-(hydroxymethyl)piperidin-1-yl, 4-hydroxypiperidin-1-yl, or morpholino. In certain embodiments, R 2d is piperidin-1-yl or morpholino.
[0230] In a specific implementation, R 2d is a substituted or unsubstituted heterocycloalkyl. In certain embodiments, R 2d is a crosslinked, fused, or spiro heterocycloalkyl, each optionally substituted. In certain embodiments, R 2d is a substituted or unsubstituted crosslinked heterocycloalkyl. In certain embodiments, R 2d is a substituted or unsubstituted 8-azabicyclo[3.2.1]octanyl. In certain embodiments, R 2d is a substituted or unsubstituted 8-azabicyclo[3.2.1]octane-8-yl. In certain embodiments, R 2dis a substituted or unsubstituted fused heterocycloalkyl. In certain embodiments, R 2d is a substituted or unsubstituted heterocycloalkyl.
[0231] In a specific implementation, R 2d is -COR', where R' is as defined herein. In certain embodiments, R 2d is -COR', where R' is the substituted or unsubstituted C1-C 10 It is an alkyl. In a specific embodiment, R 2d is -CONR'R", where R' and R" are each as defined herein. In certain embodiments, R 2d is -CONR'R", where R' and R" are independently H or substituted or unsubstituted C1-C 10 It is an alkyl. In a specific embodiment, R 2d is -OR', where R' is as defined herein. In certain embodiments, R 2d is -OR', where R' is independently H, substituted or unsubstituted C1-C 10 Alkyl or substituted or unsubstituted C6-C 14 It is Aryl. In a specific implementation, R 2d is -NR'R", where R' and R" are each as defined herein. In certain embodiments, R 2d is -NR'R", where R' and R" are independently H or substituted or unsubstituted C1-C 10 It is an alkyl. In a specific embodiment, R 2d is -S(O)2R', where R' is as defined herein. In certain embodiments, R 2d is -S(O)2R', where R' is the substituted or unsubstituted C1-C 10 It is an alkyl. In a specific embodiment, R 2d is -S(O)2NR'R"; where R' and R" are each as defined herein. In a specific embodiment, R 2dis -S(O)2NR'R"; where R' and R" are each independently H or substituted or unsubstituted C1-C 10 It is an alkyl.
[0232] In a specific implementation, R 2d is H, cyano, chloro, fluoro, methyl, trifluoromethyl, ethyl, difluoroethyl, propyl, butyl, oxanylmethyl, morpholinomethyl, hydroxymethyl, methoxymethyl, phenoxymethyl, dimethylaminomethyl, cyclobutyl, cyclohexyl, phenyl, pyrazolyl, methylpyrazolyl, oxetanyl, piperidinyl, difluoropiperidinyl, (hydroxymethyl)piperidinyl, hydroxypiperidinyl, oxanyl, morpholino, 8-azabicyclo[3.2.1]octanyl, hydroxyl, methoxy, trifluoromethoxy, hydroxyethoxy, phenoxy, benzoxy, oxanyloxy, piperidinyloxy, amino, dimethylamino, phenylamino, aminocarbonyl, methylaminocarbonyl, dimethylaminocarbonyl, methylsulfonyl or aminosulfonyl. In a specific implementation, R 2d is H, cyano, chloro, fluoro, methyl, trifluoromethyl, ethyl, difluoroethyl, propyl, butyl, oxanylmethyl, methoxymethyl, phenoxymethyl, phenyl, pyrazolyl, methylpyrazolyl, piperidinyl, morpholino, 8-azabicyclo[3.2.1]octanyl or phenoxy.
[0233] In a specific implementation, R 2d is H, cyano, chloro, fluoro, methyl, trifluoromethyl, ethyl, 1,1-difluoroethyl, isopropyl, tert -Butyl, oxane-4-ylmethyl, morpholinomethyl, hydroxymethyl, methoxymethyl, phenoxymethyl, dimethylaminomethyl, cyclobutyl, cyclohexyl, phenyl, pyrazole-1-yl, 1-methylpyrazole-3-yl, 1-methylpyrazole-4-yl, 2-methylpyrazole-3-yl, oxetane-3-yl, oxane-4-yl, piperidine-1-yl, 4,4-difluoropiperidin-1-yl, 4-(hydroxymethyl)piperidin-1-yl, 4-hydroxypiperidin-1-yl, morpholino, 8-azabicyclo[3.2.1]octane-8-yl, hydroxyl, methoxy, trifluoromethoxy, 2-hydroxyethoxy, phenoxy, benzoxy, piperidine-4-yloxy, oxane-4-yloxy, It is amino, dimethylamino, phenylamino, aminocarbonyl, methylaminocarbonyl, dimethylaminocarbonyl, methylsulfonyl, or aminosulfonyl. In certain embodiments, R 2d is H, cyano, chloro, fluoro, methyl, trifluoromethyl, ethyl, 1,1-difluoroethyl, isopropyl, tert -butyl, oxane-4-ylmethyl, methoxymethyl, phenyl, pyrazole-1-yl, 1-methylpyrazole-3-yl, 1-methylpyrazole-4-yl, piperidine-1-yl, morpholino, 8-azabicyclo[3.2.1]octane-8-yl or phenoxy.
[0234] In a specific implementation, R 2e is H, deuterium, cyano, halo, substituted or unsubstituted C1-C 10 Alkyl, substituted or unsubstituted C1-C 10 Heteroalkyl, substituted or unsubstituted C3-C 10 Cycloalkyl, substituted or unsubstituted C6-C 14 Aryl, substituted or unsubstituted C7-C 15 arylalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocycloalkyl, -COR', -CONR'R", -OR', -NR'R", -S(O)2R' or -S(O)2NR'R"; where each R' and R" is independently hydrogen, substituted or unsubstituted C1-C 10 Alkyl, substituted or unsubstituted C1-C10 Heteroalkyl, substituted or unsubstituted C1-C 10 Cycloalkyl, substituted or unsubstituted C6-C 14 Aryl, substituted or unsubstituted C7-C 15 It is an arylalkyl, a substituted or unsubstituted heteroaryl, or a substituted or unsubstituted heterocycloalkyl.
[0235] In a specific implementation, R 2e is H. In a specific embodiment, R 2e is deuterium. In a specific embodiment, R 2e is cyano. In a specific embodiment, R 2e is a halo. In a specific implementation, R 2e is fluoro or chloro. In certain embodiments, R 2e is a fluoro. In a specific embodiment, R 2e is chloro. In certain embodiments, R 2e is substituted or unsubstituted C1-C 10 It is an alkyl. In a specific embodiment, R 2e is methyl, ethyl, propyl, or butyl, each optionally substituted. In certain embodiments, R 2e is methyl, trifluoromethyl, ethyl, 1,1-difluoroethyl, isopropyl, tert -butyl, oxane-4-ylmethyl, morpholinomethyl, hydroxymethyl, methoxymethyl, phenoxymethyl, or dimethylaminomethyl. In certain embodiments, R 2e is methyl, trifluoromethyl, ethyl, difluoroethyl, propyl, butyl, oxanylmethyl, morpholinomethyl, hydroxymethyl, methoxymethyl, phenoxymethyl, or dimethylaminomethyl. In certain embodiments, R 2e is substituted or unsubstituted C1-C 10 It is a heteroalkyl.
[0236] In a specific implementation, R 2e is substituted or unsubstituted C3-C 10 It is a cycloalkyl. In certain embodiments, R 2eis cyclobutyl or cyclohexyl, each optionally substituted. In certain embodiments, R 2e is substituted or unsubstituted C6-C 14 It is Aryl. In a specific implementation, R 2e is a substituted or unsubstituted phenyl. In certain embodiments, R 2e is substituted or unsubstituted C7-C 15 It is an arylalkyl. In certain embodiments, R 2e is a substituted or unsubstituted heteroaryl. In certain embodiments, R 2e is a substituted or unsubstituted monocyclic heteroaryl. In certain embodiments, R 2e is a pentagonal or hexaagonal heteroaryl, each optionally substituted. In certain embodiments, R 2e is a substituted or unsubstituted 5-membered heteroaryl. In certain embodiments, R 2e is a substituted or unsubstituted pyrazolyl. In certain embodiments, R 2e is pyrazole-1-yl, pyrazole-3-yl, or pyrazole-4-yl, each optionally substituted. In a specific embodiment, R 2e is pyrazole-1-yl, pyrazole-3-yl, or pyrazole-4-yl, and each is a substituted or unsubstituted C1-C 10 It is optionally substituted with an alkyl group. In certain embodiments, R 2e is pyrazole-1-yl, 1-methylpyrazole-3-yl, 2-methylpyrazole-3-yl, or 1-methylpyrazole-4-yl. In certain embodiments, R 2e is pyrazole-1-yl, 1-methylpyrazole-3-yl, or 1-methylpyrazole-4-yl. In certain embodiments, R 2e is a substituted or unsubstituted 6-membered heteroaryl.
[0237] In a specific implementation, R 2e is a substituted or unsubstituted heterocycloalkyl. In certain embodiments, R 2e is a substituted or unsubstituted monocyclic heterocycloalkyl. In certain embodiments, R 2eis a ternary, quaternary, pentary, hexavalent, or heptary heterocycloalkyl, each optionally substituted. In certain embodiments, R 2e is a substituted or unsubstituted ternary heterocycloalkyl. In certain embodiments, R 2e is a substituted or unsubstituted quaternary heterocycloalkyl. In certain embodiments, R 2e is a substituted or unsubstituted pentomer heterocycloalkyl. In certain embodiments, R 2e is a substituted or unsubstituted 6-membered heterocycloalkyl. In certain embodiments, R 2e is a substituted or unsubstituted 7-membered heterocycloalkyl. In certain embodiments, R 2e is oxetanyl, oxanyl, piperidinyl, or morpholino, each optionally substituted. In certain embodiments, R 2e is oxetane-3-yl, oxane-4-yl, piperidine-1-yl, or morpholino, each optionally substituted. In certain embodiments, R 2e is oxetane-3-yl, oxane-4-yl, piperidin-1-yl, 4,4-difluoropiperidin-1-yl, 4-(hydroxymethyl)piperidin-1-yl, 4-hydroxypiperidin-1-yl, or morpholino. In certain embodiments, R 2e is piperidin-1-yl or morpholino.
[0238] In a specific implementation, R 2e is a substituted or unsubstituted heterocycloalkyl. In certain embodiments, R 2e is a crosslinked, fused, or spiro heterocycloalkyl, each optionally substituted. In certain embodiments, R 2e is a substituted or unsubstituted crosslinked heterocycloalkyl. In certain embodiments, R 2e is a substituted or unsubstituted 8-azabicyclo[3.2.1]octanyl. In certain embodiments, R 2e is a substituted or unsubstituted 8-azabicyclo[3.2.1]octane-8-yl. In certain embodiments, R 2eis a substituted or unsubstituted fused heterocycloalkyl. In certain embodiments, R 2e is a substituted or unsubstituted heterocycloalkyl.
[0239] In a specific implementation, R 2e is -COR', where R' is as defined herein. In certain embodiments, R 2e is -COR', where R' is the substituted or unsubstituted C1-C 10 It is an alkyl. In a specific embodiment, R 2e is -CONR'R", where R' and R" are each as defined herein. In certain embodiments, R 2e is -CONR'R", where R' and R" are independently H or substituted or unsubstituted C1-C 10 It is an alkyl. In a specific embodiment, R 2e is -OR', where R' is as defined herein. In certain embodiments, R 2e is -OR', where R' is independently H, substituted or unsubstituted C1-C 10 Alkyl or substituted or unsubstituted C6-C 14 It is Aryl. In a specific implementation, R 2e is -NR'R", where R' and R" are each as defined herein. In certain embodiments, R 2e is -NR'R", where R' and R" are independently H or substituted or unsubstituted C1-C 10 It is an alkyl. In a specific embodiment, R 2e is -S(O)2R', where R' is as defined herein. In certain embodiments, R 2e is -S(O)2R', where R' is the substituted or unsubstituted C1-C 10 It is an alkyl. In a specific embodiment, R 2e is -S(O)2NR'R"; where R' and R" are each as defined herein. In a specific embodiment, R 2eis -S(O)2NR'R"; where R' and R" are each independently H or substituted or unsubstituted C1-C 10 It is an alkyl.
[0240] In a specific implementation, R 2e is H, cyano, chloro, fluoro, methyl, trifluoromethyl, ethyl, difluoroethyl, propyl, butyl, oxanylmethyl, morpholinomethyl, hydroxymethyl, methoxymethyl, phenoxymethyl, dimethylaminomethyl, cyclobutyl, cyclohexyl, phenyl, pyrazolyl, methylpyrazolyl, oxetanyl, piperidinyl, difluoropiperidinyl, (hydroxymethyl)piperidinyl, hydroxypiperidinyl, oxanyl, morpholino, 8-azabicyclo[3.2.1]octanyl, hydroxyl, methoxy, trifluoromethoxy, hydroxyethoxy, phenoxy, benzoxy, oxanyloxy, piperidinyloxy, amino, dimethylamino, phenylamino, aminocarbonyl, methylaminocarbonyl, dimethylaminocarbonyl, methylsulfonyl or aminosulfonyl. In a specific implementation, R 2e is H, cyano, chloro, fluoro, methyl, trifluoromethyl, ethyl, difluoroethyl, propyl, butyl, oxanylmethyl, methoxymethyl, phenoxymethyl, phenyl, pyrazolyl, methylpyrazolyl, piperidinyl, morpholino, 8-azabicyclo[3.2.1]octanyl or phenoxy.
[0241] In a specific implementation, R 2e is H, cyano, chloro, fluoro, methyl, trifluoromethyl, ethyl, 1,1-difluoroethyl, isopropyl, tert -Butyl, oxane-4-ylmethyl, morpholinomethyl, hydroxymethyl, methoxymethyl, phenoxymethyl, dimethylaminomethyl, cyclobutyl, cyclohexyl, phenyl, pyrazole-1-yl, 1-methylpyrazole-3-yl, 1-methylpyrazole-4-yl, 2-methylpyrazole-3-yl, oxetane-3-yl, oxane-4-yl, piperidine-1-yl, 4,4-difluoropiperidin-1-yl, 4-(hydroxymethyl)piperidin-1-yl, 4-hydroxypiperidin-1-yl, morpholino, 8-azabicyclo[3.2.1]octane-8-yl, hydroxyl, methoxy, trifluoromethoxy, 2-hydroxyethoxy, phenoxy, benzoxy, piperidine-4-yloxy, oxane-4-yloxy, It is amino, dimethylamino, phenylamino, aminocarbonyl, methylaminocarbonyl, dimethylaminocarbonyl, methylsulfonyl, or aminosulfonyl. In certain embodiments, R 2e is H, cyano, chloro, fluoro, methyl, trifluoromethyl, ethyl, 1,1-difluoroethyl, isopropyl, tert -butyl, oxane-4-ylmethyl, methoxymethyl, phenyl, pyrazole-1-yl, 1-methylpyrazole-3-yl, 1-methylpyrazole-4-yl, piperidine-1-yl, morpholino, 8-azabicyclo[3.2.1]octane-8-yl or phenoxy.
[0242] In a specific implementation, R 2a and R 2b forms a substituted or unsubstituted heteroaryl or a substituted or unsubstituted heterocycloalkyl together with the carbon atoms to which they are attached. In certain embodiments, R 2a and R 2b forms a substituted or unsubstituted heteroaryl together with the carbon atoms to which they are attached. In a specific embodiment, R 2a and R 2b They form heteroaryls with the carbon atoms to which they are attached, which are optionally substituted with one, two, or three substituents, each of which is independently a deuterium, cyano, halo, substituted, or unsubstituted C1-C 10 Alkyl, substituted or unsubstituted C1-C 10Heteroalkyl, substituted or unsubstituted C3-C 10 Cycloalkyl, substituted or unsubstituted C6-C 14 Aryl, substituted or unsubstituted C7-C 15 arylalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocycloalkyl, -COR', -CONR'R", -OR', -NR'R", -S(O)2R' or -S(O)2NR'R"; where each R' and R" is independently hydrogen, substituted or unsubstituted C1-C 10 Alkyl, substituted or unsubstituted C1-C 10 Heteroalkyl, substituted or unsubstituted C1-C 10 Cycloalkyl, substituted or unsubstituted C6-C 14 Aryl, substituted or unsubstituted C7-C 15 It is an arylalkyl, a substituted or unsubstituted heteroaryl, or a substituted or unsubstituted heterocycloalkyl.
[0243] In a specific implementation, R 2a and R 2b forms a substituted or unsubstituted monocyclic heteroaryl together with the carbon atoms to which they are attached. In a specific embodiment, R 2a and R 2b They form substituted or unsubstituted pentagonal or hexaagonal heteroaryls together with the carbon atoms to which they are attached. In certain embodiments, R 2a and R 2b forms a substituted or unsubstituted pentagonal heteroaryl together with the carbon atoms to which they are attached. In a specific embodiment, R 2a and R 2b forms a substituted or unsubstituted 6-membered heteroaryl together with the carbon atoms to which they are attached. In a specific embodiment, R 2a and R 2bThey form furandyl, imidazolediyl, pyrroldyl, pyrazoldyl, 1,2,3-triazolediyl, or pyridindiyl together with the carbon atoms to which they are attached, each optionally substituted with one or two substituents, each of which is independently deuterium, cyano, halo, or substituted or unsubstituted C1-C 10 It is an alkyl. In a specific embodiment, R 2a and R 2b is formed with the carbon atoms to which they are attached to furan-2,3-diyl, imidazole-4,5-diyl, pyrrole-2,3-diyl, pyrazol-4,5-diyl, 1,2,3-triazole-4,5-diyl, or pyridine-2,3-diyl, each optionally substituted with one or two substituents, each of which is independently deuterium, cyano, fluoro, or methyl. In certain embodiments, R 2a and R 2b It forms furan-2,3-diyl, 1-methylimidazole-4,5-diyl, pyrrole-2,3-diyl, 1-methylpyrrole-2,3-diyl, pyrazole-4,5-diyl, 1-methylpyrazole-4,5-diyl, 1-methyl-1,2,3-triazole-4,5-diyl, or pyridine-2,3-diyl together with the carbon atoms to which they are attached.
[0244] In a specific implementation, R 2a and R 2b forms a substituted or unsubstituted heterocycloalkyl with the carbon atoms to which they are attached. In a specific embodiment, R 2a and R 2b They form heterocycloalkyl groups with the carbon atoms to which they are attached, which are optionally substituted with one, two, or three substituents, each of which is independently a deuterium, oxo, cyano, halo, substituted, or unsubstituted C1-C 10 Alkyl, substituted or unsubstituted C1-C 10 Heteroalkyl, substituted or unsubstituted C3-C 10 Cycloalkyl, substituted or unsubstituted C6-C 14 Aryl, substituted or unsubstituted C7-C 15arylalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocycloalkyl, -COR', -CONR'R", -OR', -NR'R", -S(O)2R' or -S(O)2NR'R"; where each R' and R" is independently hydrogen, substituted or unsubstituted C1-C 10 Alkyl, substituted or unsubstituted C1-C 10 Heteroalkyl, substituted or unsubstituted C1-C 10 Cycloalkyl, substituted or unsubstituted C6-C 14 Aryl, substituted or unsubstituted C7-C 15 It is an arylalkyl, a substituted or unsubstituted heteroaryl, or a substituted or unsubstituted heterocycloalkyl.
[0245] In a specific implementation, R 2a and R 2b forms a substituted or unsubstituted monocyclic heterocycloalkyl group together with the carbon atoms to which they are attached. In a specific embodiment, R 2a and R 2b forms a substituted or unsubstituted pentary or hexavalent heterocycloalkyl group together with the carbon atoms to which they are attached. In certain embodiments, R 2a and R 2b forms a substituted or unsubstituted pentoecycloalkyl with the carbon atoms to which they are attached. In certain embodiments, R 2a and R 2b forms a substituted or unsubstituted hexacycloalkyl group together with the carbon atoms to which they are attached. In certain embodiments, R 2a and R 2b They form tetrahydrofurandyl, pyrrolidindiyl, 1,3-dioxolandiyl, oxandyl, or morpholinediyl together with the carbon atoms to which they are attached, each optionally substituted with one or two substituents, each of which is independently an oxo, cyano, halo, or substituted or unsubstituted C1-C 10 It is an alkyl. In a specific embodiment, R 2a and R 2bThey form tetrahydrofuran-2,3-diyl, tetrahydrofuran-3,4-diyl, pyrrolidine-3,4-diyl, 1,3-dioxolane-4,5-diyl, oxane-2,3-diyl, or morpholine-2,3-diyl together with the carbon atoms to which they are attached, each optionally substituted with one or two substituents, each of which is independently oxo, fluoro, or methyl. In certain embodiments, R 2a and R 2b They form tetrahydrofuran-2,3-diyl, 5,5-dimethyltetrahydrofuran-2,3-diyl, tetrahydrofuran-3,4-diyl, pyrrolidine-3,4-diyl, 2-oxopyrrolidine-3,4-diyl, 2,2-difluoro-1,3-dioxolane-4,5-diyl, 2,2-dimethyl-1,3-dioxolane-4,5-diyl, oxane-2,3-diyl, 4-methylmorpholine-2,3-diyl, or 5-oxomorpholine-2,3-diyl together with the carbon atoms to which they are attached.
[0246] In a specific implementation, R 2b and R 2c forms a substituted or unsubstituted heteroaryl or a substituted or unsubstituted heterocycloalkyl together with the carbon atoms to which they are attached. In certain embodiments, R 2b and R 2c forms a substituted or unsubstituted heteroaryl together with the carbon atoms to which they are attached. In a specific embodiment, R 2b and R 2c They form heteroaryls with the carbon atoms to which they are attached, which are optionally substituted with one, two, or three substituents, each of which is independently a deuterium, cyano, halo, substituted, or unsubstituted C1-C 10 Alkyl, substituted or unsubstituted C1-C 10 Heteroalkyl, substituted or unsubstituted C3-C 10 Cycloalkyl, substituted or unsubstituted C6-C 14 Aryl, substituted or unsubstituted C7-C 15arylalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocycloalkyl, -COR', -CONR'R", -OR', -NR'R", -S(O)2R' or -S(O)2NR'R"; where each R' and R" is independently hydrogen, substituted or unsubstituted C1-C 10 Alkyl, substituted or unsubstituted C1-C 10 Heteroalkyl, substituted or unsubstituted C1-C 10 Cycloalkyl, substituted or unsubstituted C6-C 14 Aryl, substituted or unsubstituted C7-C 15 It is an arylalkyl, a substituted or unsubstituted heteroaryl, or a substituted or unsubstituted heterocycloalkyl.
[0247] In a specific implementation, R 2b and R 2c forms a substituted or unsubstituted monocyclic heteroaryl together with the carbon atoms to which they are attached. In a specific embodiment, R 2b and R 2c They form substituted or unsubstituted pentagonal or hexaagonal heteroaryls together with the carbon atoms to which they are attached. In certain embodiments, R 2b and R 2c forms a substituted or unsubstituted pentagonal heteroaryl together with the carbon atoms to which they are attached. In a specific embodiment, R 2b and R 2c forms a substituted or unsubstituted 6-membered heteroaryl together with the carbon atoms to which they are attached. In a specific embodiment, R 2b and R 2c They form furandyl, imidazolediyl, pyrroldyl, pyrazoldyl, 1,2,3-triazolediyl, or pyridindiyl together with the carbon atoms to which they are attached, each optionally substituted with one or two substituents, each of which is independently deuterium, cyano, halo, or substituted or unsubstituted C1-C 10 It is an alkyl. In a specific embodiment, R 2b and R 2cis formed with the carbon atoms to which they are attached to furan-2,3-diyl, imidazole-4,5-diyl, pyrrole-2,3-diyl, pyrazol-4,5-diyl, 1,2,3-triazole-4,5-diyl, or pyridine-2,3-diyl, each optionally substituted with one or two substituents, each of which is independently deuterium, cyano, fluoro, or methyl. In certain embodiments, R 2b and R 2c It forms furan-2,3-diyl, 1-methylimidazole-4,5-diyl, pyrrole-2,3-diyl, 1-methylpyrrole-2,3-diyl, pyrazole-4,5-diyl, 1-methylpyrazole-4,5-diyl, 1-methyl-1,2,3-triazole-4,5-diyl, or pyridine-2,3-diyl together with the carbon atoms to which they are attached.
[0248] In a specific implementation, R 2b and R 2c forms a substituted or unsubstituted heterocycloalkyl with the carbon atoms to which they are attached. In a specific embodiment, R 2b and R 2c They form heterocycloalkyl groups with the carbon atoms to which they are attached, which are optionally substituted with one, two, or three substituents, each of which is independently a deuterium, oxo, cyano, halo, substituted, or unsubstituted C1-C 10 Alkyl, substituted or unsubstituted C1-C 10 Heteroalkyl, substituted or unsubstituted C3-C 10 Cycloalkyl, substituted or unsubstituted C6-C 14 Aryl, substituted or unsubstituted C7-C 15 arylalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocycloalkyl, -COR', -CONR'R", -OR', -NR'R", -S(O)2R' or -S(O)2NR'R"; where each R' and R" is independently hydrogen, substituted or unsubstituted C1-C 10 Alkyl, substituted or unsubstituted C1-C 10 Heteroalkyl, substituted or unsubstituted C1-C10 Cycloalkyl, substituted or unsubstituted C6-C 14 Aryl, substituted or unsubstituted C7-C 15 It is an arylalkyl, a substituted or unsubstituted heteroaryl, or a substituted or unsubstituted heterocycloalkyl.
[0249] In a specific implementation, R 2b and R 2c forms a substituted or unsubstituted monocyclic heterocycloalkyl group together with the carbon atoms to which they are attached. In a specific embodiment, R 2b and R 2c forms a substituted or unsubstituted pentary or hexavalent heterocycloalkyl group together with the carbon atoms to which they are attached. In certain embodiments, R 2b and R 2c forms a substituted or unsubstituted pentoecycloalkyl with the carbon atoms to which they are attached. In certain embodiments, R 2b and R 2c forms a substituted or unsubstituted hexacycloalkyl group together with the carbon atoms to which they are attached. In certain embodiments, R 2b and R 2c They form tetrahydrofurandyl, pyrrolidindiyl, 1,3-dioxolandiyl, oxandyl, or morpholinediyl together with the carbon atoms to which they are attached, each optionally substituted with one or two substituents, each of which is independently an oxo, cyano, halo, or substituted or unsubstituted C1-C 10 It is an alkyl. In a specific embodiment, R 2b and R 2c They form tetrahydrofuran-2,3-diyl, tetrahydrofuran-3,4-diyl, pyrrolidine-3,4-diyl, 1,3-dioxolane-4,5-diyl, oxane-2,3-diyl, or morpholine-2,3-diyl together with the carbon atoms to which they are attached, each optionally substituted with one or two substituents, each of which is independently oxo, fluoro, or methyl. In certain embodiments, R 2b and R 2cThey form tetrahydrofuran-2,3-diyl, 5,5-dimethyltetrahydrofuran-2,3-diyl, tetrahydrofuran-3,4-diyl, pyrrolidine-3,4-diyl, 2-oxopyrrolidine-3,4-diyl, 2,2-difluoro-1,3-dioxolane-4,5-diyl, 2,2-dimethyl-1,3-dioxolane-4,5-diyl, oxane-2,3-diyl, 4-methylmorpholine-2,3-diyl, or 5-oxomorpholine-2,3-diyl together with the carbon atoms to which they are attached.
[0250] In a specific implementation, R 2 is H, substituted or unsubstituted C1-C 10 Alkyl or substituted or unsubstituted C3-C 10 It is a cycloalkyl. In certain embodiments, R 2 is H or substituted or unsubstituted C1-C 10 It is an alkyl. In a specific embodiment, R 2 is H. In a specific embodiment, R 2 is substituted or unsubstituted C1-C 10 It is an alkyl. In a specific embodiment, R 2 is substituted or unsubstituted C3-C 10 It is a cycloalkyl. In certain embodiments, R 2 is a substituted or unsubstituted monocyclic formula C3-C 10 It is a cycloalkyl.
[0251] In a specific implementation, R 3 H, substituted or unsubstituted C1-C 10 Alkyl or substituted or unsubstituted C3-C 10 It is a cycloalkyl. In certain embodiments, R 3 H or substituted or unsubstituted C1-C 10 It is an alkyl. In a specific embodiment, R 3 is H. In a specific embodiment, R 3 is substituted or unsubstituted C1-C 10 It is an alkyl. In a specific embodiment, R 3 C3-C with substituted or unsubstituted components 10 It is a cycloalkyl. In certain embodiments, R 3is a substituted or unsubstituted monocyclic C3-C 10 It is a cycloalkyl.
[0252] In a specific implementation, R 2 and R 3 Each is independently H, alkyl, or cycloalkyl. In certain embodiments, R 2 and R 3 is each independently H or alkyl. In certain embodiments, R 2 and R 3 is independently H or methyl. In certain embodiments, R 2 is methyl and R 3 is H. In a specific embodiment, R 2 and R 3 are each H. In a specific embodiment, R 2 and R 3 It forms spirocyclopropyl together.
[0253] In a specific implementation, R 2 and R 3 C(O) or substituted or unsubstituted C3-C with the carbon atoms to which they are attached 10 It forms a cycloalkyl group. In certain embodiments, R 2 and R 3 They form C(O) together with the carbon atoms to which they are attached. In a specific embodiment, R 2 and R 3 C3-C atoms that are substituted or unsubstituted together with the carbon atoms to which they are attached. 10 It forms a cycloalkyl group. In certain embodiments, R 2 and R 3 These are monocyclic C3-C atoms that are substituted or unsubstituted together with the carbon atoms to which they are attached. 10 It forms a cycloalkyl group.
[0254] In a specific implementation, R 4 is H or substituted or unsubstituted C1-C 10 It is an alkyl. In a specific embodiment, R 4 is H. In a specific embodiment, R 4is substituted or unsubstituted C1-C 10 It is an alkyl. In a specific embodiment, R 4 is unsubstituted C1-C 10 It is an alkyl. In a specific embodiment, R 4 is methyl.
[0255] In a specific implementation, R 5 is H or substituted or unsubstituted C1-C 10 It is an alkyl. In a specific embodiment, R 5 is H. In a specific embodiment, R 5 is substituted or unsubstituted C1-C 10 It is an alkyl. In a specific embodiment, R 5 is unsubstituted C1-C 10 It is an alkyl. In a specific embodiment, R 5 is methyl.
[0256] In a specific implementation, R 4 and R 5 is each independently H or alkyl. In certain embodiments, R 4 and R 5 is each independently H or methyl. In a specific embodiment, R 4 is H and R 5 is methyl. In a specific embodiment, R 4 is methyl and R 5 is H. In a specific embodiment, R 4 and R 5 are each H.
[0257] In a specific implementation, R 6 is a cycloalkyl, heterocycloalkyl, aryl, or heteroaryl. In certain embodiments, R 6 It is a heterocycloalkyl or aryl.
[0258] In a specific implementation, R 7 and R 8 Each is independently H, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl. In certain embodiments, R 7 is H and; R 8 It is a heterocycloalkyl or aryl.
[0259] In a specific implementation, R 9 , R 10 and R 11 Each is independently a monocyclic or cross-linked or spirocyclic cycloalkyl or a monocyclic or cross-linked or spirocyclic heterocycloalkyl. In certain embodiments, R 9 , R 10 and R 11 Each is independently a monocyclic, cross-linked, or spirocyclic heterocycloalkyl.
[0260] In a specific implementation, R 12 is an alkyl, aryl, or heteroaryl. In certain embodiments, R 12 is an alkyl or aryl. In certain embodiments, R 12 is an alkyl. In certain embodiments, R 12 is Aril.
[0261] In a specific implementation, R 13 is H. In a specific embodiment, R 13 It is hydroxyl.
[0262] In a specific implementation, a is an integer of 1. In a specific implementation, a is an integer of 2. In a specific implementation, a is an integer of 3.
[0263] In a specific implementation, b is an integer of 1. In a specific implementation, b is an integer of 2. In a specific implementation, b is an integer of 3.
[0264] In a specific implementation, c is an integer of 0. In a specific implementation, c is an integer of 1. In a specific implementation, c is an integer of 2.
[0265] In a specific implementation, d is an integer of 0. In a specific implementation, d is an integer of 1. In a specific implementation, d is an integer of 2.
[0266] In a specific embodiment, m, n, and q are each independently integers of 0 or 1. In a specific embodiment, m is an integer of 0. In a specific embodiment, n is an integer of 1. In a specific embodiment, p is an integer of 2. In a specific embodiment, q is an integer of 0.
[0267] In specific embodiments, each of the alkyl, alkylene, heteroalkyl, heteroalkylene, alkenyl, heteroalkenyl, alkynyl, cycloalkyl, heterocycloalkyl, cycloalkenyl, heterocycloalkenyl, aryl, arylalkyl, heteroaryl, heterocycloalkyl, alkoxy, alkylamino, and alkylthio described herein is optionally substituted with one, two, three, or four substituents, each of which is independently deuterium, cyano, halo, oxo, nitro, substituted, or unsubstituted C1-C 10 Alkyl, substituted or unsubstituted C1-C 10 Heteroalkyl, substituted or unsubstituted C3-C 10 Cycloalkyl, substituted or unsubstituted C6-C 14 Aryl, substituted or unsubstituted C7-C 15 arylalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocycloalkyl, -COR', -CO2R', -CONR'R", -OR', -OC(O)R', -OC(O)NR'R", -NR'R", -NR"C(O)R', -NR"C(O)2R', -NR'C(O)NR"R"', -NRSO2R', -NRSO2NR'R'', -SR', -S(O)R', -S(O)2R' or -S(O)2NR'R"; where R', R" and R"' are independently hydrogen, substituted or unsubstituted C1-C 10 Alkyl, substituted or unsubstituted C1-C 10 Heteroalkyl, substituted or unsubstituted C1-C 10 Cycloalkyl, substituted or unsubstituted C6-C 14 Aryl, substituted or unsubstituted C7-C 15 It is an arylalkyl, a substituted or unsubstituted heteroaryl, or a substituted or unsubstituted heterocycloalkyl.
[0268] In certain embodiments, each alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, arylalkyl, heteroaryl, heterocycloalkyl, alkoxy, and alkylamino is optionally substituted with one, two, or three substituents, each of which is independently deuterium, cyano, halo, oxo, substituted, or unsubstituted C1-C 10 Alkyl, substituted or unsubstituted C1-C 10 Heteroalkyl, substituted or unsubstituted C3-C 10 Cycloalkyl, substituted or unsubstituted C6-C 14 Aryl, substituted or unsubstituted C7-C 15 arylalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocycloalkyl, -COR', -CONR'R", -OR', -NR'R", -S(O)2R' or -S(O)2NR'R"; where each R' and R" is independently hydrogen, substituted or unsubstituted C1-C 10 Alkyl, substituted or unsubstituted C1-C 10 Heteroalkyl, substituted or unsubstituted C1-C 10 Cycloalkyl, substituted or unsubstituted C6-C 14 Aryl, substituted or unsubstituted C7-C 15 It is an arylalkyl, a substituted or unsubstituted heteroaryl, or a substituted or unsubstituted heterocycloalkyl.
[0269] In the formulas described herein, including formulas (I) to (XI) and (Ia), the group R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , R 1a , R 1b , R1c , R 1d , R 1e , R 2a , R 2b , R 2c , R 2d , R 2e , R', R", R'", R"", X, a, b, c, d, m, n, p, q, s, and t are defined in the embodiments described herein. All combinations of the embodiments provided herein for such groups are within the scope of the present disclosure.
[0270] In certain embodiments, the compound provided herein is tert -butyl 4-(6-(2,6-dioxopiperidine-3-yl)-5-oxo-6,7-dihydro-5 H -pyrrolo[3,4- b It is neither ]pyridine-2-yl)-4-hydroxypiperidin-1-carboxylate nor 3-[2-[1-[[4-[4-[6-acetyl-8-cyclopentyl-7,8-dihydro-5-methyl-7-oxopyrido[2,3- d ]pyrimidine-2-yl)amino]-3-pyridinyl]-1-piperidinyl]phenyl]methyl]-4-hydroxy-4-piperidinyl]-5,7-dihydro-5-oxo-6 H - It is not -pyrrolo[3,4-b]pyridin-6-yl]-2,6-piperidindione either.
[0271] In certain embodiments, the compound provided herein is 3-[2-[1-[[4-[4-[6-[(6-acetyl-8-cyclopentyl-7,8-dihydro-5-methyl-7-oxopyrido[2,3- d ]pyrimidine-2-yl)amino]-3-pyridinyl]-1-piperidinyl]phenyl]methyl]-4-hydroxy-4-piperidinyl]-5,7-dihydro-5-oxo-6 H - It is not pyrrolo[3,4-b]pyridin-6-yl]-2,6-piperidindione trifluoroacetate.
[0272] In certain embodiments, the compound for use in the compositions and methods provided herein is 3-(2-(1-benzyl-4-hydroxypiperidin-4-yl)-5-oxo-5,7-dihydro-6 H-pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A001 am.
[0273] In specific embodiments, the compounds for use in the compositions and methods provided herein are as follows:
[0274] 3-(2-(1-benzyl-4-hydroxypiperidin-4-yl)-5-oxo-5,7-dihydro-6 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A001 ;
[0275] 3-(2-(4-hydroxy-1-(pyridine-4-ylmethyl)piperidine-4-yl)-5-oxo-5,7-dihydro-6 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A002 ;
[0276] 3-(2-(4-hydroxy-1-(2-methylbenzyl)piperidine-4-yl)-5-oxo-5,7-dihydro-6 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A003 ;
[0277] 3-(2-(4-hydroxy-1-(4-methylbenzyl)piperidine-4-yl)-5-oxo-5,7-dihydro-6 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A004 ;
[0278] 3-(2-(4-hydroxy-1-phenetylpiperidine-4-yl)-5-oxo-5,7-dihydro-6 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A005 ;
[0279] 3-(2-(4-hydroxy-1-(2-hydroxybenzyl)piperidine-4-yl)-5-oxo-5,7-dihydro-6 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A006 ;
[0280] 3-(2-(4-hydroxy-1-(3-hydroxybenzyl)piperidine-4-yl)-5-oxo-5,7-dihydro-6 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A007 ;
[0281] 3-(2-(4-hydroxy-1-(2-cyanobenzyl)piperidine-4-yl)-5-oxo-5,7-dihydro-6 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A008 ;
[0282] 3-(2-(4-hydroxy-1-(4-cyanobenzyl)piperidin-4-yl)-5-oxo-5,7-dihydro-6 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A009 ;
[0283] 3-(2-(4-hydroxy-1-(3-cyanobenzyl)piperidine-4-yl)-5-oxo-5,7-dihydro-6 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A010 ;
[0284] 3-(2-(4-hydroxy-1-(4-(hydroxymethyl)benzyl)piperidine-4-yl)-5-oxo-5,7-dihydro-6 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A011 ;
[0285] 3-(2-(1-(4-chlorobenzyl)-4-hydroxypiperidin-4-yl)-5-oxo-5,7-dihydro-6 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A012 ;
[0286] 3-(2-(1-(2,4-difluorobenzyl)-4-hydroxypiperidin-4-yl)-5-oxo-5,7-dihydro-6 H -pyrrolo[3,4- b]pyridine-6-yl)piperidine-2,6-dione A013 ;
[0287] 3-(2-(1-(4-(dimethylamino)benzyl)-4-hydroxypiperidin-4-yl)-5-oxo-5,7-dehydro-6 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A014 ;
[0288] 3-(2-(1-([1,1'-biphenyl]-4-ylmethyl)-4-hydroxypiperidine-4-yl)-5-oxo-5,7-dihydro-6 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A015 ;
[0289] 3-(2-(4-hydroxy-1-(4-(methylsulfonyl)benzyl)piperidine-4-yl)-5-oxo-5,7-dihydro-6 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A016 ;
[0290] 3-(2-(4-hydroxy-1-(3-(trifluoromethyl)benzyl)piperidine-4-yl)-5-oxo-5,7-dihydro-6 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A017 ;
[0291] 3-(2-(4-hydroxy-1-(3-phenoxybenzyl)piperidine-4-yl)-5-oxo-5,7-dihydro-6 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A018 ;
[0292] 3-(2-(1-(cyclohexylmethyl)-4-hydroxypiperidine-4-yl)-5-oxo-5,7-dihydro-6 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A019 ;
[0293] 3-(2-(4-hydroxy-1-(3-methylbenzyl)piperidine-4-yl)-5-oxo-5,7-dihydro-6 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A020 ;
[0294] 3-(2-(1-(3-aminobenzyl)-4-hydroxypiperidin-4-yl)-5-oxo-5,7-dihydro-6 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A021 ;
[0295] 3-(2-(4-hydroxy-1-((2-oxo-1,2-dihydropyridine-4-yl)methyl)piperidine-4-yl)-5-oxo-5,7-dihydro-6 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A022 ;
[0296] 3-(2-(4-hydroxy-1-(2-methoxybenzyl)piperidine-4-yl)-5-oxo-5,7-dihydro-6 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A023 ;
[0297] 3-(2-(4-hydroxy-1-(3-methoxybenzyl)piperidine-4-yl)-5-oxo-5,7-dihydro-6 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A024 ;
[0298] 3-(2-(4-hydroxy-1-(4-methoxybenzyl)piperidine-4-yl)-5-oxo-5,7-dihydro-6 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A025 ;
[0299] 3-(2-(1-(3-chlorobenzyl)-4-hydroxypiperidin-4-yl)-5-oxo-5,7-dihydro-6 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dioneA026 ;
[0300] 3-(2-(1-(benzofuran-6-ylmethyl)-4-hydroxypiperidin-4-yl)-5-oxo-5,7-dihydro-6 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A027 ;
[0301] 3-(2-(1-((1 H -Indazole-5-yl)methyl)-4-hydroxypiperidin-4-yl)-5-oxo-5,7-dehydro-6 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A028 ;
[0302] 3-(2-(4-hydroxy-1-(pyrazolo[1,5- a ]pyridine-6-ylmethyl)piperidine-4-yl)-5-oxo-5,7-dihydro-6 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A029 ;
[0303] 3-(2-(1-((2,3-dihydro-1 H -indene-2-yl)methyl)-4-hydroxypiperidine-4-yl)-5-oxo-5,7-dehydro-6 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A030 ;
[0304] 3-(2-(4-hydroxy-1-(4-aminocarbonylphenylmethyl)piperidine-4-yl)-5-oxo-5,7-dihydro-6 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A031 ;
[0305] 3-(2-(4-hydroxy-1-(3-aminocarbonylphenylmethyl)piperidine-4-yl)-5-oxo-5,7-dihydro-6 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A032 ;
[0306] 3-(2-(1-(3-(dimethylamino)benzyl)-4-hydroxypiperidin-4-yl)-5-oxo-5,7-dehydro-6 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A033 ;
[0307] 3-(2-(4-hydroxy-1-(4-(methoxymethyl)benzyl)piperidine-4-yl)-5-oxo-5,7-dihydro-6 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A034 ;
[0308] 3-(2-(4-hydroxy-1-(quinoline-6-ylmethyl)piperidine-4-yl)-5-oxo-5,7-dihydro-6 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A035 ;
[0309] 3-(2-(4-hydroxy-1-((1-methyl-1 H -Indazole-6-yl)methyl)piperidine-4-yl)-5-oxo-5,7-dehydro-6 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A036 ;
[0310] 3-(2-(1-((1,1-deoxydotetrahydro-2 H -thiopyran-4-yl)methyl)-4-hydroxypiperidin-4-yl)-5-oxo-5,7-dehydro-6 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A037 ;
[0311] 3-(2-(4-hydroxy-1-((1-phenyl-1 H -pyrazol-4-yl)methyl)piperidine-4-yl)-5-oxo-5,7-dehydro-6 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A038 ;
[0312] 3-(2-(4-hydroxy-1-(4-(trifluoromethyl)benzyl)piperidine-4-yl)-5-oxo-5,7-dihydro-6 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A039 ;
[0313] 4-((4-(6-(2,6-dioxopiperidin-3-yl)-5-oxo-6,7-dihydro-5 H -pyrrolo[3,4- b ]pyridine-2-yl)-4-hydroxypiperidin-1-yl)methyl)- N , N -Dimethylbenzamide A040 ;
[0314] 3-(2-(1-((2,2-difluorobenzo[ d ][1,3]dioxol-5-yl)methyl)-4-hydroxypiperidin-4-yl)-5-oxo-5,7-dihydro-6 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A041 ;
[0315] 3-(2-(4-hydroxy-1-(4-(trifluoromethoxy)benzyl)piperidine-4-yl)-5-oxo-5,7-dihydro-6 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A042 ;
[0316] 3-(2-(1-(4-(benzyloxy)benzyl)-4-hydroxypiperidin-4-yl)-5-oxo-5,7-dihydro-6 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A043 ;
[0317] 3-(2-(4-hydroxy-1-((1-methyl-1 H -Indazole-5-yl)methyl)piperidine-4-yl)-5-oxo-5,7-dehydro-6 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A044 ;
[0318] 3-(2-(4-hydroxy-1-((1-methyl-1 H -pyrazol-3-yl)methyl)piperidine-4-yl)-5-oxo-5,7-dehydro-6 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A045 ;
[0319] 4-((4-(6-(2,6-dioxopiperidin-3-yl)-5-oxo-6,7-dihydro-5 H -pyrrolo[3,4- b ]pyridine-2-yl)-4-hydroxypiperidin-1-yl)methyl)- N -methylbenzamide A046 ;
[0320] 3-(2-(4-hydroxy-1-((1-(trifluoromethyl)-1 H -pyrazol-4-yl)methyl)piperidine-4-yl)-5-oxo-5,7-dehydro-6 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A047 ;
[0321] 3-(2-(4-hydroxy-1-(4-(1-methyl-1 H -pyrazol-4-yl)benzyl)piperidine-4-yl)-5-oxo-5,7-dehydro-6 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A048 ;
[0322] 3-(2-(4-hydroxy-1-((1-phenylpiperidine-4-yl)methyl)piperidine-4-yl)-5-oxo-7 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A049 ;
[0323] 3-(2-(4-hydroxy-1-(4-(phenylamino)benzyl)piperidine-4-yl)-5-oxo-5,7-dihydro-6 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A050 ;
[0324] 3-(2-(4-hydroxy-1-(4-hydroxypiperidin-1-yl)benzyl)piperidin-4-yl)-5-oxo-5,7-dihydro-6 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A051 ;
[0325] 3-(2-(1-((1 H -pyrrolo[3,2- b ]pyridine-6-yl)methyl)-4-hydroxypiperidin-4-yl)-5-oxo-5,7-dihydro-6 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A052 ;
[0326] 3-(2-(1-((2,2-dimethylbenzo[ d ][1,3]dioxol-5-yl)methyl)-4-hydroxypiperidin-4-yl)-5-oxo-5,7-dihydro-6 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A053 ;
[0327] 3-(2-(1-((2,2-dimethyl-2,3-dihydrobenzofuran-6-yl)methyl)-4-hydroxypiperidin-4-yl)-5-oxo-5,7-dihydro-6 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A054 ;
[0328] 3-(2-(4-hydroxy-1-(isoxazole-4-ylmethyl)piperidine-4-yl)-5-oxo-5,7-dihydro-6 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A055 ;
[0329] 3-(2-(4-hydroxy-1-((tetrahydro-2 H -pyran-4-yl)methyl)piperidine-4-yl)-5-oxo-5,7-dehydro-6 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A056 ;
[0330] 3-(2-(4-hydroxy-1-((1-methyl-1 H -Benzo[ d ][1,2,3]triazole-5-yl)methyl)piperidine-4-yl)-5-oxo-5,7-dihydro-6 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A057 ;
[0331] 3-(2-(1-(4-((dimethylamino)methyl)benzyl)-4-hydroxypiperidin-4-yl)-5-oxo-5,7-dehydro-6 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A058 ;
[0332] 3-(2-(4-hydroxy-1-(4-phenoxybenzyl)piperidine-4-yl)-5-oxo-5,7-dihydro-6 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A059 ;
[0333] 3-(2-(4-hydroxy-1-(4-((tetrahydro-2 H -pyran-4-yl)oxy)benzyl)piperidin-4-yl)-5-oxo-5,7-dehydro-6 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A060 ;
[0334] 3-(2-(4-hydroxy-1-(4-(4-(hydroxymethyl)piperidine-1-yl)benzyl)piperidine-4-yl)-5-oxo-5,7-dihydro-6 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A061 ;
[0335] 3-(2-(4-hydroxy-1-(4-(phenoxymethyl)benzyl)piperidine-4-yl)-5-oxo-5,7-dihydro-6 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A062 ;
[0336] 3-(2-(1-((1-(3-chlorophenyl)-4-piperidyl)methyl)-4-hydroxy-4-piperidyl)-5-oxo-7 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A063 ;
[0337] 3-(2-(1-((1-(2-chlorophenyl)-4-piperidyl)methyl)-4-hydroxy-4-piperidyl)-5-oxo-7 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A064 ;
[0338] 3-(2-(1-((1-(4-chlorophenyl)piperidine-4-yl)methyl)-4-hydroxypiperidine-4-yl)-5-oxo-5,7-dihydro-6 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A065 ;
[0339] 3-(2-(4-hydroxy-1-((4-(1-methylpyrazole-3-yl)phenyl)methyl)-4-piperidyl)-5-oxo-7 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A066 ;
[0340] 3-(2-(4-hydroxy-1-((4-(2-methylpyrazole-3-yl)phenyl)methyl)-4-piperidyl)-5-oxo-7 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A067 ;
[0341] 3-(2-(4-hydroxy-1-((4-pyrazol-1-ylphenyl)methyl)-4-piperidyl)-5-oxo-7 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A068 ;
[0342] 3-(2-(4-hydroxy-1-((1-(2-pyridyl)-4-piperidyl)methyl)-4-piperidyl)-5-oxo-7 H -pyrrolo[3,4- b]pyridine-6-yl)piperidine-2,6-dione A069 ;
[0343] 3-(2-(4-hydroxy-1-((( R )-1-phenylpiperidine-3-yl)methyl)piperidine-4-yl)-5-oxo-5,7-dihydro-6 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A070 ;
[0344] 3-(2-(4-hydroxy-1-((1-(pyridine-3-yl)piperidine-4-yl)methyl)piperidine-4-yl)-5-oxo-5,7-dihydro-6 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A071 ;
[0345] 3-(2-(4-hydroxy-1-((8-phenyl-8-azabicyclo[3.2.1]octane-3-yl)methyl)-4-piperidyl)-5-oxo-7 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A072 ;
[0346] 3-(2-(4-hydroxy-1-((1-phenylazetidin-3-yl)methyl)piperidine-4-yl)-5-oxo-5,7-dihydro-6 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A073 ;
[0347] 3-(2-(1-(4-chlorobenzoyl)-4-hydroxypiperidin-4-yl)-5-oxo-5,7-dihydro-6 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A074 ;
[0348] 3-(2-(1-(3,4-dimethoxybenzyl)-4-hydroxypiperidin-4-yl)-5-oxo-5,7-dihydro-6 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A075 ;
[0349] 3-(2-(4-hydroxy-1-((1-methylindole-5-yl)methyl)-4-piperidyl)-5-oxo-7 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A076 ;
[0350] 3-(2-(4-hydroxy-1-((1-methylindazole-4-yl)methyl)-4-piperidyl)-5-oxo-7 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A077 ;
[0351] 3-(2-(4-hydroxy-1-((4-(oxetane-3-yl)phenyl)methyl)-4-piperidyl)-5-oxo-7 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A078 ;
[0352] 3-(2-(4-hydroxy-1-((3-(1-piperidyl)phenyl)methyl)-4-piperidyl)-5-oxo-7 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A079 ;
[0353] 3-(2-(1-((4-(4,4-difluoro-1-piperidyl)phenyl)methyl)-4-hydroxy-4-piperidyl)-5-oxo-7 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A080 ;
[0354] 3-(2-(4-hydroxy-1-(4-(piperidin-1-yl)benzyl)piperidin-4-yl)-5-oxo-5,7-dihydro-6 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A081 ;
[0355] 3-(2-(4-hydroxy-1-((4-tetrahydropyran-4-ylphenyl)methyl)-4-piperidyl)-5-oxo-7 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dioneA082 ;
[0356] 3-(2-(4-hydroxy-1-(3-(tetrahydro-2 H -pyran-4-yl)benzyl)piperidin-4-yl)-5-oxo-5,7-dehydro-6 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A083 ;
[0357] 3-(2-(1-((3-fluorophenyl)methyl)-4-hydroxy-4-piperidyl)-5-oxo-7 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A084 ;
[0358] 3-(2-(4-hydroxy-1-((4-morpholinophenyl)methyl)-4-piperidyl)-5-oxo-7 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A085 ;
[0359] 3-(2-(4-hydroxy-1-((3-morpholinophenyl)methyl)-4-piperidyl)-5-oxo-7 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A086 ;
[0360] 3-(2-(4-hydroxy-1-((3-(oxetane-3-yl)phenyl)methyl)-4-piperidyl)-5-oxo-7 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A087 ;
[0361] 3-(2-(4-hydroxy-1-((4-(tetrahydropyran-4-ylmethyl)phenyl)methyl)-4-piperidyl)-5-oxo-7 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A088 ;
[0362] 3-(2-(1-((2-fluorophenyl)methyl)-4-hydroxy-4-piperidyl)-5-oxo-7 H -pyrrolo[3,4-b ]pyridine-6-yl)piperidine-2,6-dione A089 ;
[0363] 3-(2-(4-hydroxy-1-isobutyl-4-piperidyl)-5-oxo-7 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A090 ;
[0364] 3-(2-(1-((3-fluorobicyclo[1.1.1]pentane-1-yl)methyl)-4-hydroxypiperidine-4-yl)-5-oxo-5,7-dihydro-6 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A091 ;
[0365] 3-(2-(4-hydroxy-1-((1-methylbenzimidazole-5-yl)methyl)-4-piperidyl)-5-oxo-7 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A092 ;
[0366] 3-(2-(4-hydroxy-1-((3-methylbenzimidazole-5-yl)methyl)-4-piperidyl)-5-oxo-7 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A093 ;
[0367] 3-(2-(4-hydroxy-1-((1-methylindole-6-yl)methyl)-4-piperidyl)-5-oxo-7 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A094 ;
[0368] 3-(2-(4-hydroxy-1-((4-(morpholinomethyl)phenyl)methyl)-4-piperidyl)-5-oxo-7 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A095 ;
[0369] 3-(2-(1-((4-fluorophenyl)methyl)-4-hydroxy-4-piperidyl)-5-oxo-7H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A096 ;
[0370] (3 S )-3-((7 S )-2-(1-benzyl-4-hydroxy-4-piperidyl)-7-methyl-5-oxo-7 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A097 ;
[0371] ( S )-3-(( R )-2-(4-hydroxy-1-((1-phenylpiperidine-4-yl)methyl)piperidine-4-yl)-7-methyl-5-oxo-5,7-dihydro-6 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A098 ;
[0372] 3-(2-(1-(2-(3-fluorophenyl)ethyl)-4-hydroxy-4-piperidyl)-5-oxo-7 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A099 ;
[0373] 3-(2-(1-(chroman-7-ylmethyl)-4-hydroxy-4-piperidyl)-5-oxo-7 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A100 ;
[0374] 3-(2-(1-(chroman-6-ylmethyl)-4-hydroxypiperidin-4-yl)-5-oxo-5,7-dihydro-6 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A101 ;
[0375] 3-(2-(1-((2,3-dihydrobenzofuran-6-yl)methyl)-4-hydroxypiperidin-4-yl)-5-oxo-5,7-dihydro-6 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dioneA102 ;
[0376] 3-(2-(1-(2,3-dihydrobenzofuran-5-ylmethyl)-4-hydroxy-4-piperidyl)-5-oxo-7 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A103 ;
[0377] 3-(2-(1-(1,3-dihydroisobenzofuran-5-ylmethyl)-4-hydroxy-4-piperidyl)-5-oxo-7 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A104 ;
[0378] 3-(2-((3 S ,4 S )-1-benzyl-3,4-dihydroxy-4-piperidyl)-5-oxo-7 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A105 ;
[0379] 3-(2-((3 R ,4 R )-1-benzyl-3,4-dihydroxy-4-piperidyl)-5-oxo-7 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A106 ;
[0380] 3-(2-(1-((3,4-bis(trifluoromethyl)phenyl)methyl)-4-hydroxy-4-piperidyl)-5-oxo-7 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A107 ;
[0381] 3-(2-(1-((4- tert -butylphenyl)methyl)-4-hydroxy-4-piperidyl)-5-oxo-7 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A108 ;
[0382] 3-(2-(1-((3- tert -butylphenyl)methyl)-4-hydroxy-4-piperidyl)-5-oxo-7 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A109 ;
[0383] 3-(2-(4-hydroxy-1-((4-isopropylphenyl)methyl)-4-piperidyl)-5-oxo-7 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A110 ;
[0384] 3-(2-(4-hydroxy-1-((3-isopropylphenyl)methyl)-4-piperidyl)-5-oxo-7 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A111 ;
[0385] 3-(2-(1-((3-(1,1-difluoroethyl)phenyl)methyl)-4-hydroxy-4-piperidyl)-5-oxo-7 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A112 ;
[0386] 3-(2-(1-((4-(1,1-difluoroethyl)phenyl)methyl)-4-hydroxy-4-piperidyl)-5-oxo-7 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A113 ;
[0387] 3-(2-(1-(4-ethylbenzyl)-4-hydroxypiperidin-4-yl)-5-oxo-5,7-dihydro-6 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A114 ;
[0388] 3-(2-(1-(4-chloro-3-methylbenzyl)-4-hydroxypiperidin-4-yl)-5-oxo-5,7-dihydro-6 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A115 ;
[0389] 3-(2-(1-(4-((1 R ,5 S )-8-azabicyclo[3.2.1]octane-8-yl)benzyl)-4-hydroxypiperidine-4-yl)-5-oxo-5,7-dihydro-6 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A116 ;
[0390] 3-(2-(1-(4-cyclobutylbenzyl)-4-hydroxypiperidin-4-yl)-5-oxo-5,7-dihydro-6 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A117 ;
[0391] 3-(2-(1-(3-ethylbenzyl)-4-hydroxypiperidin-4-yl)-5-oxo-5,7-dihydro-6 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A118 ;
[0392] 3-(2-(1-(4-chloro-3-fluorobenzyl)-4-hydroxypiperidin-4-yl)-5-oxo-5,7-dihydro-6 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A119 ;
[0393] 3-(2-(1-(3-cyclobutylbenzyl)-4-hydroxypiperidin-4-yl)-5-oxo-5,7-dihydro-6 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A120 ;
[0394] 3-(2-(1-((3-((1 R ,5 S )-8-azabicyclo[3.2.1]octane-8-yl)phenyl)methyl)-4-hydroxy-4-piperidyl)-5-oxo-7 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A121 ;
[0395] 3-(2-(1-(4-cyclohexylbenzyl)-4-hydroxypiperidin-4-yl)-5-oxo-5,7-dihydro-6 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A122 ;
[0396] 4-((4-(6-(( S )-2,6-dioxopiperidine-3-yl)-7-methyl-5-oxo-6,7-dihydro-5 H -pyrrolo[3,4- b ]pyridine-2-yl)-4-hydroxypiperidin-1-yl)methyl)benzonitrile A123 ;
[0397] 4-((4-(( R )-6-(( S )-2,6-dioxopiperidine-3-yl)-7-methyl-5-oxo-6,7-dihydro-5 H -pyrrolo[3,4- b ]pyridine-2-yl)-4-hydroxypiperidin-1-yl)methyl)benzonitrile A124 ;
[0398] 3-(2-{4-hydroxy-1-[(1 H -pyrazol-4-yl)methyl]piperidine-4-yl}-5-oxo-5 H ,6 H ,7 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A125 ;
[0399] 3-(2-{4-hydroxy-1-[(1,3-oxazole-2-yl)methyl]piperidine-4-yl}-5-oxo-5 H ,6 H ,7 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A126 ;
[0400] 3-(2-{4-hydroxy-1-[(1 H -1,2,4-triazole-3-yl)methyl]piperidine-4-yl}-5-oxo-5 H ,6 H ,7 H -pyrrolo[3,4- b]pyridine-6-yl)piperidine-2,6-dione A127 ;
[0401] 3-(2-{4-hydroxy-1-[(pyridine-3-yl)methyl]piperidine-4-yl}-5-oxo-5 H ,6 H ,7 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A128 ;
[0402] 3-(2-{4-hydroxy-1-[(pyridine-2-yl)methyl]piperidine-4-yl}-5-oxo-5 H ,6 H ,7 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A129 ;
[0403] 3-(2-{4-hydroxy-1-[(1-methyl-1 H -pyrazol-4-yl)methyl]piperidine-4-yl}-5-oxo-5 H ,6 H ,7 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A130 ;
[0404] 3-(2-{4-hydroxy-1-[(1,3-thiazole-2-yl)methyl]piperidine-4-yl}-5-oxo-5 H ,6 H ,7 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A131 ;
[0405] 3-(2-{4-hydroxy-1-[(piperidine-4-yl)methyl]piperidine-4-yl}-5-oxo-5 H ,6 H ,7 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A132 ;
[0406] 3-(2-{4-hydroxy-1-[(oxane-2-yl)methyl]piperidine-4-yl}-5-oxo-5 H ,6H ,7 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A133 ;
[0407] 3-(2-{4-hydroxy-1-[(oxane-3-yl)methyl]piperidine-4-yl}-5-oxo-5 H ,6 H ,7 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A134 ;
[0408] 3-(2-{4-hydroxy-1-[(4-hydroxyphenyl)methyl]piperidine-4-yl}-5-oxo-5 H ,6 H ,7 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A135 ;
[0409] 3-{2-[1-({2-azaspiro[3.3]heptane-6-yl}methyl)-4-hydroxypiperidin-4-yl]-5-oxo-5 H ,6 H ,7 H -pyrrolo[3,4- b ]pyridine-6-yl}piperidin-2,6-dion A136 ;
[0410] 3-(2-{4-hydroxy-1-[(5-methyl-1,3-thiazole-2-yl)methyl]piperidine-4-yl}-5-oxo-5 H ,6 H ,7 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A137 ;
[0411] 3-[2-(4-hydroxy-1-{[(1 r ,4 r )-4-aminocyclohexyl]methyl}piperidine-4-yl)-5-oxo-5 H ,6 H ,7 H -pyrrolo[3,4- b ]pyridine-6-yl]piperidin-2,6-dione A138 ;
[0412] 3-{2-[4-hydroxy-1-({5 H ,6 H ,7 H -pyrrolo[1,2- a ]imidazole-2-yl}methyl)piperidine-4-yl]-5-oxo-5 H ,6 H ,7 H -pyrrolo[3,4- b ]pyridine-6-yl}piperidin-2,6-dion A139 ;
[0413] 3-(2-{4-hydroxy-1-[(1-methyl-2-oxo-1,2-dihydropyridine-4-yl)methyl]piperidine-4-yl}-5-oxo-5 H ,6 H ,7 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A140 ;
[0414] 3-[2-(4-hydroxy-1-{[1-(propane-2-yl)-1 H -pyrazol-4-yl]methyl}piperidine-4-yl)-5-oxo-5 H ,6 H ,7 H -pyrrolo[3,4- b ]pyridine-6-yl]piperidin-2,6-dione A141 ;
[0415] 3-{2-[4-hydroxy-1-({imidazo[1,2- a ]pyridine-2-yl}methyl)piperidine-4-yl]-5-oxo-5 H ,6 H ,7 H -pyrrolo[3,4- b ]pyridine-6-yl}piperidin-2,6-dion A142 ;
[0416] 3-{2-[4-hydroxy-1-({1 H -pyrrolo[2,3- b ]pyridine-5-yl}methyl)piperidine-4-yl]-5-oxo-5 H ,6 H ,7 H -pyrrolo[3,4- b ]pyridine-6-yl}piperidin-2,6-dionA143 ;
[0417] 3-(2-{1-[(1,3-benzoxazole-2-yl)methyl]-4-hydroxypiperidin-4-yl}-5-oxo-5 H ,6 H ,7 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A144 ;
[0418] 3-{2-[4-hydroxy-1-({[1,2,4]triazolo[1,5- a ]pyridine-7-yl}methyl)piperidine-4-yl]-5-oxo-5 H ,6 H ,7 H -pyrrolo[3,4- b ]pyridine-6-yl}piperidin-2,6-dion A145 ;
[0419] 3-(2-{1-[(2,3-dihydro-1 H -isoindole-5-yl)methyl]-4-hydroxypiperidin-4-yl}-5-oxo-5 H ,6 H ,7 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A146 ;
[0420] 3-{2-[4-hydroxy-1-({4 H ,5 H ,6 H ,7 H -pyrazolo[1,5- a ]pyridine-3-yl}methyl)piperidine-4-yl]-5-oxo-5 H ,6 H ,7 H -pyrrolo[3,4- b ]pyridine-6-yl}piperidin-2,6-dion A147 ;
[0421] 3-{2-[1-({4 H ,5 H ,6 H -Cyclopenta[ d ][1,3]thiazole-2-yl}methyl)-4-hydroxypiperidin-4-yl]-5-oxo-5 H ,6H ,7 H -pyrrolo[3,4- b ]pyridine-6-yl}piperidin-2,6-dion A148 ;
[0422] 3-{2-[1-({2-azaspiro[3.5]nonan-7-yl}methyl)-4-hydroxypiperidin-4-yl]-5-oxo-5 H ,6 H ,7 H -pyrrolo[3,4- b ]pyridine-6-yl}piperidin-2,6-dion A149 ;
[0423] 3-(2-{1-[(1-acetylpiperidin-4-yl)methyl]-4-hydroxypiperidin-4-yl}-5-oxo-5 H ,6 H ,7 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A150 ;
[0424] 3-[2-(4-hydroxy-1-{[1-(propane-2-yl)piperidine-4-yl]methyl}piperidine-4-yl)-5-oxo-5 H ,6 H ,7 H -pyrrolo[3,4- b ]pyridine-6-yl]piperidin-2,6-dione A151 ;
[0425] 3-(2-{4-hydroxy-1-[(quinoline-2-yl)methyl]piperidine-4-yl}-5-oxo-5 H ,6 H ,7 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A152 ;
[0426] 3-(2-{4-hydroxy-1-[(3-oxo-2,3-dihydro-1 H -isoindole-5-yl)methyl]piperidine-4-yl}-5-oxo-5 H ,6 H ,7 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A153 ;
[0427] 3-[(4-{6-[2,6-dioxopiperidin-3-yl]-5-oxo-5 H ,6 H ,7 H -pyrrolo[3,4- b ]pyridine-2-yl}-4-hydroxypiperidin-1-yl)methyl]- N -methylbenzamide A154 ;
[0428] 3-(2-{1-[(1,3-benzothiazole-2-yl)methyl]-4-hydroxypiperidin-4-yl}-5-oxo-5 H ,6 H ,7 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A155 ;
[0429] 3-[2-(4-hydroxy-1-{[4-(2-hydroxyethoxy)phenyl]methyl}piperidine-4-yl)-5-oxo-5 H ,6 H ,7 H -pyrrolo[3,4- b ]pyridine-6-yl]piperidin-2,6-dione A156 ;
[0430] 3-[2-(4-hydroxy-1-{[4-(2 H -1,2,3,4-tetrazole-5-yl)phenyl]methyl}piperidine-4-yl)-5-oxo-5 H ,6 H ,7 H -pyrrolo[3,4- b ]pyridine-6-yl]piperidin-2,6-dione A157 ;
[0431] 3-(2-{4-hydroxy-1-[(3-oxo-3,4-dihydro-2 H -1,4-benzoxazine-6-yl)methyl]piperidine-4-yl}-5-oxo-5 H ,6 H ,7 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A158 ;
[0432] 3-{2-[4-hydroxy-1-({4-methyl-2H ,3 H ,4 H -Pirido[3,2- b ][1,4]oxazine-7-yl}methyl)piperidine-4-yl]-5-oxo-5 H ,6 H ,7 H -pyrrolo[3,4- b ]pyridine-6-yl}piperidin-2,6-dion A159 ;
[0433] 3-{2-[1-({3-azaspiro[5.5]undecane-9-yl}methyl)-4-hydroxypiperidin-4-yl]-5-oxo-5 H ,6 H ,7 H -pyrrolo[3,4- b ]pyridine-6-yl}piperidin-2,6-dion A160 ;
[0434] 4-[(4-{6-[2,6-dioxopiperidin-3-yl]-5-oxo-5 H ,6 H ,7 H -pyrrolo[3,4- b ]pyridine-2-yl}-4-hydroxypiperidin-1-yl)methyl]benzene-1-sulfonamide A161 ;
[0435] 3-(2-{4-hydroxy-1-[(5-methyl-1 H -pyrazol-4-yl)methyl]piperidine-4-yl}-5-oxo-5 H ,6 H ,7 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A162 ;
[0436] 3-(2-{4-hydroxy-1-[(5-methyl-1,3,4-thiadiazole-2-yl)methyl]piperidine-4-yl}-5-oxo-5 H ,6 H ,7 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A163 ;
[0437] 3-[2-(4-hydroxy-1-{[1-(propane-2-yl)-1 H-pyrazol-3-yl]methyl}piperidine-4-yl)-5-oxo-5 H ,6 H ,7 H -pyrrolo[3,4- b ]pyridine-6-yl]piperidin-2,6-dione A164 ;
[0438] 3-{2-[4-hydroxy-1-({1 H -pyrrolo[3,2- b ]pyridine-2-yl}methyl)piperidine-4-yl]-5-oxo-5 H ,6 H ,7 H -pyrrolo[3,4- b ]pyridine-6-yl}piperidin-2,6-dion A165 ;
[0439] 3-{2-[4-hydroxy-1-({5 H ,6 H ,7 H ,8 H -Imidajo[1,2- a ]pyridine-2-yl}methyl)piperidine-4-yl]-5-oxo-5 H ,6 H ,7 H -pyrrolo[3,4- b ]pyridine-6-yl}piperidin-2,6-dion A166 ;
[0440] 3-[2-(4-hydroxy-1-{[4-(piperidin-4-yloxy)phenyl]methyl}piperidin-4-yl)-5-oxo-5 H ,6 H ,7 H -pyrrolo[3,4- b ]pyridine-6-yl]piperidin-2,6-dione A167 ;
[0441] 3-(2-{1-[(1-benzylpiperidin-4-yl)methyl]-4-hydroxypiperidin-4-yl}-5-oxo-5 H ,6 H ,7 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A168 ; or
[0442] 3-(2-{4-hydroxy-1-[(quinoline-3-yl)methyl]piperidine-4-yl}-5-oxo-5 H ,6 H ,7 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A169 ;
[0443] or its enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, or a mixture of two or more tautomers; or its pharmaceutically acceptable salt, solvate, hydrate, or prodrug.
[0444] III. Synthesis of compounds
[0445] The compounds provided herein can be synthesized using methods widely known to those skilled in the art. In one embodiment, the compounds provided herein are prepared as shown in Reaction Scheme I, where R 1 , R 2 , R 3 , X, a, b, c and d are each as defined herein; LG is a leaving group, e.g., chloro, bromo, iodo, or tosyloxy.
[0446]
[0447] In another embodiment, the compound provided herein is prepared as shown in Reaction Scheme II, where R 1 , R 2 , R 3 , X, LG, a, b, c, and d are each as defined herein.
[0448]
[0449] IV. Pharmaceutical composition
[0450] The pharmaceutical composition provided herein contains a therapeutically effective amount of one or more of the compounds provided herein and a pharmaceutically acceptable carrier, diluent, or excipient.
[0451] The compound may be formulated into suitable pharmaceutical preparations for oral administration, such as solutions, suspensions, tablets, dispersible tablets, pills, capsules, powders, sustained-release formulations, or elixirs; or into sterile solutions or suspensions for ophthalmic or parenteral administration; and into transdermal patch formulations and dry powder inhalers. Typically, the compound described above is formulated into a pharmaceutical composition using techniques and procedures widely known in the art. For example, Pharmaceutical Dosage Forms and Drug Delivery Systems , 7th ed.; Ansel et al. , See Ed.; Lippincott Williams & Williams, 1999.
[0452] In the composition, an effective concentration of one or more compounds or pharmaceutically acceptable salts is mixed with a suitable pharmaceutical carrier or vehicle. In certain embodiments, the concentration of the compound in the composition is effective to deliver an amount that, upon administration, treats, prevents, or alleviates one or more of the symptoms and / or progression of the disease or disorder disclosed herein.
[0453] Typically, the composition is formulated for a single dose administration. To formulate the composition, a weight fraction of the compound is dissolved, suspended, dispersed, or otherwise mixed in a vehicle selected at an effective concentration to alleviate or relieve the condition being treated. A pharmaceutical carrier or vehicle suitable for administering the compound provided herein comprises any such carrier known to those skilled in the art as suitable for a particular mode of administration.
[0454] Additionally, the compound may be formulated as the sole pharmaceutically active ingredient in the composition or combined with other active ingredients. Liposomal suspensions containing tissue-targeting liposomes, such as tumor-targeting liposomes, may also be suitable as pharmaceutically acceptable carriers. These may be prepared according to methods known to those skilled in the art. For example, liposomal formulations may be prepared as known in the art. Briefly, liposomes such as multilamellar vesicles (MLVs) may be formed by drying egg yolk phosphatidylcholine and brain phosphatidylserine (7:3 molar ratio) inside a flask. A solution of the compound provided herein is added in phosphate buffered saline (PBS) free of divalent cations, and the flask is shaken until the lipid membrane is dispersed. The resulting vesicles are washed to remove unencapsulated compound, pelleted by centrifugation, and then resuspended in PBS.
[0455] The active compound is contained in a pharmaceutically acceptable carrier in an amount sufficient to exert a therapeutically useful effect without undesirable side effects on the subject being treated. The therapeutically effective concentration can be determined empirically by testing the compound in the in vitro and in vivo systems described herein, and then the dosage for humans can be extrapolated from this. In some embodiments, the active compound is administered by a method to achieve a therapeutically effective concentration of the drug. In some embodiments, companion diagnostics are used to determine the therapeutic concentration and safety profile of the active compound in a specific subject or population of subjects. Olsen and Jorgensen, Front. Oncol. 2014 , 4 , 105.
[0456] The concentration of the active compound in the pharmaceutical composition will depend on the absorption, tissue distribution, inactivation and excretion rates of the active compound, the physicochemical properties of the compound, the administration schedule and dosage, as well as other factors known to those skilled in the art. For example, the amount delivered is sufficient to alleviate one or more of the symptoms of the disease or disorder disclosed herein.
[0457] In a specific embodiment, the therapeutically effective dose should produce a serum concentration of the active ingredient of about 0.1 ng / mL to about 50-100 μg / mL. In one embodiment, the pharmaceutical composition provides a dose of the compound of about 0.001 mg to about 2000 mg per kilogram of body weight per day. The pharmaceutical dosage unit form is prepared to provide about 1 mg to about 1,000 mg, and in a specific embodiment, about 10 to about 500 mg of the essential active ingredient or combination of essential ingredients per dosage unit form.
[0458] The active ingredient may be administered at once or divided into multiple smaller doses administered at time intervals. It is understood that the exact dosage and duration of treatment are a function of the disease being treated and may be determined empirically by using known test protocols or by extrapolating from in vivo or in vitro test data. It should be noted that concentration and dosage values may vary depending on the severity of the condition to be relieved. Furthermore, for any specific subject, the specific administration regimen should be adjusted over time according to the individual's needs and the professional judgment of the person administering or supervising the administration of the composition, and it should be understood that the concentration ranges presented herein are merely exemplary and are not intended to limit the scope or practice of the claimed composition.
[0459] Accordingly, one or more effective concentrations or amounts of the compounds described herein or pharmaceutically acceptable salts thereof are mixed with a suitable pharmaceutical carrier or vehicle for systemic, local, or topical administration to form a pharmaceutical composition. The compounds are included in an amount effective for relieving, treating, delaying the progression, or preventing one or more symptoms. The concentration of the active compound in the composition will depend on the absorption, tissue distribution, inactivation, and excretion rates of the active compound, the administration schedule, dosage, specific formulation, as well as other factors known to those skilled in the art.
[0460] The composition is intended to be administered by a suitable route including, but not limited to, oral, parenteral, subcutaneous, intravenous, intramuscular, intraperitoneal, intrathecal, mucosal, dermal, transdermal, buccal, rectal, topical, local, nasal, or inhalation. For oral administration, capsules and tablets may be formulated. The composition is in liquid, semi-liquid, or solid form and is formulated in a manner suitable for each respective route of administration.
[0461] Solutions or suspensions used for parenteral, intradermal, subcutaneous, or topical application may contain any of the following components: sterile diluents such as water for injection, saline solution, fixative oil, polyethylene glycol, glycerin, propylene glycol, dimethylacetamide, or other synthetic solvents; antimicrobial agents such as benzyl alcohol and methyl paraben; antioxidants such as ascorbic acid and sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid (EDTA); buffers such as acetates, citrates, and phosphates; and isotonic modifiers such as sodium chloride or dextrose. Parenteral formulations may be encapsulated in ampoules, pens, disposable syringes, or single or multiple dose vials made of glass, plastic, or other suitable materials.
[0462] If the compound exhibits insufficient solubility, a method to solubilize the compound may be used. Such methods are known to those skilled in the art and include, but are not limited to, the use of a co-solvent such as dimethyl sulfoxide (DMSO), the use of a surfactant such as TWEEN®, or dissolution in aqueous sodium bicarbonate.
[0463] When compound(s) are mixed or added, the resulting mixture may be a solution, suspension, emulsion, etc. The form of the resulting mixture depends on a number of factors, including the intended mode of administration and the solubility of the compound in a selected carrier or vehicle. The effective concentration is sufficient to alleviate the symptoms of the disease, disorder, or condition being treated and can be determined empirically.
[0464] Pharmaceutical compositions are provided for administration to humans and animals in unit dosage forms, such as tablets, capsules, pills, powders, granules, sterile parenteral solutions or suspensions, and oral solutions or suspensions, and oil-water emulsions containing suitable amounts of a compound or a pharmaceutically acceptable salt thereof. Compounds that are pharmaceutically therapeutically active and salts thereof are formulated and administered in unit dosage forms or multiple dosage forms. As used herein, a unit dosage form refers to physically distinct units that are individually packaged and suitable for human and animal subjects and are known in the art. Each unit dose contains a predetermined amount of the therapeutically active compound sufficient to produce the desired therapeutic effect, together with the necessary pharmaceutical carrier, vehicle, or diluent. Examples of unit dosage forms include ampoules and syringes and individually packaged tablets or capsules. A unit dosage form may be administered in fractions or multiples thereof. A multiple dosage form is a plurality of identical unit dosage forms packaged in a single container to be administered as separate unit dosage forms. Examples of multiple-dose forms include vials, tablets or capsule bottles, or pint or gallon bottles. Thus, a multiple-dose form is a multiple of the unit dose that is not separated from the packaging.
[0465] Sustained-release formulations may also be manufactured. Suitable examples of sustained-release formulations include a semipermeable matrix of a solid hydrophobic polymer containing the compounds provided herein, such matrix in the form of a molded article such as a film or microcapsule. Examples of sustained-release matrices include iontophoresis patches, polyesters, hydrogels (e.g., poly(2-hydroxyethyl-methacrylate) or poly(vinyl alcohol)), polylactide, copolymers of L-glutamic acid and ethyl-L-glutamate, non-degradable ethylene-vinyl acetate, degradable lactic acid-glycolic acid copolymers such as LUPRON DEPOT™ (injectable microspheres composed of a lactic acid-glycolic acid copolymer and leuprolide acetate), and poly-D-(-)-3-hydroxybutyric acid. Polymers such as ethylene-vinyl acetate and lactic acid-glycolic acid enable the release of molecules for more than 100 days, whereas certain hydrogels release proteins for a shorter period. If encapsulated compounds remain in the body for a long time, exposure to moisture at 37°C may result in denaturation or aggregation, leading to a loss of biological activity and structural changes. Reasonable strategies for stabilization can be devised based on the relevant mechanisms of action. For example, if the aggregation mechanism is found to be the formation of intermolecular SS bonds via thio-disulfide exchange, stabilization can be achieved through modification of sulfhydryl residues, freeze-drying from acidic solutions, control of moisture content, use of appropriate additives, and the development of specific polymer matrix compositions.
[0466] A dosage form or composition may be prepared containing an active ingredient in the range of 0.005% to 100% and the remainder consisting of a non-toxic carrier. For oral administration, a pharmaceutically acceptable non-toxic composition is formed by incorporating any of the excipients commonly used, such as pharmaceutical-grade mannitol, lactose, starch, magnesium stearate, talc, cellulose derivatives, sodium croscarmellose, glucose, sucrose, magnesium carbonate, or sodium saccharin. Such compositions include sustained-release formulations, comprising but not limited to solutions, suspensions, tablets, capsules, powders, and implants and microencapsulation delivery systems, and biodegradable biocompatible polymers such as collagen, ethylene vinyl acetate, polyanhydride, polyglycolic acid, polyorthoester, polylactic acid, etc. Methods for preparing such compositions are known to those skilled in the art. The composition under consideration may contain about 0.001% to 100% of an active ingredient, about 0.1% to 85% of an active ingredient in certain embodiments, or about 75% to 95% of an active ingredient in other embodiments.
[0467] The active compound or pharmaceutically acceptable salt may be prepared with a carrier that protects the compound against rapid removal from the body, such as in time-release formulations or coatings.
[0468] The composition may include other active compounds to obtain a desired combination of properties. The compounds provided herein or pharmaceutically acceptable salts thereof as described herein may also be advantageously administered for therapeutic or prophylactic purposes in combination with other pharmacological agents known in the art as useful for treating one or more of the aforementioned diseases or medical conditions, such as oxidative stress-related diseases. It should be understood that such combination therapy constitutes additional embodiments of the compositions and therapeutic methods provided herein.
[0469] The muractose compositions provided herein may contain excipients that are widely known in the art and, for example, listed in the United States Pharmacopeia (USP) SP (XXI) / NF (XVI). Generally, muractose compositions contain pharmaceutically compatible and pharmaceutically acceptable amounts of an active ingredient, a binder / filler, and a lubricant. An exemplary muractose dosage form contains an active ingredient, microcrystalline cellulose, pregelatinized starch, and magnesium stearate.
[0470] Anhydrous pharmaceutical compositions and dosage forms containing the compounds provided herein are also included. For example, the addition of water (e.g., 5%) is widely accepted in the pharmaceutical field as a means of simulating long-term storage to determine properties such as shelf life or the stability of the formulation over time. In practice, water and heat accelerate the degradation of some compounds. Therefore, since moisture and / or humidity are typically present during the manufacture, handling, packaging, storage, transport, and use of the formulation, the effect of water on the formulation can be very important.
[0471] The anhydrous pharmaceutical compositions and dosage forms provided herein may be prepared using an anhydrous or low-moisture containing ingredient and low-moisture or low-humidity conditions. Pharmaceutical compositions and dosage forms comprising at least one active ingredient including lactose and a primary or secondary amine are anhydrous when significant contact with moisture and / or humidity is expected during preparation, packaging, and / or storage.
[0472] Anhydrous pharmaceutical compositions must be manufactured and stored so that their anhydrous properties are maintained. Accordingly, anhydrous compositions are packaged using materials known to prevent exposure to water so that they can be included in a suitable formulation kit. Examples of suitable packaging include, but are not limited to, sealing foil, plastic, unit volume containers (e.g., vials), blister packs, and strip packs.
[0473] A. Oral administration form
[0474] Oral pharmaceutical dosage forms are solid, gel, or liquid. Solid dosage forms are tablets, capsules, granules, and bulk powders. Types of oral tablets include compressed tablets, chewable lozenges, and tablets that may be enteric-coated, sugar-coated, or film-coated. Capsules may be hard or soft gelatin capsules, while granules and powders may be provided in non-foaming or foaming forms with combinations of other ingredients known to those skilled in the art.
[0475] In certain embodiments, the formulation is a solid dosage form such as a capsule or tablet. Tablets, pills, capsules, troches, etc. may contain any of the following components or compounds of similar properties: binders; diluents; disintegrants; lubricants; lubricants; sweeteners; and flavorings.
[0476] Examples of binders include microcrystalline cellulose, tragacanth gum, glucose solution, acacia mucilage, gelatin solution, sucrose, and starch paste. Lubricants include talc, starch, magnesium stearate or calcium stearate, lycopodium, and stearic acid. Diluents include, for example, lactose, sucrose, starch, kaolin, salts, mannitol, and dicalcium phosphate. Lubricants include, but are not limited to, colloidal silicon dioxide. Disintegrants include sodium croscarmellose, sodium starch glycolate, crospovidone, alginic acid, corn starch, potato starch, bentonite, methylcellulose, agar, and carboxymethylcellulose. Colorants include, for example, any approved and certified water-soluble FD and C dyes, mixtures thereof; and water-insoluble FD and C dyes suspended in alumina hydrate. Sweeteners include artificial sweeteners such as sucrose, lactose, mannitol, and saccharin, and any number of spray-dried flavorings. Flavorings include, but are not limited to, natural flavorings extracted from plants such as fruits, and synthetic blends of compounds that produce a pleasant sensation, such as peppermint and methyl salicylate. Wetting agents include propylene glycol monostearate, sorbitan monooleate, diethylene glycol monolaurate, and polyoxyethylene lauryl ether. Enteric coatings include fatty acids, fats, waxes, shellac, ammonia-treated shellac, and cellulose acetate phthalate. Film coatings include hydroxyethylcellulose, sodium carboxymethylcellulose, polyethylene glycol 4000, and cellulose acetate phthalate.
[0477] When oral administration is desired, the compound may be provided as a composition that protects it from the acidic environment of the stomach. For example, the composition may be formulated as an enteric coating that maintains its integrity in the stomach and releases the active compound in the intestine. The composition may also be formulated in combination with an antacid or other such components.
[0478] If the dosage unit form is a capsule, it may contain a liquid carrier such as a fatty oil in addition to the above-mentioned type of material. Additionally, the dosage unit form may contain various other materials that modify the physical form of the dosage unit, such as a sugar coating and other enteric agents. The compound may also be administered as a component of elixirs, suspensions, syrups, wafers, sprinkles, chewing gums, etc. Syrups may contain sucrose as a sweetener and certain preservatives, dyes, colorings, and flavorings in addition to the active compound.
[0479] The active substance may be mixed with other active substances that do not impair the desired action, or with substances that supplement the desired action, such as antacids, H2 blockers, and diuretics. The active ingredient is a compound as described herein or a pharmaceutically acceptable salt thereof. Higher concentrations of up to about 98% by weight of the active ingredient may be included.
[0480] Pharmaceutically acceptable carriers included in tablets are binders, lubricants, diluents, disintegrants, colorants, flavorings, and wetting agents. Enteric-coated tablets resist the action of gastric acid due to the enteric coating and dissolve or disintegrate in a neutral or alkaline intestine. Sugar-coated tablets are compressed tablets with different layers of pharmaceutically acceptable material applied. Film-coated tablets are compressed tablets coated with a polymer or other suitable coating. Multi-compressed tablets are compressed tablets manufactured by more than one compression cycle utilizing the aforementioned pharmaceutically acceptable materials. Colorants may also be used in the above dosage forms. Flavorings and sweeteners are used in compressed tablets, sugar-coated tablets, multi-compressed tablets, and chewable tablets. Flavorings and sweeteners are particularly useful in the formation of chewable tablets and lozenges.
[0481] Liquid oral administration forms include aqueous solutions, emulsions, suspensions, solutions and / or suspensions reconstituted from non-effervescent granules, and effervescent formulations reconstituted from effervescent granules. Aqueous solutions include, for example, elixirs and syrups. Emulsions are of the water-in-water type or water-in-oil type. In some embodiments, suspensions are suspensions of microparticles or nanoparticles. In some embodiments, emulsions are emulsions of microparticles or nanoparticles.
[0482] Elixirs are clear, sweetened aqueous alcohol preparations. Pharmaceutically acceptable carriers used in elixirs include solvents. Syrups are concentrated aqueous solutions of sugars, such as sucrose, and may contain preservatives. Emulsions are two-phase systems in which one liquid is dispersed throughout another liquid in the form of small spheres. Pharmaceutically acceptable carriers used in emulsions are non-aqueous liquids, emulsifiers, and preservatives. Suspensions use pharmaceutically acceptable suspending agents and preservatives. Pharmaceutically acceptable materials used in non-effervescent granules reconstituted into liquid oral dosage forms include diluents, sweeteners, and wetting agents. Pharmaceutically acceptable materials used in effervescent granules reconstituted into liquid oral dosage forms include organic acids and carbon dioxide sources. Colorants and flavoring agents are used in all of the above dosage forms.
[0483] Solvents include glycerin, sorbitol, ethyl alcohol, and syrup. Examples of preservatives include glycerin, methyl and propylparaben, benzoic acid, sodium benzoate, and alcohol. Examples of non-aqueous liquids used in emulsions include mineral oil and cottonseed oil. Examples of emulsifiers include surfactants such as gelatin, acacia, tragacanth, bentonite, and polyoxyethylene sorbitan monooleate. Suspending agents include sodium carboxymethylcellulose, pectin, tragacanth, beegum, and acacia. Diluents include lactose and sucrose. Sweeteners include artificial sweeteners such as sucrose, syrup, glycerin, and saccharin. Wetting agents include propylene glycol monostearate, sorbitan monooleate, diethylene glycol monolaurate, and polyoxyethylene lauryl ether. Organic acids include citric acid and tartaric acid. Carbon dioxide sources include sodium bicarbonate and sodium carbonate. Colorants include any approved and certified water-soluble FD and C dyes and mixtures thereof. Flavoring agents include natural flavorings extracted from plants such as fruits and synthetic blends of compounds that produce a pleasant taste.
[0484] For solid dosage forms, a solution or suspension in, for example, propylene carbonate, vegetable oil, or triglyceride is enclosed in a gelatin capsule. Such solutions and their preparation and encapsulation are disclosed in U.S. Patents No. 4,328,245; No. 4,409,239; and No. 4,410,545. For liquid dosage forms, a solution in, for example, polyethylene glycol may be diluted with a sufficient amount of a pharmaceutically acceptable liquid carrier, for example, water, so that it can be easily metered for administration.
[0485] Alternatively, liquid or semi-solid oral formulations may be prepared by dissolving or dispersing an active compound or salt in vegetable oil, glycol, triglyceride, propylene glycol ester (e.g., propylene carbonate) and other such carriers, and encapsulating such solution or suspension in a hard or soft gelatin capsule shell. Other useful formulations include the compounds provided herein, 1,2-dimethoxyethane, diglaime, triglaime, tetraglaime, dialkylated mono- or polyalkylene glycols including but not limited to polyethylene glycol-350-dimethyl ether, polyethylene glycol-550-dimethyl ether, and polyethylene glycol-750-dimethyl ether (wherein 350, 550, and 750 refer to the approximate average molecular weight of polyethylene glycol), and one or more antioxidants such as butylated hydroxy-toluene (BHT), butylated hydroxyanisole (BHA), propyl gallate, vitamin E, hydroquinone, hydroxycoumarin, ethanolamine, lecithin, cephalin, ascorbic acid, malic acid, sorbitol, phosphoric acid, thiodipropionic acid and its esters, and dithiocarbamate. It includes, but is not limited to, formulations containing
[0486] Other formulations include, but are not limited to, aqueous alcohol solutions containing pharmaceutically acceptable acetals. The alcohol used in these formulations is any pharmaceutically acceptable water-miscible solvent having one or more hydroxyl groups, including but not limited to propylene glycol and ethanol. The acetal includes, but is not limited to, di(lower alkyl)acetals of lower alkyl aldehydes, such as acetaldehyde diethyl acetal.
[0487] In all embodiments, tablet and capsule formulations may be coated as known to those skilled in the art to modify or sustain the dissolution of the active ingredient. Thus, for example, they may be coated with conventional enteric digestive coatings such as phenyl salicylate, wax, and cellulose acetate phthalate.
[0488] B. Injectables, solutions, and emulsions
[0489] Parenteral administration, generally characterized by subcutaneous, intramuscular, or intravenous injection, is also considered herein. The injectable formulation may be prepared in a liquid solution or suspension, or in a conventional form as a solid or emulsion suitable for a solution or suspension in liquid prior to injection. In some embodiments, the suspension is a suspension of microparticles or nanoparticles. In some embodiments, the emulsion is an emulsion of microparticles or nanoparticles. Suitable excipients are, for example, water, saline solution, dextrose, glycerol, or ethanol. Additionally, if desired, the pharmaceutical composition to be administered may also contain small amounts of non-toxic auxiliary substances such as wetting agents or emulsifiers, pH buffers, stabilizers, solubility enhancers, and other such agents, for example, sodium acetate, sorbitan monolaurate, triethanolamine oleate, and cyclodextrin. The implantation of a sustained-release or continuous-release system to maintain a constant dosage level is also considered herein.Briefly, the compounds provided herein are dispersed in a solid inner matrix, e.g., hydrophilic polymers such as polymethyl methacrylate, polybutyl methacrylate, plasticized or unplasticized polyvinyl chloride, plasticized nylon, plasticized polyethylene-terephthalate, natural rubber, polyisoprene, polyisobutylene, polybutadiene, polyethylene, ethylene-vinyl acetate copolymer, silicone rubber, polydimethylsiloxane, silicone carbonate copolymer, hydrogels of acrylic acid and methacrylic acid esters, collagen, cross-linked polyvinyl alcohol, and cross-linked partially hydrolyzed polyvinyl acetate, which are insoluble in body fluids, in an outer polymer membrane, e.g., polyethylene, polypropylene, ethylene / propylene copolymer, ethylene / ethyl acrylate copolymer, ethylene / vinyl acetate copolymer, silicone rubber, polydimethylsiloxane, neoprene rubber, chlorinated polyethylene, polyvinyl chloride, vinyl acetate, and vinylidene. It is surrounded by vinyl chloride copolymers with chloride, ethylene and propylene, ionomer polyethylene terephthalate, butyl rubber epichlorohydrin rubber, ethylene / vinyl alcohol copolymer, ethylene / vinyl acetate / vinyl alcohol terpolymer, and ethylene / vinyl oxyethanol copolymer. The compound diffuses through an outer polymer membrane during the release rate control step. The percentage of the active compound contained in these parenteral compositions depends largely on the specific properties of the compound, as well as the activity and needs of the target.
[0490] Parenteral administration of the composition includes intravenous, subcutaneous, and intramuscular administration. Preparations for parenteral administration include sterile solutions prepared for injection, sterile dry soluble products such as lyophilized powders prepared for combination with a solvent immediately before use (including subcutaneous tablets), sterile suspensions prepared for injection, sterile dry insoluble products prepared for combination with a vehicle immediately before use, and sterile emulsions. The solution may be aqueous or non-aqueous.
[0491] When administered intravenously, suitable carriers include physiological saline or phosphate-buffered saline (PBS), and solutions containing thickeners and solubilizers such as glucose, polyethylene glycol and polypropylene glycol and mixtures thereof.
[0492] Pharmaceutically acceptable carriers used in parenteral formulations include aqueous vehicles, non-aqueous vehicles, antimicrobial agents, isotonic agents, buffers, antioxidants, local anesthetics, suspending agents and dispersants, emulsifiers, chelating agents or chelating agents, and other pharmaceutically acceptable substances.
[0493] Examples of aqueous vehicles include sodium chloride injection, Ringer's injection, isotonic dextrose injection, sterile water for injection, and dextrose and lactate Ringer's injection. Non-aqueous parenteral vehicles include plant-derived fixed oils, cottonseed oil, corn oil, sesame oil, and peanut oil. Antimicrobial agents at bacteriostatic or fungistatic concentrations include phenol or cresol, mercury compounds, benzyl alcohol, chlorobutanol, methyl, and propyl. p It must be added to parenteral formulations packaged in multi-dose containers containing hydroxybenzoic acid esters, thimerosal, benzalkonium chloride, and benzethonium chloride. Isotonic agents include sodium chloride and dextrose. Buffers include phosphates and citrates. Antioxidants include sodium bisulfate. Local anesthetics include procaine hydrochloride. Suspending agents and dispersants include sodium carboxymethylcellulose, hydroxypropyl methylcellulose, and polyvinylpyrrolidone. Emulsifiers include polysorbate 80 (TWEEN® 80). Metal ion chelating agents or chelating agents include EDTA. Pharmaceutical carriers also include ethyl alcohol, polyethylene glycol, and propylene glycol for water-miscible vehicles, and sodium hydroxide, hydrochloric acid, citric acid, or lactic acid for pH adjustment.
[0494] The concentration of the pharmaceutically active compound is adjusted so that the injection provides an effective amount to produce the desired pharmacological effect. The precise dosage depends on the age, weight, and condition of the subject or animal, as is known in the art.
[0495] Unit dose parenteral formulations are packaged in ampoules, vials, or syringes with needles. All formulations for parenteral administration must be sterilized as is known and practiced in the art.
[0496] For example, intravenous or intra-arterial infusion of a sterile aqueous solution containing an active compound is an effective method of administration. Another embodiment is a sterile aqueous or oily solution or suspension containing an active substance that is injected as needed to produce a desired pharmacological effect.
[0497] Injectable formulations are designed for local and systemic administration. Typically, the therapeutically effective dose is formulated to contain a concentration of at least about 0.1% w / w to about 90% w / w or more of the active compound, e.g., exceeding 1% w / w, for the tissue(s) being treated. The active ingredient may be administered at once or divided into multiple smaller doses administered at time intervals. It is understood that the precise dose and duration of treatment are functions of the tissue being treated and may be determined empirically by using known test protocols or by extrapolating from in vivo or in vitro test data. It should be noted that concentration and dose values may vary depending on the age of the subject being treated. Furthermore, for any specific subject, the specific administration regimen should be adjusted over time according to the individual's needs and the professional judgment of the person administering the formulation or supervising its administration, and it should be understood that the concentration ranges presented herein are merely exemplary and are not intended to limit the scope or practice of the claimed formulation.
[0498] The compound may be micronized or suspended in other suitable forms, or derivatized to produce a more soluble active product or a prodrug. The form of the resulting mixture depends on a number of factors, including the intended mode of administration and the solubility of the compound in the selected carrier or vehicle. The effective concentration is sufficient to alleviate the symptoms of the pathological condition and can be determined empirically.
[0499] C. freeze-dried powder
[0500] Lyophilized powders that can be reconfigured for administration as solutions, emulsions, and other mixtures are also of interest. These can also be reconfigured and formulated into solids or gels.
[0501] Sterile lyophilized powders are prepared by dissolving the compound provided herein or a pharmaceutically acceptable salt thereof in a suitable solvent. The solvent may contain excipients that improve the stability of the powder or the reconstituted solution prepared from the powder, or other pharmacological components. Excipients that may be used include, but are not limited to, dextrose, sorbitol, fructose, corn syrup, xylitol, glycerin, glucose, sucrose, or other suitable preparations. The solvent may also contain a buffer such as citrate, sodium phosphate, or potassium phosphate at a weakly neutral pH in one embodiment, or other such buffers known to those skilled in the art. A desired formulation is provided by lyophilizing the solution under standard conditions known to those skilled in the art following subsequent sterile filtration. Generally, the resulting solution is dispensed into vials for lyophilization. Each vial will contain a single dose (containing, but not limited to, 10–1,000 mg or 100–500 mg) or multiple doses of the compound. Freeze-dried powder can be stored under suitable conditions, such as about 4°C to room temperature.
[0502] Reconstituted such lyophilized powder with water for injection provides a formulation for use in parenteral administration. For reconstitution, about 1-50 mg, about 5-35 mg, or about 9-30 mg of lyophilized powder is added per 1 mL of sterile water or other suitable carrier. The exact amount depends on the selected compound. These amounts can be determined empirically.
[0503] D. Local administration
[0504] Topical mixtures are prepared as described for local and systemic administration. The resulting mixture may be a solution, suspension, emulsion, etc., and is formulated into a cream, gel, ointment, emulsion, solution, elixir, lotion, suspension, tincture, paste, foam, aerosol, cleanser, spray, suppository, bandage, dermal patch, or any other formulation suitable for topical administration.
[0505] A compound or a pharmaceutically acceptable salt thereof may be formulated into an aerosol for topical application, such as by inhalation (see, for example, U.S. Patents No. 4,044,126, 4,414,209 and 4,364,923 describing aerosols for the delivery of steroids useful for the treatment of inflammatory diseases, particularly asthma). Such formulations for administration into a breathing tube may be in the form of a nebulizer aerosol or solution, or may exist as a fine powder for blowing, either alone or in combination with an inert carrier such as lactose. In such cases, the particles of the formulation will have a diameter of less than 50 microns or less than 10 microns.
[0506] The compound may be formulated in the form of gels, creams, and lotions for topical application to the skin and mucous membranes, e.g., the eyes, and for local or topical application such as application to the eyes or intraventricular or spinal cord application. Topical administration is considered for transdermal delivery, as well as for administration to the eyes or mucous membranes, or for inhalation therapy. Nasal solutions may also be administered of the active compound alone or in combination with other pharmaceutically acceptable excipients.
[0507] These solutions, particularly those intended for ophthalmic use, can be formulated as 0.01%–10% isotonic solutions with a pH of about 5–7 using appropriate salts.
[0508] E. Composition for other administration routes
[0509] Other routes of administration, such as topical application, transdermal patches, and rectal administration, are also considered at this institution.
[0510] For example, pharmaceutical dosage forms for rectal administration are rectal suppositories, capsules, and tablets for systemic effects. As used herein, a rectal suppository refers to a solid body for insertion into the rectum that melts or softens at body temperature to release one or more pharmacological or therapeutic active ingredients. Pharmaceutically acceptable materials used in rectal suppositories are a base or vehicle and a preparation to increase the melting point. Examples of bases include cocoa butter (theobroma oil), glycerin gelatin, carbowax (polyoxyethylene glycol), and suitable mixtures of mono, di, and triglycerides of fatty acids. Various combinations of bases may be used. Preparations to increase the melting point of the suppository include spermaceti and waxes. Rectal suppositories may be manufactured by compression or molding. An exemplary weight of a rectal suppository is about 2 to 3 grams.
[0511] Tablets and capsules for rectal administration are manufactured by the same method using the same pharmaceutically acceptable material as the oral administration formulation.
[0512] F. Continuous release composition
[0513] The active ingredient provided herein may be administered by a controlled-release means or delivery device widely known to those skilled in the art. Examples are U.S. Patents No. 3,845,770; No. 3,916,899; No. 3,536,809; and No. 3,598,123. and U.S. Patents No. 4,008,719, No. 5,674,533, No. 5,059,595, No. 5,591,767, No. 5,120,548, No. 5,073,543, No. 5,639,476, No. 5,354,556, No. 5,639,480, No. 5,733,566, No. 5,739,108, No. 5,891,474, No. 5,922,356, No. 5,972,891, No. 5,980,945, No. 5,993,855, No. 6,045,830, No. 6,087,324, No. 6,113,943, No. 6,197,350, Includes, but not limited to, those described in 6,248,363, 6,264,970, 6,267,981, 6,376,461, 6,419,961, 6,589,548, 6,613,358, 6,699,500 and 6,740,634. Such dosage forms may be used to provide desired release profiles at various rates by providing sustained or controlled release of one or more active ingredients, for example, using hydroxypropylmethylcellulose, other polymer matrices, gels, permeable membranes, osmotic systems, multilayer coatings, microparticles, liposomes, microspheres, or combinations thereof. Suitable controlled-release formulations known to those skilled in the art, including those described herein, may be readily selected for use with the active ingredients provided herein.
[0514] All controlled-release pharmaceutical products have the common goal of improving drug therapy compared to what is achieved by their non-controlled counterparts. In one embodiment, the use of an optimally designed controlled-release formulation in medical treatment is characterized by the use of a minimum amount of drug material to cure or control a condition within a minimum amount of time. In a specific embodiment, the benefits of the controlled-release formulation include extended drug activity, reduced frequency of administration, and increased subject compliance. Additionally, the controlled-release formulation may be used to influence other characteristics, such as the time to onset of action or blood levels of the drug, and thus may influence the occurrence of side effects (e.g., adverse effects).
[0515] Most controlled-release formulations are designed to initially release an amount of the drug (active ingredient) that rapidly produces the desired therapeutic effect, and then gradually and continuously release a different amount of the drug to maintain this level of therapeutic or preventive effect over an extended period. To maintain these constant drug levels in the body, the drug must be released from the dosage form at a rate that replenishes the amount of drug metabolized and excreted from the body. The controlled release of the active ingredient may be stimulated by various conditions, including but not limited to pH, temperature, enzymes, water, or other physiological conditions or compounds.
[0516] In certain embodiments, the formulation may be administered using an intravenous infusion, an implantable osmotic pump, a transdermal patch, a liposome, or other administration method. In one embodiment, a pump may be used. For example, Buchwald et al. , Surgery 1980 , 88 , 507-16; Sefton, Crit. Ref. Biomed. Eng. 1987 , 14 , 201-40; Saudek et al. , N. Engl. J. Med. 1989 , 321See , 574-9. In other embodiments, polymeric materials may be used. In yet another embodiment, the controlled-release system may be positioned close to the therapeutic target, i.e., thereby requiring only a portion of the systemic dose.
[0517] In a specific embodiment, the controlled release device is introduced into the target in proximity to an inappropriate immune activation site or tumor. Other controlled release systems are based on Langer's review ( Science 1990 , 249 It is discussed in , 1527-33). The active ingredient may be dispersed in a solid internal matrix, e.g., hydrophilic polymers such as polymethyl methacrylate, polybutyl methacrylate, plasticized or unplasticized polyvinyl chloride, plasticized nylon, plasticized polyethylene terephthalate, natural rubber, polyisoprene, polyisobutylene, polybutadiene, polyethylene, ethylene-vinyl acetate copolymer, silicone rubber, polydimethylsiloxane, silicone carbonate copolymer, hydrogels of acrylic acid and methacrylic acid esters, collagen, cross-linked polyvinyl alcohol, and cross-linked partially hydrolyzed polyvinyl acetate, which is insoluble in body fluids, e.g., polyethylene, polypropylene, ethylene / propylene copolymer, ethylene / ethyl acrylate copolymer, ethylene / vinyl acetate copolymer, silicone rubber, polydimethylsiloxane, neoprene rubber, chlorinated polyethylene, polyvinyl chloride, vinyl acetate, vinylidene chloride, It is surrounded by vinyl chloride copolymers with ethylene and propylene, ionomer polyethylene terephthalate, butyl rubber epichlorohydrin rubber, ethylene / vinyl alcohol copolymers, ethylene / vinyl acetate / vinyl alcohol terpolymers, and ethylene / vinyl oxyethanol copolymers. Subsequently, the active ingredient diffuses through an outer polymer membrane during the release rate control step. The percentage of the active ingredient contained in these parenteral compositions depends significantly on the specific properties of the target as well as its needs.
[0518] G. Targeted formulation
[0519] The compounds provided herein or pharmaceutically acceptable salts thereof may be formulated to target specific tissues, receptors, or other body regions of the target to be treated, including liposome-, resealed erythrocyte-, and antibody-based delivery systems. Many of these targeting methods are widely known to those skilled in the art. All of these targeting methods are considered herein for use in the compositions. For non-limiting examples of targeting methods, see, for example, U.S. Patents No. 6,316,652, 6,274,552, 6,271,359, 6,253,872, 6,139,865, 6,131,570, 6,120,751, 6,071,495, 6,060,082, 6,048,736, 6,039,975, 6,004,534, 5,985,307, 5,972,366, 5,900,252, 5,840,674, 5,759,542 and 5,709,874.
[0520] In one embodiment, a liposomal suspension comprising tissue-targeting liposomes, such as tumor-targeting liposomes, may be suitable as a pharmaceutically acceptable carrier. These may be prepared according to methods known to those skilled in the art. For example, liposomal formulations may be prepared as described in U.S. Patent No. 4,522,811. Briefly, liposomes such as multilayer vesicles (MLVs) may be formed by drying egg yolk phosphatidylcholine and brain phosphatidylserine (7:3 molar ratio) inside a flask. A solution of the compound provided herein is added in phosphate-buffered saline (PBS) free of divalent cations, and the flask is shaken until the lipid membrane is dispersed. The resulting vesicles are washed to remove unencapsulated compounds, pelleted by centrifugation, and then resuspended in PBS.
[0521] H. Manufactured goods
[0522] The compound or pharmaceutically acceptable salt may be packaged in a manufactured article containing packaging material, the compound provided herein or its pharmaceutically acceptable salt used to treat, prevent, or alleviate one or more symptoms or progression of the disease or disorder disclosed herein, and a label indicating that the compound or its pharmaceutically acceptable salt is used to treat, prevent, or alleviate one or more symptoms or progression of the disease or disorder disclosed herein.
[0523] The manufactured articles provided herein contain packaging materials. Packaging materials used for packaging pharmaceutical products are widely known to those skilled in the art. For example, see U.S. Patents No. 5,323,907, No. 5,052,558, and No. 5,033,252. Examples of pharmaceutical packaging materials include, but are not limited to, blister packs, bottles, tubes, inhalers, pumps, bags, vials, containers, syringes, pens, bottles, and any packaging material suitable for selected formulations, intended modes of administration, and treatments. A wide variety of formulations of the compounds and compositions provided herein are considered.
[0524] In certain embodiments, the present invention also provides a kit that can simplify the administration of an appropriate amount of active ingredient to a subject when used by a healthcare professional. In certain embodiments, the kit provided herein comprises a container and a dosage form of the compound provided herein, comprising a mixture of a single enantiomer or a diastereomer thereof; or a pharmaceutically acceptable salt, solvate, or prodrug thereof.
[0525] In a specific embodiment, the kit comprises a container comprising a single enantiomer or a mixture of its diastereomers; or a dosage form of a compound provided herein comprising a pharmaceutically acceptable salt, solvate, or prodrug thereof, within a container comprising one or more other therapeutic agents described herein.
[0526] The kit provided herein may additionally include a device used for administering the active ingredient. Examples of such devices include, but are not limited to, syringes, needleless syringe drop bags, patches, and inhalers. The kit provided herein may also include a condom for administering the active ingredient.
[0527] The kit provided herein may further comprise a pharmaceutically acceptable vehicle that can be used to administer one or more active ingredients. For example, if the active ingredient is provided in a solid form that must be reconstituted for parenteral administration, the kit may comprise a sealed container of a suitable vehicle capable of dissolving the active ingredient to form a particulate-free sterile solution suitable for parenteral administration. Examples of pharmaceutically acceptable vehicles include, but are not limited to: aqueous vehicles including, but not limited to, USP water for injection, sodium chloride injection, Ringer's injection, dextrose injection, dextrose and sodium chloride injection, and lactate Ringer's injection; water-miscible vehicles including, but not limited to, ethyl alcohol, polyethylene glycol, and polypropylene glycol; and non-aqueous vehicles including, but not limited to, corn oil, cottonseed oil, peanut oil, sesame oil, ethyl oleate, isopropyl myristate, and benzyl benzoate.
[0528] V. Dosage
[0529] The compounds and pharmaceutical compositions provided herein may be administered in a specific therapeutic or prophylactic effective amount, at a specific time interval, in a specific dosage form, and by a specific dosage method as described herein.
[0530] In certain embodiments, the therapeutic or prophylactic effective amount of the compound provided herein is about 0.005 to about 1,000 mg per day, about 0.01 to about 500 mg per day, about 0.01 to about 250 mg per day, about 0.01 to about 100 mg per day, about 0.1 to about 100 mg per day, about 0.5 to about 100 mg per day, about 1 to about 100 mg per day, about 0.01 to about 50 mg per day, about 0.1 to about 50 mg per day, about 0.5 to about 50 mg per day, about 1 to about 50 mg per day, about 0.02 to about 25 mg per day, about 0.05 to about 10 mg per day, and about It is 0.05 to about 5 mg, about 0.1 to about 5 mg per day, or about 0.5 to about 5 mg per day.
[0531] In certain embodiments, the therapeutic or prophylactic effective amount of the compound provided herein is about 0.1, about 0.2, about 0.5, about 1, about 2, about 3, about 4, about 5, about 6, about 7, about 8, about 9, about 10, about 15, about 20, about 25, about 30, about 40, about 45, about 50, about 60, about 70, about 80, about 90, about 100, or about 150 mg per day.
[0532] In certain embodiments, the recommended daily dose range of the compound or derivative thereof provided herein for the conditions described herein is within the range of about 0.5 mg to about 50 mg per day, provided as a single once-daily dose or as divided doses over a day. In certain embodiments, the daily dose is in the range of about 1 mg to about 50 mg per day. In certain embodiments, the daily dose is in the range of about 0.5 to about 5 mg per day. Specific daily doses include 0.1, 0.2, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 mg per day.
[0533] In certain embodiments, the recommended starting dose is 0.5, 1, 2, 3, 4, 5, 10, 15, 20, 25, or 50 mg per day. In certain embodiments, the recommended starting dose may be 0.5, 1, 2, 3, 4, or 5 mg per day. In certain embodiments, the dose is increased to 15, 20, 25, 30, 35, 40, 45, and 50 mg / day. In certain embodiments, the compound provided herein is administered in an amount of about 25 mg / day. In certain embodiments, the compound provided herein is administered in an amount of about 10 mg / day. In certain embodiments, the compound provided herein is administered in an amount of about 5 mg / day. In certain embodiments, the compound provided herein is administered in an amount of about 4 mg / day. In certain embodiments, the compound provided herein is administered in an amount of about 3 mg / day.
[0534] In certain embodiments, the therapeutic or prophylactic effective dose is about 0.001 to about 100 mg / kg / day, about 0.01 to about 50 mg / kg / day, about 0.01 to about 25 mg / kg / day, about 0.01 to about 10 mg / kg / day, about 0.01 to about 9 mg / kg / day, 0.01 to about 8 mg / kg / day, about 0.01 to about 7 mg / kg / day, about 0.01 to about 6 mg / kg / day, about 0.01 to about 5 mg / kg / day, about 0.01 to about 4 mg / kg / day, about 0.01 to about 3 mg / kg / day, about 0.01 to about 2 mg / kg / day, about 0.01 to about 1 mg / kg / day, or about 0.01 to about 0.05 mg / kg / day.
[0535] The administered dose may also be expressed in units other than mg / kg / day. For example, the parenteral dose is mg / m² 2 It can be expressed in / day. A person skilled in the art, given either the height or weight of the subject or both, will be able to express it in mg / kg / day or mg / m² 2 You will easily understand how to convert the dose to / day. For example, a dose of 1 mg / kg / day for a 65 kg person is approximately 38 mg / m² 2 It is like work.
[0536] In a specific embodiment, the amount of compound administered is sufficient to provide a plasma concentration of the compound in a steady state in the range of about 0.001 to about 500 μM, about 0.002 to about 200 μM, about 0.005 to about 100 μM, about 0.01 to about 50 μM, about 1 to about 50 μM, about 0.02 to about 25 μM, about 0.05 to about 20 μM, about 0.1 to about 20 μM, about 0.5 to about 20 μM, or about 1 to about 20 μM.
[0537] In a specific embodiment, the amount of compound administered is sufficient to provide a steady-state plasma concentration of the compound in the range of about 5 to about 100 nM, about 5 to about 50 nM, about 10 to about 100 nM, about 10 to about 50 nM, or about 50 to about 100 nM.
[0538] As used herein, the term "plasma concentration at steady state" refers to the concentration reached after administration of the compound or its derivative provided herein for a certain period. Once steady state is reached, small peaks and troughs exist in the time-dependent curve of the plasma concentration of the compound.
[0539] In a specific embodiment, the amount of compound administered is sufficient to provide a maximum plasma concentration (peak concentration) of the compound in the range of about 0.001 to about 50 μM, about 0.002 to about 200 μM, about 0.005 to about 100 μM, about 0.01 to about 50 μM, about 1 to about 50 μM, about 0.02 to about 25 μM, about 0.05 to about 20 μM, about 0.1 to about 20 μM, about 0.5 to about 20 μM, or about 1 to about 20 μM.
[0540] In a specific embodiment, the amount of compound administered is sufficient to provide a minimum plasma concentration (trough concentration) of the compound in the range of about 0.001 to about 500 μM, about 0.002 to about 200 μM, about 0.005 to about 100 μM, about 0.01 to about 50 μM, about 1 to about 50 μM, about 0.01 to about 25 μM, about 0.01 to about 20 μM, about 0.02 to about 20 μM, about 0.02 to about 20 μM, or about 0.01 to about 20 μM.
[0541] In certain embodiments, the amount of compound administered is sufficient to provide an area under the curve (AUC) of the compound in the range of about 100 to about 100,000 ng*hr / mL, about 1,000 to about 50,000 ng*hr / mL, about 5,000 to about 25,000 ng*hr / mL, or about 5,000 to about 10,000 ng*hr / mL.
[0542] The method provided herein includes steps for treating patients regardless of age, even if some diseases or disorders are more common in specific age groups.
[0543] Depending on the disease to be treated and the condition of the subject, the compounds or derivatives provided herein may be administered via oral, parenteral (e.g., intramuscular, intraperitoneal, intravenous, CIV, intra-water injection or infusion, subcutaneous injection or implant), inhalation, nasal, vaginal, rectal, sublingual, or topical (e.g., transdermal or local) routes of administration. The compounds or derivatives provided herein may be formulated alone or together in suitable dosage units with pharmaceutically acceptable excipients, carriers, adjuvants, and vehicles suitable for each route of administration.
[0544] In one embodiment, the compound or derivative thereof provided herein is administered orally. In another embodiment, the compound or derivative thereof provided herein is administered parenterally. In yet another embodiment, the compound or derivative thereof provided herein is administered intravenously.
[0545] The compounds or derivatives provided herein may be delivered as a single dose, for example, as a single bolus injection or as an oral tablet or pill; or over time, for example, as a continuous infusion over time or as divided bolus doses over time. The compounds may be administered repeatedly if necessary, for example, until the subject experiences stable disease or regression, or until the subject experiences disease progression or unacceptable toxicity. For example, stable disease for solid tumors generally means that the orthogonal diameter of the measurable lesion has not increased by more than 25% from the final measurement. Response Evaluation Criteria in Solid Tumors (RECIST) guidelines ( J. Nat'l Cancer Inst. 2000 , 92 , 205-16). Stable disease or its absence is determined by methods known in the art, such as evaluation of patient symptoms, physical examination, visualization of tumors imaged using X-ray, CAT, PET or MRI scans, and other generally accepted modes of evaluation.
[0546] The compounds or derivatives provided herein may be administered once a day (QD) or divided into multiple daily doses, such as twice a day (BID), three times a day (TID), and four times a day (QID). Additionally, administration may be continuous (i.e., for a continuous number of days or daily), intermittent, e.g., periodic (i.e., including days, weeks, or months without the drug). As used herein, the term “daily” is intended to mean that a therapeutic compound, such as the compounds or derivatives provided herein, is administered at least once a day for a period of time, e.g., for a period of time. The term “continuous” is intended to mean that a therapeutic compound, such as the compounds or derivatives provided herein, is administered daily for an uninterrupted period of at least 10 days to 52 weeks. As used herein, the terms “intermittent” or “intermittently” are intended to mean stopping and starting at regular or irregular intervals. For example, intermittent administration of the compounds or derivatives provided herein is administration 1 to 6 days per week, cyclic administration (e.g., daily administration for 2 to 8 consecutive weeks followed by a rest period of up to 1 week), or administration every other day. As used herein, the term “cycling” is intended to mean that a therapeutic compound, such as the compounds or derivatives provided herein, is administered daily or consecutively but with a rest period. In some of these embodiments, administration is once daily for 2 to 6 days, followed by a rest period of 5 to 7 days.
[0547] In certain embodiments, the frequency of administration is in the range of a daily dose to a monthly dose. In certain embodiments, administration is once a day, twice a day, three times a day, four times a day, once every other day, twice a week, once a week, once every two weeks, once every three weeks, or once every four weeks. In one embodiment, the compound or derivative provided herein is administered once a day. In another embodiment, the compound or derivative provided herein is administered twice a day. In yet another embodiment, the compound or derivative provided herein is administered three times a day. In yet another embodiment, the compound or derivative provided herein is administered four times a day.
[0548] In a specific embodiment, the compound or derivative thereof provided herein is administered once daily for 1 to 6 months, 1 to 3 months, 1 to 4 weeks, 1 to 3 weeks, or 1 to 2 weeks. In a specific embodiment, the compound or derivative thereof provided herein is administered once daily for 1 week, 2 weeks, 3 weeks, or 4 weeks. In one embodiment, the compound or derivative thereof provided herein is administered once daily for 4 days. In another embodiment, the compound or derivative thereof provided herein is administered once daily for 5 days. In yet another embodiment, the compound or derivative thereof provided herein is administered once daily for 6 days. In yet another embodiment, the compound or derivative thereof provided herein is administered once daily for 1 week. In yet another embodiment, the compound or derivative thereof provided herein is administered once daily for 2 weeks. In another embodiment, the compound or derivative thereof provided herein is administered once daily for 3 weeks. In another embodiment, the compound or derivative thereof provided herein is administered once daily for 4 weeks.
[0549] VI. Treatment methods
[0550] In one embodiment, the present invention provides a method for treating, preventing, or alleviating one or more symptoms of a disease or disorder in which ARNT is overexpressed and / or ARNT activity is not desired and / or ARNT acts as a factor of carcinogenic promoting activity.
[0551] In another embodiment, the present invention provides a method for treating, preventing, or alleviating one or more symptoms of an ARNT-mediated disease or disorder in a subject, comprising the step of administering to a subject in need a therapeutically effective amount of a compound provided herein, for example, a compound of formula (A) or (I) or a mirror image isomer thereof, a mixture of mirror image isomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, or a mixture of two or more tautomers; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; or a pharmaceutically acceptable derivative thereof.
[0552] In a specific embodiment, the ARNT-mediated disease or disorder is cancer.
[0553] In another embodiment, the present invention provides a method for treating, preventing, or alleviating one or more symptoms of cancer in a subject, comprising the step of administering to a subject in need a therapeutically effective amount of a compound provided herein, for example, a compound of formula (A) or (I) or a mirror image isomer thereof, a mixture of mirror image isomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, or a mixture of two or more tautomers; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; or a pharmaceutically acceptable derivative thereof.
[0554] In another embodiment, the present invention provides a method for inhibiting cell growth comprising the step of contacting a cell with an effective amount of a compound provided herein, for example, a compound of formula (A) or (I) or a mirror image isomer thereof, a mixture of mirror image isomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, or a mixture of two or more tautomers; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; or a pharmaceutically acceptable derivative thereof.
[0555] In a specific embodiment, the cell is a cancerous cell.
[0556] In another embodiment, the present invention provides a method for inducing degradation of ARNT, comprising the step of contacting ARNT with an effective amount of a compound provided herein, e.g., a compound of formula (A) or (I) or a mirror image isomer thereof, a mixture of mirror image isomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, or a mixture of two or more tautomers; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; or a pharmaceutically acceptable derivative thereof.
[0557] VII. Combination therapy with a second treatment
[0558] The compounds or derivatives provided herein may be used in combination with a second therapeutic agent useful for the treatment and / or prevention of diseases or disorders in which ARNT is overexpressed and / or ARNT activity is not desired and / or ARNT acts as a factor of carcinogenic promoting activity.
[0559] In one embodiment, the present invention provides a method for treating, preventing, or managing cancer, comprising the step of administering to a subject a compound provided in the present invention or a derivative thereof in combination with a second therapeutic agent.
[0560] As used herein, the term “in combination” includes the use of more than one therapy (e.g., one or more prophylactic and / or therapeutic agents). However, the use of the term “in combination” does not limit the order in which the therapies (e.g., prophylactic and / or therapeutic agents) are administered. A first therapy (e.g., a prophylactic or therapeutic agent such as a compound provided herein or a derivative thereof) may be administered before the administration of a second therapy (e.g., a prophylactic or therapeutic agent) (e.g., 5 minutes, 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 12 hours, 24 hours, 48 hours, 72 hours, 96 hours, 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 8 weeks, or 12 weeks prior), simultaneously with or after the administration thereof (e.g., 5 minutes, 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 12 hours, 24 hours, 48 hours, 72 hours, 96 hours, 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 8 weeks, or 12 weeks later). Triple therapy is also considered at this hospital.
[0561] The compound or derivative thereof and the second therapeutic agent provided herein may be administered simultaneously or sequentially by the same or different routes of administration. The suitability of a specific route of administration used for a specific therapeutic agent will depend on the activator itself (e.g., whether it can be administered orally without being broken down before entering the bloodstream) and the disease or disorder being treated.
[0562] The route of administration of the compound or derivative thereof provided herein is independent of the route of administration of the second therapy. In one embodiment, the compound or derivative thereof provided herein is administered orally. In another embodiment, the compound or derivative thereof provided herein is administered intravenously. Accordingly, according to these embodiments, the compound or derivative thereof provided herein is administered orally or intravenously, and the second therapy may be administered orally, parenterally, intraperitoneally, intravenously, intra-arterially, percutaneously, subcutaneously, subcutaneously, intramuscularly, rectalally, transbuccally, intranasally, liposomally, via inhalation, vaginally, intraocularly, via local delivery by catheter or stent, subcutaneously, intrafatally, intra-articularly, intrathecally, or in a sustained-release form. In one embodiment, the compound or derivative thereof provided herein and the second therapy are administered orally or intravenously (IV) in the same manner of administration. In another embodiment, the compound or derivative provided herein is administered in one mode of administration, e.g., IV, while the second formulation is administered in another mode of administration, e.g., orally.
[0563] In one embodiment, the second activator is administered intravenously or subcutaneously once or twice daily in an amount of about 1 to about 1,000 mg, about 5 to about 500 mg, about 10 to about 350 mg, or about 50 to about 200 mg. The specific amount of the second activator will depend on the specific agent used, the type of disease being treated or managed, the severity and stage of the disease, the amount of the compound or derivative provided herein, and any optional additional activator administered concurrently to the subject.
[0564] VIII. Examples
[0565] The following examples are intended to illustrate specific embodiments provided herein and are not intended to limit the scope of the disclosure.
[0566] As used herein, the symbols and conventions used in these processes, reaction schemes, and examples are consistent with those used in modern scientific literature, e.g., the Journal of the American Chemical Society, the Journal of Medicinal Chemistry, or the Journal of Biological Chemistry, regardless of whether specific abbreviations are specifically defined. Specifically, but without limitation, the following abbreviations may be used throughout the examples and specifications: g (gram); mg (milligram); mL (milliliter); μL (microliter); mM (millimolecular); μM (micromolar); mmol (millimolecular); min (min); h (hour); ACN (acetonitrile); AcOH (acetic acid); AIBN (azobis-isobutyronitrile); BINAP (2,2'-bis(diphenylphosphino)-1,1'-vinaphyl); Boc ( tert- Butoxycarbonyl); t Bu( tert- butyl); t BuOH( tert- Butanol); Cbz (benzyl oxycarbonyl); DCE (dichloroethane); DCM (dichloromethane); DIBAL-H (diisobutyl aluminum hydride); DIPEA ( N , N -Diisopropylethyl-amine); DMAP(4-Dimethylamino-pyridine); DME(Dimethyl ether); DMF(Dimethylformamide); DMSO(Dimethyl sulfoxide); EtOAc(ethyl acetate); EtOH(ethanol); FA(formic acid); HATU(Hexafluorophosphate Azabenzotriazole Tetramethyluronium); IPA(Isopropanol); MeOH(Methanol); MsNH2(Methanesulfonamide); MTBE(methyl tert- Butyl ether); NaBH(OAc)3(sodium triacetoxyborohydride); Mn(dpm)3(tris(2,2,6,6-tetramethyl-3,5-heptanedioneto)-manganese(III)); NaBH(OAc)3(sodium triacetoxyborohydride); NBS(N -Bromosuccinimide); NiCl2·dtbpy((4,4'-bis(1,1-dimethylethyl)-2,2'-bipyridine) nickel(II) dichloride); Pd2(dppf)Cl2((1,1'-bis(diphenylphosphino)ferrocene)dichloropalladium(II)); Pd(OAc)2(palladium acetate); PE(petroleum ether); SO3·Py(pyridine trioxide complex); TEA(triethylamine); TFA(trifluoroacetic acid); TFE(tetrafluoroethylene); THF(tetrahydrofuran); TMSCF3(trifluoro-methyltrimethylsilane); T4P(3-(2,6,8-trioxo-9-((2 R ,3 R ,4 R )-2,3,4,5-tetrahydroxypentyl)-3 H -purine-7-yl)propyl dihydrogen phosphate); Ts(tosyl); TsCl(tosyl chloride); TsOH(tosylic acid); TTMSS(tris(trimethylsilyl)silane); MS(mass spectrometry); NMR(nuclear magnetic resonance); prep-HPLC(preparative high-performance liquid chromatography); SFC(supercritical fluid chromatography); and prep-TLC(preparative thin-layer chromatography).
[0567] For all of the following examples, standard post-treatment and purification methods known to those skilled in the art may be utilized. Unless otherwise indicated, all temperatures are expressed in °C (degrees Celsius). Unless otherwise specified, all reactions are carried out at room temperature. The synthesis methodologies illustrated herein are intended to illustrate applicable chemistry through the use of specific examples and do not represent the scope of this disclosure.
[0568] General Reducing Amination Procedure
[0569]
[0570] Procedure 1: Compound as HCl Salt 1a (100 μmol, 1 equivalent) and compound 1bDIPEA (3 equivalents) and NaBH(OAc)3 (2 equivalents) were added to a solution of DMF (0.5 mL) and DCM (0.5 mL) at a concentration of (120 μmol, 1.2 equivalents). After stirring at 30°C for 16 hours, the reaction mixture was concentrated and purified by prep-HPLC to obtain the compound 1c obtained.
[0571] Procedure 2: Compound 1a (100 μmol, 1 equivalent) and compound 1b AcOH (300 μmol, 3 equivalents) and NaBH3CN (200 μmol, 2 equivalents) were added to a solution in 1 mL of MeOH (120 μmol, 1.2 equivalents). After stirring at 50°C for 16 hours, the reaction mixture was concentrated and purified by prep-HPLC to obtain the compound 1c obtained.
[0572] Procedure 3: Compound 1a (100 μmol, 1 equivalent) and compound 1b AcOH (300 μmol, 3 equivalents) and NaBH3CN (200 μmol, 2 equivalents) were added to a solution in 1 mL of MeOH (120 μmol, 1.2 equivalents). After stirring at 120°C under microwave for 6 hours, the reaction mixture was concentrated and purified by prep-HPLC to obtain the compound 1c obtained.
[0573] Example 1
[0574] 3-(2-(1-benzyl-4-hydroxypiperidin-4-yl)-5-oxo-5,7-dihydro-6 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A001 Synthesis of
[0575]
[0576] compound A001 It was prepared as shown in reaction scheme 1.
[0577]
[0578] Methyl 2-(bromomethyl)-6-chloronicotinate 1.2 Preparation of. Methyl 6-chloro-2-methylnicotinate in CCl4 (120 mL). 1.1 NBS (26.3 g, 148 mmol) was added to a mixture of (25 g, 134 mmol) and AIBN (4.42 g, 26.9 mmol) under N2. After stirring at 80°C for 12 hours under N2, the reaction mixture was filtered, concentrated, and purified by column chromatography (SiO2, EtOAc / PE) to obtain the compound 1.2 (30g) was obtained with a 50% yield. 1 ¹H NMR (400 MHz, CDCl₃) δ 8.26-8.24 (m, 1H), 7.38-7.36 (m, 1H), 4.98 (s, 2H), 3.98 (s, 3H); MS (ESI) m / z : 265.8 [M+H] + .
[0579] 3-(2-chloro-5-oxo-5,7-dihydro-6 H -pyrrolo[3,4- b ]pyridine-6-yl)-piperidine-2,6-dion 1.3 Preparation of. Compound in DMF (300 mL) 1.2 A mixture of (30 g, 65.7 mmol), 3-aminopiperidin-2,6-dione (10.8 g, 65.7 mmol) as an HCl salt, and DIPEA (25.5 g, 197 mmol) was stirred under N2 at 110°C for 3 hours. Subsequently, the reaction mixture was diluted with H2O (500 mL) and extracted with DCM (3 x 500 mL). The combined organic layer was washed with brine (3 x 500 mL), dried over anhydrous Na2SO4, filtered, concentrated, and purified by column chromatography (SiO2, MeOH / DCM) to obtain the compound 1.3 (11g) was obtained with a 44% yield. 1 ¹H NMR (400 MHz, CDCl₃) δ 8.13-8.11 (m, 1H), 7.50-7.48 (m, 1H), 5.26-5.21 (m, 1H), 4.56-4.37 (m, 2H), 3.95 (s, 1H), 2.90-2.85 (m, 1H), 2.44-2.39 (m, 2H), 2.89-2.7 (m, 2H); MS (ESI) m / z : 279.9 [M+H] + .
[0580] tert -butyl 4-(6-(2,6-dioxopiperidine-3-yl)-5-oxo-6,7-dihydro-5 H -pyrrolo[3,4- b ]pyridine-2-yl)-3,6-dihydropyridine-1(2 H )-carboxylate 1.5 Preparation of. Compound in DMF (160 mL) 1.3 In a mixture of (10g, 35.7mmol) tert -butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxa-borolan-2-yl)-3,6-dihydropyridine-1(2 H )-carboxylate 1.4 (16.5 g, 53.6 mmol), K3PO4 (9.11 g, 42.9 mmol), and Pd(dppf)Cl2 (2.92 g, 3.58 mmol) were added under N2. After stirring at 90°C for 16 hours under N2, the reaction mixture was diluted with H2O (600 mL) and extracted with EtOAc (3 x 500 mL). The combined organic layer was washed with brine (3 x 500 mL), dried over anhydrous Na2SO4, filtered, concentrated, and purified by column chromatography (SiO2, MeOH / DCM) to obtain the compound 1.5 (3.8g) was obtained with a 24% yield. 1 ¹H NMR (400 MHz, DMSO- d 6 ) δ 11.0 (s, 1H), 8.12-8.10 (m, 1H), 7.72-7.70 (m, 1H), 6.88 (s, 1H), 5.19-5.15 (m, 1H), 4.53-4.31 (m, 2H), 4.09 (s, 2H), 3.57-3.54 (m, 2H), 2.97-2.88 (m, 1H), 2.62-2.60 (m, 4H), 2.04-2.01 (m, 1H), 1.43 (s, 9H); MS (ESI) m / z : 371.0 [M-55] + .
[0581] tert -butyl 4-(6-(2,6-dioxopiperidine-3-yl)-5-oxo-6,7-dihydro-5 H -pyrrolo[3,4- b ]pyridine-2-yl)-4-hydroxypiperidine-1-carboxylate 1.6 Preparation of. Compound at 0°C 1.5 Phenylsilane (512 mg, 4.74 mmol) and Mn(dpm)3 (709 mg, 1.17 mmol) were added to a solution of DCM (12 mL), DMF (4 mL), and IPA (12 mL) containing 1 g (2.34 mmol). After stirring at 0°C under O2 for 16 hours, the reaction was quenched with a saturated aqueous solution of Na2S2O3 (30 mL), and the reaction mixture was extracted with EtOAc (3 x 50 mL). The combined organic layer was dried over anhydrous Na2SO4, filtered, concentrated, and purified by column chromatography (SiO2, MeOH / DCM) to obtain the compound 1.6 (0.34g) was obtained with a 35% yield. 1 ¹H NMR (400 MHz, DMSO- d 6 ) δ 11.0 (s, 1H), 8.16-8.14 (m, 1H), 7.86-7.84 (m, 1H), 5.19-5.14 (m, 1H), 4.52-4.30 (m, 2H), 4.10-4.07 (m, 1H), 3.90-3.87 (m, 2H), 3.17-3.16 (m, 3H), 2.90-2.88 (m, 1H), 2.44-2.41 (m, 1H), 2.08-2.00 (m, 3H), 1.78-1.53 (m, 2H), 1.42 (s, 9H); MS (ESI) m / z : 389.1 [M-55] + .
[0582] 3-(2-(4-hydroxypiperidin-4-yl)-5-oxo-5,7-dihydro-6 H -pyrrolo[3,4- b ]-pyridine-6-yl)piperidine-2,6-dione 1.7 Manufacture of. Compound 1.6 A 10 mL solution of 4 M HCl in 340 mg (764 μmol) of dioxane was stirred under N2 for 4 hours. Subsequently, the reaction mixture was filtered and concentrated to obtain the compound as the HCl salt. 1.7 (280 mg) was obtained with a 95% yield. 1 ¹H NMR (400 MHz, DMSO- d 6 ) δ 11.0 (s, 1H), 8.89-8.86 (m, 1H), 8.57-8.50 (m, 1H), 5.19-5.14 (m, 1H), 8.21-8.19 (m, 1H), 7.87-7.85 (m, 1H), 5.21-5.16 (m, 1H), 4.54-4.32 (m, 2H), 3.57 (s, 1H), 3.24-3.18 (m, 4H), 2.90-2.59 (m, 1H), 2.45-2.36 (m, 3H), 2.11-1.98 (m, 1H), 1.79-1.75 (m, 2H); MS (ESI) m / z : 345.1 [M+H] + .
[0583] 3-(2-(1-benzyl-4-hydroxypiperidin-4-yl)-5-oxo-5,7-dihydro-6 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A001 Preparation of. Compound as a...
Claims
Claim 1 A compound having the structure of the following chemical formula (A) or its enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, or a mixture of two or more tautomers; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; or a pharmaceutically acceptable derivative thereof: Here:R 1 C1-C 10 Alkyl, C3-C 10 Cycloalkyl, C6-C 14 Aryl, C7-C 15 It is an arylalkyl, heteroaryl, or heterocycloalkyl and; R 2 and R 3 Each independently consists of H, deuterium, and C1-C 10 alkyl or C3-C 10 Cycloalkyl or; R 2 and R 3 C(O) or C3-C together with the carbon atoms to which they are attached 10 Forming a cycloalkyl; R 13 is H, deuterium, or hydroxyl; X is CR 4 R 5 or C(O), where R 4 and R 5 Each independently consists of H, deuterium, or C1-C 10 alkyl; c and d are each independently integers of 0, 1, or 2; each alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl, and heterocycloalkyl is optionally substituted with 1, 2, 3, or 4 substituents, each of which is independently deuterium, cyano, halo, oxo, nitro, substituted or unsubstituted C1-C 10 Alkyl, substituted or unsubstituted C1-C 10 Heteroalkyl, substituted or unsubstituted C3-C 10 Cycloalkyl, substituted or unsubstituted C6-C 14 Aryl, substituted or unsubstituted C7-C 15 arylalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocycloalkyl, -COR', -CO2R', -CONR'R", -OR', -OC(O)R', -OC(O)NR'R", -NR'R", -NR"C(O)R', -NR"C(O)2R', -NR'C(O)NR"R"', -NRSO2R', -NRSO2NR'R'', -SR', -S(O)R', -S(O)2R' or -S(O)2NR'R"; and each R', R" and R"' is independently hydrogen, substituted or unsubstituted C1-C 10 Alkyl, substituted or unsubstituted C1-C 10 Heteroalkyl, substituted or unsubstituted C1-C 10 Cycloalkyl, substituted or unsubstituted C6-C 14 Aryl, substituted or unsubstituted C7-C 15 It is an arylalkyl, a substituted or unsubstituted heteroaryl, or a substituted or unsubstituted heterocycloalkyl. Claim 2 In claim 1, a compound having the structure of the following formula (I) or a pharmaceutically acceptable derivative thereof: Here:R 1 is a cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, and R 2 and R 3 Each is independently H, alkyl, or cycloalkyl, or R 2 and R 3 ...to form a spirocycloalkyl group together; a and b are each independently integers from 1 to 3; and X is CR 4 R 5 or C(O), where R 4 and R 5 Each is independently H, alkyl, or aralkyl. Claim 3 In paragraph 2, a compound having the structure of the following chemical formula (Ia) or a pharmaceutically acceptable derivative thereof: Here:R 1 is a cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, and R 2 is H, alkyl, or cycloalkyl; X is CR 4 R 5 or C(O), where R 4 and R 5 Each is independently H, alkyl, or aralkyl. Claim 4 In any one of paragraphs 1 through 3, X is CR 4 R 5 Phosphorus, compound. Claim 5 In claim 1 or 4, a compound having the structure of the following formula (II) or its enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, or a mixture of two or more tautomers; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; or a pharmaceutically acceptable derivative thereof: . Claim 6 In any one of paragraphs 1 through 5, (i) R 1 is an aryl or heteroaryl, and -OR 6 , -NR 7 R 8 , -(CH2) n -R 9 , -C(O)NR 7 R 8 , -NR 7 C(O)R 12 , -S(O) p NR 7 R 8 , -NR 7 S(O) p R 12 , -C(O)-(CH2) m -R 10 or -S(O) p -(CH2) q -R 11 It is optionally substituted as; where R 6 is H, alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; and each R 7 and R 8 is independently H, alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, or R 7 and R 8 ... forms a heterocycloalkyl with the atom(s) to which they are attached; R 9 , R 10 and R 11 Each is independently a monocyclic or fused, bridged, or spirocyclic cycloalkyl or a monocyclic or fused, bridged, or spirocyclic heterocycloalkyl; R 12 is an alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; each of m, n, p, and q is independently an integer from 0 to 2; or (ii) R 1 A compound that is an aryl or heteroaryl, each optionally fused to a cycloalkyl or heterocycloalkyl ring. Claim 7 In any one of paragraphs 1 through 6, R 1 is an aryl or heteroaryl, and -OR 6 , -NR 7 R 8 , -(CH2) n -R 9 , -C(O)NR 7 R 8 , -NR 7 C(O)R 12 , -S(O) p NR 7 R 8 , -NR 7 S(O) p R 12 , -C(O)-(CH2) m -R 10 or -S(O) p -(CH2) q -R 11 It is optionally substituted as; where R 6 is H, alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; and each R 7 and R 8 is independently H, alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, or R 7 and R 8 ... forms a heterocycloalkyl with the atom(s) to which they are attached; R 9 , R 10 and R 11 Each is independently a monocyclic or fused, cross-linked or spiro-cyclic cycloalkyl or a monocyclic or fused, cross-linked or spiro-cyclic heterocycloalkyl; R 12 is an alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl compound, wherein each of m, n, p, and q is independently an integer from 0 to 2. Claim 8 In any one of paragraphs 1 through 7, R 1 is aryl, and is -OR 6 , -NR 7 R 8 , -(CH2) n -R 9 , -C(O)NR 7 R 8 , -NR 7 C(O)R 12 , -S(O) p NR 7 R 8 , -NR 7 S(O) p R 12 , -C(O)R 10 or -S(O)2R 11 It is optionally substituted as; where R 6 is a cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; and each R 7 and R 8 is independently H, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, or R 7 and R 8 ... forms a heterocycloalkyl with the atom(s) to which they are attached; R 9 , R 10 and R 11 Each is independently a monocyclic or fused, cross-linked or spiro-cyclic cycloalkyl or a monocyclic or fused, cross-linked or spiro-cyclic heterocycloalkyl; R 12 is an alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl compound, wherein each n and p are independently integers from 0 to 2. Claim 9 In any one of paragraphs 1 through 8, R 1 is aryl, and -OR 6 , -NR 7 R 8 , -(CH2) n -R 9 , -C(O)NR 7 R 8 , -NR 7 C(O)R 12 , -S(O) p NR 7 R 8 , -NR 7 S(O) p R 12 , -C(O)R 10 or -S(O)2R 11 It is optionally substituted as; where R 6 is a heterocycloalkyl or aryl; R 7 is H and; R 8 is a heterocycloalkyl or aryl; R 9 , R 10 and R 11 Each is independently a monocyclic or fused, crosslinked, or spirocyclic heterocycloalkyl; R 12 is an alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl compound, wherein n is an integer of 0 or 1 and p is an integer from 0 to 2. Claim 10 In any one of paragraphs 1 through 9, R 1 is aryl, and is -OR 6 , -NR 7 R 8 , -(CH2) n -R 9 , -C(O)R 10 or -S(O)2R 11 It is optionally substituted as; where R 6 is a heterocycloalkyl or aryl; R 7 is H and; R 8 is a heterocycloalkyl or aryl; R 9 , R 10 and R 11 A compound in which each is independently a monocyclic or fused, crosslinked, or spirocyclic heterocycloalkyl; and n is an integer of 0 or 1. Claim 11 In any one of paragraphs 1 through 10, R 1 A compound that is an optionally substituted phenyl. Claim 12 In any one of paragraphs 1 through 9 and paragraph 11, R 1 is phenyl, and this is -OR 6 , -NR 7 R 8 , -(CH2) n -R 9 , -C(O)NR 7 R 8 , -NR 7 C(O)R 8 , -C(O)R 10 or -S(O)2R 11 It is optionally substituted as; where R 6 is a heterocycloalkyl or aryl; R 7 is H and; R 8 is a heterocycloalkyl or aryl; R 9 , R 10 and R 11 A compound in which each is independently a monocyclic or fused, crosslinked, or spirocyclic heterocycloalkyl; and n is an integer of 0 or 1. Claim 13 In any one of paragraphs 1 through 12, R 1 A compound that is an unsubstituted phenyl. Claim 14 In any one of paragraphs 1 through 6, R 1 A compound that is an aryl and is optionally fused to a cycloalkyl or heterocycloalkyl ring. Claim 15 In any one of paragraphs 1 through 6 and paragraph 14, R 1 A compound that is phenyl and is selectively fused to a heterocycloalkyl ring. Claim 16 In any one of paragraphs 1, 4, and 5, R 1 C1-C 10 Alkyl, C3-C 10 Cycloalkyl, C6-C 14 Aryl, C7-C 15 It is arylalkyl, heteroaryl, or heterocycloalkyl, each optionally substituted with 1, 2, 3, or 4 substituents, each of which is independently deuterium, cyano, halo, oxo, substituted or unsubstituted C1-C 10 Alkyl, substituted or unsubstituted C1-C 10 Heteroalkyl, substituted or unsubstituted C3-C 10 Cycloalkyl, substituted or unsubstituted C6-C 14 Aryl, substituted or unsubstituted C7-C 15 Compounds that are arylalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocycloalkyl, -COR', -CONR'R", -OR', -NR'R", -S(O)2R' or -S(O)2NR'R". Claim 17 In any one of paragraphs 1, 4, 5 and 16, R 1 C1-C 10 It is an alkyl group, which is optionally substituted with one, two, or three substituents, each of which is independently a deuterium, cyano, halo, oxo, substituted, or unsubstituted C1-C 10 Alkyl, substituted or unsubstituted C1-C 10 Heteroalkyl, substituted or unsubstituted C3-C 10 Cycloalkyl, substituted or unsubstituted C6-C 14 Aryl, substituted or unsubstituted C7-C 15 Compounds that are arylalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocycloalkyl, -COR', -CONR'R", -OR', -NR'R", -S(O)2R' or -S(O)2NR'R". Claim 18 In any one of paragraphs 1, 4, 5, 16 and 17, R 1 A compound that is isopropyl. Claim 19 In any one of paragraphs 1 through 5 and paragraph 16, R 1 C3-C 10 It is a cycloalkyl, which is optionally substituted with one, two, or three substituents, each of which is independently a deuterium, cyano, halo, oxo, substituted, or unsubstituted C1-C 10 Alkyl, substituted or unsubstituted C1-C 10 Heteroalkyl, substituted or unsubstituted C3-C 10 Cycloalkyl, substituted or unsubstituted C6-C 14 Aryl, substituted or unsubstituted C7-C 15 Compounds that are arylalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocycloalkyl, -COR', -CONR'R", -OR', -NR'R", -S(O)2R' or -S(O)2NR'R". Claim 20 In any one of paragraphs 1 through 5, paragraph 16 and paragraph 19, R 1 It is a monocyclic or bicyclic C3-C 10 It is cycloalkyl, optionally substituted with one, two, or three substituents, each of which is independently a deuterium, cyano, halo, oxo, substituted, or unsubstituted C1-C 10 Alkyl, substituted or unsubstituted C1-C 10 Heteroalkyl, substituted or unsubstituted C3-C 10 Cycloalkyl, substituted or unsubstituted C6-C 14 Aryl, substituted or unsubstituted C7-C 15 Compounds that are arylalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocycloalkyl, -COR', -CONR'R", -OR', -NR'R", -S(O)2R' or -S(O)2NR'R". Claim 21 In any one of paragraphs 1 through 5, 16, 19 and 20, R 1 A compound that is cyclohexyl, 4-aminocyclohexyl, or 3-fluorobicyclo[1.1.1]pentane-1-yl. Claim 22 In any one of paragraphs 1 through 5 and paragraph 16, R 1 C6-C 14 It is an aryl, which is optionally substituted with one, two, or three substituents, each of which is independently a deuterium, cyano, halo, substituted, or unsubstituted C1-C 10 Alkyl, substituted or unsubstituted C1-C 10 Heteroalkyl, substituted or unsubstituted C3-C 10 Cycloalkyl, substituted or unsubstituted C6-C 14 Aryl, substituted or unsubstituted C7-C 15 Compounds that are arylalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocycloalkyl, -COR', -CONR'R", -OR', -NR'R", -S(O)2R' or -S(O)2NR'R". Claim 23 In any one of paragraphs 1 through 5, paragraph 16 and paragraph 22, R 1 is phenyl, which is optionally substituted with one, two, or three substituents, each of which is independently a deuterium, cyano, halo, substituted, or unsubstituted C1-C 10 Alkyl, substituted or unsubstituted C1-C 10 Heteroalkyl, substituted or unsubstituted C3-C 10 Cycloalkyl, substituted or unsubstituted C6-C 14 Aryl, substituted or unsubstituted C7-C 15 Compounds that are arylalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocycloalkyl, -COR', -CONR'R", -OR', -NR'R", -S(O)2R' or -S(O)2NR'R". Claim 24 In any one of paragraphs 1 through 5, 16, 22 and 23, R 1 is phenyl, which is optionally substituted with one, two, or three substituents, each of which is independently a deuterium, cyano, halo, substituted, or unsubstituted C1-C 10 Alkyl, substituted or unsubstituted C1-C 10 Heteroalkyl, substituted or unsubstituted C6-C 14 aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocycloalkyl or -OR'; where R' is a substituted or unsubstituted C1-C 10 Alkyl or substituted or unsubstituted C6-C 14 Aryl compounds. Claim 25 In any one of paragraphs 1 through 5, 16, 22 and 23, R 1 ... is phenyl, which is optionally substituted with one or two substituents, each of which is independently deuterium, cyano, chloro, fluoro, methyl, trifluoromethyl, ethyl, difluoroethyl, propyl, butyl, oxanylmethyl, morpholinomethyl, hydroxymethyl, methoxymethyl, phenoxymethyl, dimethylaminomethyl, cyclobutyl, cyclohexyl, phenyl, pyrazolyl, methylpyrazolyl, oxetanyl, piperidinyl, difluoropiperidinyl, (hydroxymethyl)piperidinyl, hydroxypiperidinyl, oxanyl, morpholino, 8-azabicyclo[3.2.1]octanyl, hydroxyl, methoxy, trifluoromethoxy, hydroxyethoxy, phenoxy, benzoxy, oxanyloxy, piperidinyloxy, amino, dimethylamino, phenylamino, aminocarbonyl, A compound that is methylaminocarbonyl, dimethylaminocarbonyl, methylsulfonyl, or aminosulfonyl. Claim 26 In any one of paragraphs 1 through 5, 16 and 22 through 25, R 1 is phenyl, which is optionally substituted with one or two substituents, each of which is independently deuterium, cyano, chloro, fluoro, methyl, trifluoromethyl, ethyl, difluoroethyl, propyl, butyl, morpholinomethyl, methoxymethyl, phenoxymethyl, phenyl, pyrazolyl, methylpyrazolyl, piperidinyl, morpholino, 8-azabicyclo[3.2.1]octanyl or phenoxyin, compound. Claim 27 In any one of paragraphs 1 through 5, 16, 22, 23 and 25, R 1 is phenyl, which is optionally substituted with one or two substituents, each of which is independently deuterium, cyano, chloro, fluoro, methyl, trifluoromethyl, ethyl, 1,1-difluoroethyl, isopropyl, tert -Butyl, oxane-4-ylmethyl, morpholinomethyl, hydroxymethyl, methoxymethyl, phenoxymethyl, dimethylaminomethyl, cyclobutyl, cyclohexyl, phenyl, pyrazole-1-yl, 1-methylpyrazole-3-yl, 1-methylpyrazole-4-yl, 2-methylpyrazole-3-yl, oxetane-3-yl, oxane-4-yl, piperidine-1-yl, 4,4-difluoropiperidin-1-yl, 4-(hydroxymethyl)piperidin-1-yl, 4-hydroxypiperidin-1-yl, morpholino, 8-azabicyclo[3.2.1]octane-8-yl, hydroxyl, methoxy, trifluoromethoxy, 2-hydroxyethoxy, phenoxy, benzoxy, piperidine-4-yloxy, oxane-4-yloxy, A compound that is amino, dimethylamino, phenylamino, aminocarbonyl, methylaminocarbonyl, dimethylaminocarbonyl, methylsulfonyl, or aminosulfonyl. Claim 28 In any one of paragraphs 1 through 5, 16 and 22 through 27, R 1 is phenyl, which is optionally substituted with one or two substituents, each of which is independently deuterium, cyano, chloro, fluoro, methyl, trifluoromethyl, ethyl, 1,1-difluoroethyl, isopropyl, tert -Butyl, morpholinomethyl, methoxymethyl, phenoxymethyl, phenyl, pyrazole-1-yl, 1-methylpyrazole-3-yl, 1-methylpyrazole-4-yl, piperidine-1-yl, morpholino, 8-azabicyclo[3.2.1]octan-8-yl or phenoxyin, compound. Claim 29 In any one of paragraphs 1 through 5, paragraph 16, paragraph 22, paragraph 23, paragraph 25 and paragraph 27, R 1 phenyl, 2-cyanophenyl, 3-cyanophenyl, 4-cyanophenyl, 3-chlorophenyl, 4-chlorophenyl, 2-fluorophenyl, 3-fluorophenyl, 4-fluorophenyl, 2,4-difluorophenyl, 2-methylphenyl, 3-methylphenyl, 4-methylphenyl, 3-trifluoromethylphenyl, 4-trifluoromethylphenyl, 3-ethylphenyl, 4-ethylphenyl, 3-(1,1-difluoroethyl)phenyl, 4-(1,1-difluoroethyl)phenyl, 3-isopropylphenyl, 4-isopropylphenyl, 3- tert -butylphenyl, 4- tert -butylphenyl, 4-(oxane-4-ylmethyl)phenyl, 4-(morpholinomethyl)phenyl, 4-hydroxymethylphenyl, 4-methoxymethylphenyl, 4-phenoxymethylphenyl, 4-((dimethylamino)methyl)phenyl, 4-chloro-3-fluorophenyl, 4-chloro-3-methylphenyl, 3,4-di(trifluoromethyl)phenyl, 3-cyclobutylphenyl, 4-cyclobutylphenyl, 4-cyclohexylphenyl, 4-phenylphenyl, 4-pyrazole-1-ylphenyl, 4-(1-methylpyrazole-3-yl)phenyl, 4-(1-methylpyrazole-4-yl)phenyl, 4-(2-methylpyrazole-3-yl)phenyl, 3-(oxetane-3-yl)phenyl, 4-(oxetane-3-yl)phenyl, 3-oxane-4-ylphenyl, 4-oxane-4-ylphenyl, 3-(piperidin-1-yl)phenyl, 4-(piperidin-1-yl)phenyl, 4-(4,4-difluoropiperidin-1-yl)phenyl, 4-(4-(hydroxymethyl)piperidin-1-yl)phenyl, 4-(4-hydroxypiperidin-1-yl)phenyl, 3-morpholinophenyl, 4-morpholinophenyl, 3-(8-azabicyclo[3.2.1]octane-8-yl)phenyl, 4-(8-azabicyclo[3.2.1]octane-8-yl)phenyl, 2-hydroxyphenyl, 3-hydroxyphenyl, 4-hydroxyphenyl, 2-methoxyphenyl, 3-methoxyphenyl, 4-methoxyphenyl, 4-trifluoromethoxyphenyl, Compounds that are 4-(2-hydroxyethoxy)phenyl, 3-phenoxyphenyl, 4-phenoxyphenyl, 4-benzoxyphenyl, 4-(piperidin-4-yloxy)phenyl, 4-(oxane-4-yl)oxyphenyl, 3,4-dimethoxyphenyl, 3-aminophenyl, 3-dimethylaminophenyl, 4-dimethylaminophenyl, 4-phenylaminophenyl, 3-aminocarbonylphenyl, 4-aminocarbonylphenyl, 3-methylaminocarbonylphenyl, 4-methylaminocarbonylphenyl, 4-dimethylaminocarbonylphenyl, 4-(methylsulfonyl)phenyl, or 4-aminosulfonylphenyl. Claim 30 In any one of paragraphs 1 through 5, 16 and 22 through 29, R 1 phenyl, 3-cyanophenyl, 4-cyanophenyl, 3-chlorophenyl, 4-chlorophenyl, 3-fluorophenyl, 4-fluorophenyl, 4-methylphenyl, 3-trifluoromethylphenyl, 4-trifluoromethylphenyl, 4-ethylphenyl, 3-(1,1-difluoroethyl)phenyl, 4-(1,1-difluoroethyl)phenyl, 4-isopropylphenyl, 4- tert - A compound that is -butylphenyl, 4-(oxane-4-ylmethyl)phenyl, 4-methoxymethylphenyl, 4-phenylphenyl, 4-pyrazole-1-ylphenyl, 4-(1-methylpyrazole-3-yl)phenyl, 4-(1-methylpyrazole-4-yl)phenyl, 4-(piperidine-1-yl)phenyl, 3-morpholinophenyl, 3-(8-azabicyclo[3.2.1]octan-8-yl)phenyl, 4-(8-azabicyclo[3.2.1]octan-8-yl)phenyl, 3-phenoxyphenyl, or 4-phenoxyphenyl. Claim 31 In any one of paragraphs 1 through 5, paragraph 16 and paragraph 22, R 1 Eun Hwan-sik C8-C 14 It is an aryl, which is optionally substituted with one, two, or three substituents, each of which is independently a deuterium, cyano, halo, substituted, or unsubstituted C1-C 10 Alkyl, substituted or unsubstituted C1-C 10 Heteroalkyl, substituted or unsubstituted C3-C 10 Cycloalkyl, substituted or unsubstituted C6-C 14 Aryl, substituted or unsubstituted C7-C 15 Compounds that are arylalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocycloalkyl, -COR', -CONR'R", -OR', -NR'R", -S(O)2R' or -S(O)2NR'R". Claim 32 In any one of paragraphs 1, 4, 5, 16, 22 and 31, R 1 2,3-dihydroindene-2-yl, a compound. Claim 33 In any one of paragraphs 1, 4, 5 and 16, R 1 C7-C 15 It is an arylalkyl, which is optionally substituted with one, two, or three substituents, each of which is independently a deuterium, cyano, halo, substituted, or unsubstituted C1-C 10 Alkyl, substituted or unsubstituted C1-C 10 Heteroalkyl, substituted or unsubstituted C3-C 10 Cycloalkyl, substituted or unsubstituted C6-C 14 Aryl, substituted or unsubstituted C7-C 15 Compounds that are arylalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocycloalkyl, -COR', -CONR'R", -OR', -NR'R", -S(O)2R' or -S(O)2NR'R". Claim 34 In any one of paragraphs 1, 4, 5, 16 and 33, R 1 A compound that is benzyl or 3-fluorobenzyl. Claim 35 In any one of paragraphs 1 through 5 and paragraph 16, R 1 It is a heteroaryl, which is optionally substituted with one, two, or three substituents, each of which is independently a deuterium, cyano, halo, substituted, or unsubstituted C1-C 10 Alkyl, substituted or unsubstituted C1-C 10 Heteroalkyl, substituted or unsubstituted C3-C 10 Cycloalkyl, substituted or unsubstituted C6-C 14 Aryl, substituted or unsubstituted C7-C 15 Compounds that are arylalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocycloalkyl, -COR', -CONR'R", -OR', -NR'R", -S(O)2R' or -S(O)2NR'R". Claim 36 In any one of paragraphs 1 through 5, paragraph 16 and paragraph 35, R 1 A compound that is a substituted or unsubstituted monocyclic heteroaryl. Claim 37 In any one of paragraphs 1 through 5, 16, 35 and 36, R 1 It is a pentagonal or hexaagonal heteroaryl, optionally substituted with 1, 2, or 3 substituents, each of which is independently a deuterium, cyano, halo, substituted, or unsubstituted C1-C 10 Alkyl, substituted or unsubstituted C1-C 10 Heteroalkyl, substituted or unsubstituted C3-C 10 Cycloalkyl, substituted or unsubstituted C6-C 14 Aryl, substituted or unsubstituted C7-C 15 Compounds that are arylalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocycloalkyl, -COR', -CONR'R", -OR', -NR'R", -S(O)2R' or -S(O)2NR'R". Claim 38 In any one of paragraphs 1 through 5, paragraph 16, and paragraphs 35 through 37, R 1 is isoxazolyl, oxazolyl, pyrazolyl, thiazolyl, 1,2,4-triazolyl, 1,3,4-thiadiazolyl, tetrazolyl or pyridinyl, each optionally substituted with one or two substituents, each of which is independently deuterium, cyano, chloro, fluoro, methyl, trifluoromethyl, isopropyl or phenyl, compound. Claim 39 In any one of paragraphs 1 through 5, 16 and 35 through 38, R 1 is isoxazole-4-yl, oxazole-2-yl, pyrazol-3-yl, pyrazol-4-yl, thiazole-2-yl, 1,2,4-triazole-3-yl, 1,3,4-thiadiazole-2-yl, tetrazole-5-yl, pyridine-2-yl, pyridine-3-yl, or pyridine-4-yl, each optionally substituted with one or two substituents, each of which is independently deuterium, cyano, chloro, fluoro, methyl, trifluoromethyl, isopropyl, or phenyl, compound. Claim 40 In any one of paragraphs 1, 4, 5, 16 and 35 through 39, R 1 isosxazole-4-yl, oxazole-2-yl, pyrazole-4-yl, 1-methylpyrazole-3-yl, 1-methylpyrazole-4-yl, 3-methylpyrazole-4-yl, 1-(trifluoromethyl)pyrazole-4-yl, 1-(isopropyl)pyrazole-3-yl, 1-(isopropyl)pyrazole-4-yl, 1-phenylpyrazole-4-yl, thiazole-2-yl, 5-methylthiazole-2-yl, 1,2,4-triazole-3-yl, 5-methyl-1,3,4-thiadiazole-2-yl, tetrazole-5-yl, pyridine-2-yl, pyridine-3-yl, pyridine-4-yl, 2-hydroxypyridine-4-yl or 1-methyl-2-oxo-1,2-dihydropyridine-4-yl phosphine, compound. Claim 41 In any one of paragraphs 1 through 5, paragraph 16 and paragraph 35, R 1 A compound that is a substituted or unsubstituted cyclic heteroaryl. Claim 42 In any one of paragraphs 1 through 5, 16, 35 and 41, R 1 It is a 5,5-, 5,6-, or 6,6-fused heteroaryl, each optionally substituted with 1, 2, or 3 substituents, each of which is independently a deuterium, cyano, halo, substituted, or unsubstituted C1-C 10 Alkyl, substituted or unsubstituted C1-C 10 Heteroalkyl, substituted or unsubstituted C3-C 10 Cycloalkyl, substituted or unsubstituted C6-C 14 Aryl, substituted or unsubstituted C7-C 15 Compounds that are arylalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocycloalkyl, -COR', -CONR'R", -OR', -NR'R", -S(O)2R' or -S(O)2NR'R". Claim 43 In any one of paragraphs 1 through 5, paragraph 16, paragraph 35, paragraph 41 and paragraph 42, R 1 5,6-dihydrocyclopenta[ d ]thiazolyl, 6,7-dihydropyrrolo[1,2- a ]Imidazolyl benzofuranil, benzimidazolyl, benzoxazolyl, benzothiazollil, benzo[ d ][1,2,3]Triazolyl, imidazo[1,2- a ]pyridinyl, indolyl, indazolyl, pyrazolo[1,5- a ]pyridinyl, pyrrolo[2,3- b ]pyridinyl, pyrrolo[3,2- b ]pyridinyl, [1,2,4]triazolo[1,5- a ]pyridinyl, 2,3-dihydroisoindolyl, 2,3-dihydrobenzofuranyl, 1,3-dihydroisobenzofuranyl, benzo[ d ][1,3]dioxolyl, 5,6,7,8-tetrahydroimidazo[1,2- a ]pyridinyl, 4,5,6,7-tetrahydropyrazolo[1,5- a ]pyridinyl, quinolinyl, chromanyl, 3,4-dihydropyrido[3,2- b ][1,4]oxazinyl or 3,4-dihydro-1,4-benzoxazinyl, each optionally substituted with one or two substituents, each of which is independently deuterium, cyano, chloro, fluoro, methyl, trifluoromethyl, isopropyl, or phenyl, compound. Claim 44 In any one of paragraphs 1 through 5, 16, 35 and 41 through 43, R 1 5,6-dihydrocyclopenta[ d ]thiazole-2-yl, 6,7-dihydropyrrolo[1,2- a ]Imidazole-2-yl, benzofuran-6-yl, benzimidazole-5-yl, benzoxazole-2-yl, benzothiazole-2-yl, benzo[ d ][1,2,3]triazole-5-yl, imidazo[1,2- a ]pyridin-2-yl, indole-5-yl, indole-6-yl, indazole-4-yl, indazole-5-yl, indazole-6-yl, pyrazolo[1,5- a ]pyridin-6-yl, pyrrolo[2,3- b ]pyridin-5-yl, pyrrolo[3,2- b ]pyridin-2-yl, pyrrolo[3,2- b ]pyridin-6-yl, [1,2,4]triazolo[1,5- a ]pyridine-7-yl, 2,3-dihydroisoindole-5-yl, 2,3-dihydrobenzofuran-5-yl, 2,3-dihydrobenzofuran-6-yl, 1,3-dihydroisobenzofuran-5-yl, benzo[ d ][1,3]dioxol-5-yl, 5,6,7,8-tetrahydroimidazo[1,2- a ]pyridine-2-yl, 4,5,6,7-tetrahydropyrazolo[1,5- a ]pyridine-3-yl, quinoline-2-yl, quinoline-3-yl, quinoline-6-yl, chroman-6-yl, chroman-7-yl, 3,4-dihydropyrido[3,2- b ][1,4]oxazine-7-yl or 3,4-dihydro-1,4-benzoxazine-6-yl, each optionally substituted with one or two substituents, each of which is independently deuterium, cyano, chloro, fluoro, methyl, trifluoromethyl, isopropyl, or phenyl, compound. Claim 45 In any one of paragraphs 1 through 5, 16, 35, and 41 through 44, R 1 5,6-dihydrocyclopenta[ d ]thiazole-2-yl, 6,7-dihydropyrrolo[1,2- a ]Imidazole-2-yl, benzofuran-6-yl, 1-methylbenzimidazole-5-yl, 3-methylbenzimidazole-5-yl, benzoxazole-2-yl, benzothiazole-2-yl, 1-methylbenzo[ d ][1,2,3]triazole-5-yl, imidazo[1,2- a ]pyridine-2-yl, 1-methylindole-5-yl, 1-methylindole-6-yl, indazole-5-yl, 1-methylindazole-4-yl, 1-methylindazole-5-yl, 1-methylindazole-6-yl, pyrazolo[1,5- a ]pyridine-6-yl, 2,2-difluorobenzo[ d ][1,3]dioxol-5-yl, pyrrolo[2,3- b ]pyridin-5-yl, pyrrolo[3,2- b ]pyridin-2-yl, pyrrolo[3,2- b ]pyridine-6-yl, 2,2-dimethylbenzo[ d ][1,3]dioxol-5-yl, 2,2-dimethyl-2,3-dihydrobenzofuran-6-yl, [1,2,4]triazolo[1,5- a ]pyridine-7-yl, 1,3-dihydroisobenzofuran-5-yl, 2,3-dihydrobenzofuran-5-yl, 3-oxo-3,4-dihydro-1,4-benzoxazine-6-yl, 2,3-dihydroindene-2-yl, 2,3-dihydroisoindole-5-yl, 3-oxo-2,3-dihydroisoindole-5-yl, 2,3-dihydrobenzofuran-6-yl, 5,6,7,8-tetrahydroimidazo[1,2- a ]pyridine-2-yl, 4,5,6,7-tetrahydropyrazolo[1,5- a ]pyridine-3-yl, quinoline-2-yl, quinoline-3-yl, quinoline-6-yl, chroman-6-yl, chroman-7-yl, 4-methyl-3,4-dihydropyrido[3,2- b ][1,4]oxazine-7-yl or 3-oxo-3,4-dihydro-1,4-benzoxazine-6-yl, a compound. Claim 46 In any one of paragraphs 1 through 5 and paragraph 16, R 1 is a heterocycloalkyl, which is optionally substituted with one, two, or three substituents, each of which is independently a deuterium, cyano, halo, substituted, or unsubstituted C1-C 10 Alkyl, substituted or unsubstituted C1-C 10 Heteroalkyl, substituted or unsubstituted C3-C 10 Cycloalkyl, substituted or unsubstituted C6-C 14 Aryl, substituted or unsubstituted C7-C 15 Compounds that are arylalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocycloalkyl, -COR', -CONR'R", -OR', -NR'R", -S(O)2R' or -S(O)2NR'R". Claim 47 In any one of paragraphs 1 through 5, paragraph 16 and paragraph 46, R 1 A compound that is a substituted or unsubstituted monocyclic heterocycloalkyl. Claim 48 In any one of paragraphs 1 through 5, paragraph 16, paragraph 46 and paragraph 47, R 1 is a ternary, quaternary, pentary, hexavalent, or heptary heterocycloalkyl, each optionally substituted with one, two, or three substituents, each of which is independently a deuterium, cyano, halo, substituted, or unsubstituted C1-C 10 Alkyl, substituted or unsubstituted C1-C 10 Heteroalkyl, substituted or unsubstituted C3-C 10 Cycloalkyl, substituted or unsubstituted C6-C 14 Aryl, substituted or unsubstituted C7-C 15 Compounds that are arylalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocycloalkyl, -COR', -CONR'R", -OR', -NR'R", -S(O)2R' or -S(O)2NR'R". Claim 49 In any one of paragraphs 1 through 5, paragraph 16, and paragraphs 46 through 48, R 1 A compound that is azathidinyl, oxanyl, piperidinyl, tetrahydrothiopyranill, 2-azaspiro[3.3]heptanyl, 2-azaspiro[3.5]nonanyl, 3-azaspiro[5.5]undecanyl or 8-azabicyclo[3.2.1]octanyl, each optionally substituted with one or two substituents, each of which is independently oxo, cyano, chloro, fluoro, methyl, trifluoromethyl, isopropyl, phenyl, or pyridinyl. Claim 50 In any one of paragraphs 1 through 5, paragraph 16, and paragraphs 46 through 49, R 1 A compound that is azetidin-3-yl, oxane-2-yl, oxane-3-yl, piperidin-3-yl, piperidin-4-yl, tetrahydrothiopyran-4-yl, 2-azaspiro[3.3]heptane-6-yl, 2-azaspiro[3.5]nonane-7-yl, 3-azaspiro[5.5]undecane-9-yl, or 8-azabicyclo[3.2.1]octane-3-yl, each optionally substituted with one or two substituents, each of which is independently oxo, cyano, chloro, fluoro, methyl, trifluoromethyl, isopropyl, phenyl, pyridin-2-yl, pyridin-3-yl, or pyridin-4-yl. Claim 51 In any one of paragraphs 1 through 5, paragraph 16, and paragraphs 46 through 50, R 1 1-phenylazetidin-3-yl, oxane-2-yl, oxane-3-yl, piperidin-4-yl, 1-(isopropyl)piperidin-4-yl, 1-phenylpiperidin-3-yl, 1-phenylpiperidin-4-yl, 1-(2-chlorophenyl)piperidin-4-yl, 1-(3-chlorophenyl)piperidin-4-yl, 1-(4-chlorophenyl)piperidin-4-yl, 1-benzylpiperidin-4-yl, 1-(pyridin-3-yl)piperidin-4-yl, 1-(pyridin-2-yl)piperidin-4-yl, 1-acetylpiperidin-4-yl, 1,1-deoxydotetrahydrothiopyran-4-yl, A compound that is 2-azaspiro[3.3]heptane-6-yl, 2-azaspiro[3.5]nonane-7-yl, 8-phenyl-8-azabicyclo[3.2.1]octane-3-yl or 3-azaspiro[5.5]undecane-9-yl. Claim 52 In any one of paragraphs 1 through 5, paragraph 16, and paragraphs 46 through 51, R 1 A compound that is 1-phenylpiperidine-3-yl, 1-phenylpiperidine-4-yl, 1-(3-chlorophenyl)piperidine-4-yl, or 1-(4-chlorophenyl)piperidine-4-yl. Claim 53 In any one of claims 1, 4 and 5, a compound having the structure of the following formula (IV) or its enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, or a mixture of two or more tautomers; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; or a pharmaceutically acceptable derivative thereof: Here:R 1a , R 1b , R 1c , R 1d and R 1e Each is independently H, deuterium, cyano, halo, substituted, or unsubstituted C1-C 10 Alkyl, substituted or unsubstituted C1-C 10 Heteroalkyl, substituted or unsubstituted C3-C 10 Cycloalkyl, substituted or unsubstituted C6-C 14 Aryl, substituted or unsubstituted C7-C 15 Arylalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocycloalkyl, -COR', -CONR'R", -OR', -NR'R", -S(O)2R' or -S(O)2NR'R" or; R 1a and R 1b is formed with the carbon atoms to which they are attached a substituted or unsubstituted heteroaryl or a substituted or unsubstituted heterocycloalkyl; R 1b and R 1c A compound that forms a substituted or unsubstituted heteroaryl or a substituted or unsubstituted heterocycloalkyl together with the carbon atoms to which they are attached. Claim 54 In paragraph 53, a compound having the structure of the following formula (V) or its enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, or a mixture of two or more tautomers; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; or a pharmaceutically acceptable derivative thereof: . Claim 55 In paragraph 53 or 54, R 1a , R 1b , R 1c , R 1d and R 1e Each is independently H, deuterium, cyano, halo, substituted, or unsubstituted C1-C 10 Alkyl, substituted or unsubstituted C1-C 10 Heteroalkyl, substituted or unsubstituted C3-C 10 Cycloalkyl, substituted or unsubstituted C6-C 14 Aryl, substituted or unsubstituted C7-C 15 Compounds that are arylalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocycloalkyl, -COR', -CONR'R", -OR', -NR'R", -S(O)2R' or -S(O)2NR'R". Claim 56 In any one of paragraphs 53 through 55, R 1a is H, deuterium, cyano, halo, substituted or unsubstituted C1-C 10 Alkyl, substituted or unsubstituted C1-C 10 Heteroalkyl, substituted or unsubstituted C3-C 10 Cycloalkyl, substituted or unsubstituted C6-C 14 Aryl, substituted or unsubstituted C7-C 15 Compounds that are arylalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocycloalkyl, -COR', -CONR'R", -OR', -NR'R", -S(O)2R' or -S(O)2NR'R". Claim 57 In any one of paragraphs 53 through 56, R 1a Compounds that are H, cyano, chloro, fluoro, methyl, trifluoromethyl, ethyl, difluoroethyl, propyl, butyl, oxanylmethyl, morpholinomethyl, hydroxymethyl, methoxymethyl, phenoxymethyl, dimethylaminomethyl, cyclobutyl, cyclohexyl, phenyl, pyrazolyl, methylpyrazolyl, oxetanyl, piperidinyl, difluoropiperidinyl, (hydroxymethyl)piperidinyl, hydroxypiperidinyl, oxanyl, morpholino, 8-azabicyclo[3.2.1]octanyl, hydroxyl, methoxy, trifluoromethoxy, hydroxyethoxy, phenoxy, benzoxy, oxanyloxy, piperidinyloxy, amino, dimethylamino, phenylamino, aminocarbonyl, methylaminocarbonyl, dimethylaminocarbonyl, methylsulfonyl or aminosulfonyl. Claim 58 In any one of paragraphs 53 through 57, R 1a is H, cyano, chloro, fluoro, methyl, trifluoromethyl, ethyl, 1,1-difluoroethyl, isopropyl, tert -Butyl, oxane-4-ylmethyl, morpholinomethyl, hydroxymethyl, methoxymethyl, phenoxymethyl, dimethylaminomethyl, cyclobutyl, cyclohexyl, phenyl, pyrazole-1-yl, 1-methylpyrazole-3-yl, 1-methylpyrazole-4-yl, 2-methylpyrazole-3-yl, oxetane-3-yl, oxane-4-yl, piperidine-1-yl, 4,4-difluoropiperidin-1-yl, 4-(hydroxymethyl)piperidin-1-yl, 4-hydroxypiperidin-1-yl, morpholino, 8-azabicyclo[3.2.1]octane-8-yl, hydroxyl, methoxy, trifluoromethoxy, 2-hydroxyethoxy, phenoxy, benzoxy, piperidine-4-yloxy, oxane-4-yloxy, A compound that is amino, dimethylamino, phenylamino, aminocarbonyl, methylaminocarbonyl, dimethylaminocarbonyl, methylsulfonyl, or aminosulfonyl. Claim 59 In any one of paragraphs 53 through 58, R 1a is H, cyano, chloro, fluoro, methyl, trifluoromethyl, ethyl, 1,1-difluoroethyl, isopropyl, tert -butyl, oxane-4-ylmethyl, methoxymethyl, phenyl, pyrazole-1-yl, 1-methylpyrazole-3-yl, 1-methylpyrazole-4-yl, piperidine-1-yl, morpholino, 8-azabicyclo[3.2.1]octane-8-yl or phenoxyin, compound. Claim 60 In any one of paragraphs 53 through 59, R 1a is a compound that is H. Claim 61 In any one of paragraphs 53 through 60, R 1b is H, deuterium, cyano, halo, substituted or unsubstituted C1-C 10 Alkyl, substituted or unsubstituted C1-C 10 Heteroalkyl, substituted or unsubstituted C3-C 10 Cycloalkyl, substituted or unsubstituted C6-C 14 Aryl, substituted or unsubstituted C7-C 15 Compounds that are arylalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocycloalkyl, -COR', -CONR'R", -OR', -NR'R", -S(O)2R' or -S(O)2NR'R". Claim 62 In any one of paragraphs 53 through 61, R 1b Compounds that are H, cyano, chloro, fluoro, methyl, trifluoromethyl, ethyl, difluoroethyl, propyl, butyl, oxanylmethyl, morpholinomethyl, hydroxymethyl, methoxymethyl, phenoxymethyl, dimethylaminomethyl, cyclobutyl, cyclohexyl, phenyl, pyrazolyl, methylpyrazolyl, oxetanyl, piperidinyl, difluoropiperidinyl, (hydroxymethyl)piperidinyl, hydroxypiperidinyl, oxanyl, morpholino, 8-azabicyclo[3.2.1]octanyl, hydroxyl, methoxy, trifluoromethoxy, hydroxyethoxy, phenoxy, benzoxy, oxanyloxy, piperidinyloxy, amino, dimethylamino, phenylamino, aminocarbonyl, methylaminocarbonyl, dimethylaminocarbonyl, methylsulfonyl or aminosulfonyl. Claim 63 In any one of paragraphs 53 through 62, R 1b is H, cyano, chloro, fluoro, methyl, trifluoromethyl, ethyl, 1,1-difluoroethyl, isopropyl, tert -Butyl, oxane-4-ylmethyl, morpholinomethyl, hydroxymethyl, methoxymethyl, phenoxymethyl, dimethylaminomethyl, cyclobutyl, cyclohexyl, phenyl, pyrazole-1-yl, 1-methylpyrazole-3-yl, 1-methylpyrazole-4-yl, 2-methylpyrazole-3-yl, oxetane-3-yl, oxane-4-yl, piperidine-1-yl, 4,4-difluoropiperidin-1-yl, 4-(hydroxymethyl)piperidin-1-yl, 4-hydroxypiperidin-1-yl, morpholino, 8-azabicyclo[3.2.1]octane-8-yl, hydroxyl, methoxy, trifluoromethoxy, 2-hydroxyethoxy, phenoxy, benzoxy, piperidine-4-yloxy, oxane-4-yloxy, A compound that is amino, dimethylamino, phenylamino, aminocarbonyl, methylaminocarbonyl, dimethylaminocarbonyl, methylsulfonyl, or aminosulfonyl. Claim 64 In any one of paragraphs 53 through 63, R 1b is H, cyano, chloro, fluoro, methyl, trifluoromethyl, ethyl, 1,1-difluoroethyl, isopropyl, tert -butyl, oxane-4-ylmethyl, methoxymethyl, phenyl, pyrazole-1-yl, 1-methylpyrazole-3-yl, 1-methylpyrazole-4-yl, piperidine-1-yl, morpholino, 8-azabicyclo[3.2.1]octane-8-yl or phenoxyin, compound. Claim 65 In any one of paragraphs 53 through 64, R 1c is H, deuterium, cyano, halo, substituted or unsubstituted C1-C 10 Alkyl, substituted or unsubstituted C1-C 10 Heteroalkyl, substituted or unsubstituted C3-C 10 Cycloalkyl, substituted or unsubstituted C6-C 14 Aryl, substituted or unsubstituted C7-C 15 Compounds that are arylalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocycloalkyl, -COR', -CONR'R", -OR', -NR'R", -S(O)2R' or -S(O)2NR'R". Claim 66 In any one of paragraphs 53 through 65, R 1c Compounds that are H, cyano, chloro, fluoro, methyl, trifluoromethyl, ethyl, difluoroethyl, propyl, butyl, oxanylmethyl, morpholinomethyl, hydroxymethyl, methoxymethyl, phenoxymethyl, dimethylaminomethyl, cyclobutyl, cyclohexyl, phenyl, pyrazolyl, methylpyrazolyl, oxetanyl, piperidinyl, difluoropiperidinyl, (hydroxymethyl)piperidinyl, hydroxypiperidinyl, oxanyl, morpholino, 8-azabicyclo[3.2.1]octanyl, hydroxyl, methoxy, trifluoromethoxy, hydroxyethoxy, phenoxy, benzoxy, oxanyloxy, piperidinyloxy, amino, dimethylamino, phenylamino, aminocarbonyl, methylaminocarbonyl, dimethylaminocarbonyl, methylsulfonyl or aminosulfonyl. Claim 67 In any one of paragraphs 53 through 66, R 1c is H, cyano, chloro, fluoro, methyl, trifluoromethyl, ethyl, 1,1-difluoroethyl, isopropyl, tert -Butyl, oxane-4-ylmethyl, morpholinomethyl, hydroxymethyl, methoxymethyl, phenoxymethyl, dimethylaminomethyl, cyclobutyl, cyclohexyl, phenyl, pyrazole-1-yl, 1-methylpyrazole-3-yl, 1-methylpyrazole-4-yl, 2-methylpyrazole-3-yl, oxetane-3-yl, oxane-4-yl, piperidine-1-yl, 4,4-difluoropiperidin-1-yl, 4-(hydroxymethyl)piperidin-1-yl, 4-hydroxypiperidin-1-yl, morpholino, 8-azabicyclo[3.2.1]octane-8-yl, hydroxyl, methoxy, trifluoromethoxy, 2-hydroxyethoxy, phenoxy, benzoxy, piperidine-4-yloxy, oxane-4-yloxy, A compound that is amino, dimethylamino, phenylamino, aminocarbonyl, methylaminocarbonyl, dimethylaminocarbonyl, methylsulfonyl, or aminosulfonyl. Claim 68 In any one of paragraphs 53 through 67, R 1c is H, cyano, chloro, fluoro, methyl, trifluoromethyl, ethyl, 1,1-difluoroethyl, isopropyl, tert -butyl, oxane-4-ylmethyl, methoxymethyl, phenyl, pyrazole-1-yl, 1-methylpyrazole-3-yl, 1-methylpyrazole-4-yl, piperidine-1-yl, morpholino, 8-azabicyclo[3.2.1]octane-8-yl or phenoxyin, compound. Claim 69 In any one of paragraphs 53 through 68, R 1d is a compound that is H. Claim 70 In any one of paragraphs 53 through 69, R 1e is a compound that is H. Claim 71 In any one of paragraphs 53 through 55 and 65 through 68, R 1a and R 1b They form heteroaryl or heterocycloalkyl groups with the carbon atoms to which they are attached, and are each optionally substituted with one, two, or three substituents, each of which is independently a deuterium, oxo, cyano, halo, substituted, or unsubstituted C1-C 10 Alkyl, substituted or unsubstituted C1-C 10 Heteroalkyl, substituted or unsubstituted C3-C 10 Cycloalkyl, substituted or unsubstituted C6-C 14 Aryl, substituted or unsubstituted C7-C 15 Compounds that are arylalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocycloalkyl, -COR', -CONR'R", -OR', -NR'R", -S(O)2R' or -S(O)2NR'R". Claim 72 In any one of paragraphs 53 through 55 and 65 through 69, R 1a and R 1b Compounds that, together with the carbon atoms to which they are attached, form tetrahydrofuran-2,3-diyl, 5,5-dimethyltetrahydrofuran-2,3-diyl, tetrahydrofuran-3,4-diyl, pyrrolidine-3,4-diyl, 2-oxopyrrolidine-3,4-diyl, 2,2-difluoro-1,3-dioxolane-4,5-diyl, 2,2-dimethyl-1,3-dioxolane-4,5-diyl, oxane-2,3-diyl, 4-methylmorpholine-2,3-diyl, or 5-oxomorpholine-2,3-diyl. Claim 73 In any one of paragraphs 53 through 60, 69 and 70, R 1b and R 1c They form heteroaryl or heterocycloalkyl groups with the carbon atoms to which they are attached, and are each optionally substituted with one, two, or three substituents, each of which is independently a deuterium, oxo, cyano, halo, substituted, or unsubstituted C1-C 10 Alkyl, substituted or unsubstituted C1-C 10 Heteroalkyl, substituted or unsubstituted C3-C 10 Cycloalkyl, substituted or unsubstituted C6-C 14 Aryl, substituted or unsubstituted C7-C 15 Compounds that are arylalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocycloalkyl, -COR', -CONR'R", -OR', -NR'R", -S(O)2R' or -S(O)2NR'R". Claim 74 In any one of paragraphs 53 through 60 and 69 through 73, R 1b and R 1c Compounds that, together with the carbon atoms to which they are attached, form tetrahydrofuran-2,3-diyl, 5,5-dimethyltetrahydrofuran-2,3-diyl, tetrahydrofuran-3,4-diyl, pyrrolidine-3,4-diyl, 2-oxopyrrolidine-3,4-diyl, 2,2-difluoro-1,3-dioxolane-4,5-diyl, 2,2-dimethyl-1,3-dioxolane-4,5-diyl, oxane-2,3-diyl, 4-methylmorpholine-2,3-diyl, or 5-oxomorpholine-2,3-diyl. Claim 75 In any one of paragraphs 1 through 74, R 2 is a compound that is H. Claim 76 In any one of paragraphs 1 through 75, R 3 A compound that is H. Claim 77 In any one of paragraphs 1 through 74, R 2 and R 3 A compound that forms C(O) together with the carbon atoms to which they are attached. Claim 78 In any one of paragraphs 1 through 77, R 4 is H or substituted or unsubstituted C1-C 10 Alkyl compounds. Claim 79 In any one of paragraphs 1 through 78, R 4 is a compound that is H. Claim 80 In any one of paragraphs 1 through 78, R 4 is a methyl compound. Claim 81 In any one of paragraphs 1 through 80, R 5 is H or substituted or unsubstituted C1-C 10 Alkyl compounds. Claim 82 In any one of paragraphs 1 through 81, R 5 is a compound that is H. Claim 83 In any one of paragraphs 1 through 82, R 5 is a methyl compound. Claim 84 In any one of paragraphs 1 through 83, R 13 A compound that is H. Claim 85 In any one of paragraphs 1 through 83, R 13 A compound that is hydroxyl. Claim 86 In paragraph 1, the compound is a compound as follows: 3-(2-(1-benzyl-4-hydroxypiperidin-4-yl)-5-oxo-5,7-dihydro-6 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A001 ; 3-(2-(4-hydroxy-1-(pyridine-4-ylmethyl)piperidine-4-yl)-5-oxo-5,7-dihydro-6 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A002 ; 3-(2-(4-hydroxy-1-(2-methylbenzyl)piperidine-4-yl)-5-oxo-5,7-dihydro-6 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A003 ; 3-(2-(4-hydroxy-1-(4-methylbenzyl)piperidine-4-yl)-5-oxo-5,7-dihydro-6 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A004 ; 3-(2-(4-hydroxy-1-phenetylpiperidine-4-yl)-5-oxo-5,7-dihydro-6 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A005 ; 3-(2-(4-hydroxy-1-(2-hydroxybenzyl)piperidine-4-yl)-5-oxo-5,7-dihydro-6 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A006 ; 3-(2-(4-hydroxy-1-(3-hydroxybenzyl)piperidine-4-yl)-5-oxo-5,7-dihydro-6 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A007 ; 3-(2-(4-hydroxy-1-(2-cyanobenzyl)piperidine-4-yl)-5-oxo-5,7-dihydro-6 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A008 ; 3-(2-(4-hydroxy-1-(4-cyanobenzyl)piperidin-4-yl)-5-oxo-5,7-dihydro-6 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A009 ; 3-(2-(4-hydroxy-1-(3-cyanobenzyl)piperidine-4-yl)-5-oxo-5,7-dihydro-6 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A010 ; 3-(2-(4-hydroxy-1-(4-(hydroxymethyl)benzyl)piperidine-4-yl)-5-oxo-5,7-dihydro-6 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A011 ; 3-(2-(1-(4-chlorobenzyl)-4-hydroxypiperidin-4-yl)-5-oxo-5,7-dihydro-6 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A012 ; 3-(2-(1-(2,4-difluorobenzyl)-4-hydroxypiperidin-4-yl)-5-oxo-5,7-dihydro-6 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A013 ; 3-(2-(1-(4-(dimethylamino)benzyl)-4-hydroxypiperidin-4-yl)-5-oxo-5,7-dehydro-6 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A014 ; 3-(2-(1-([1,1'-biphenyl]-4-ylmethyl)-4-hydroxypiperidine-4-yl)-5-oxo-5,7-dihydro-6 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A015 ; 3-(2-(4-hydroxy-1-(4-(methylsulfonyl)benzyl)piperidine-4-yl)-5-oxo-5,7-dihydro-6 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A016 ; 3-(2-(4-hydroxy-1-(3-(trifluoromethyl)benzyl)piperidine-4-yl)-5-oxo-5,7-dihydro-6 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A017 ; 3-(2-(4-hydroxy-1-(3-phenoxybenzyl)piperidine-4-yl)-5-oxo-5,7-dihydro-6 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A018 ; 3-(2-(1-(cyclohexylmethyl)-4-hydroxypiperidine-4-yl)-5-oxo-5,7-dihydro-6 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A019 ; 3-(2-(4-hydroxy-1-(3-methylbenzyl)piperidine-4-yl)-5-oxo-5,7-dihydro-6 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A020 ; 3-(2-(1-(3-aminobenzyl)-4-hydroxypiperidin-4-yl)-5-oxo-5,7-dihydro-6 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A021 ; 3-(2-(4-hydroxy-1-((2-oxo-1,2-dihydropyridine-4-yl)methyl)piperidine-4-yl)-5-oxo-5,7-dihydro-6 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A022 ; 3-(2-(4-hydroxy-1-(2-methoxybenzyl)piperidine-4-yl)-5-oxo-5,7-dihydro-6 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A023 ; 3-(2-(4-hydroxy-1-(3-methoxybenzyl)piperidine-4-yl)-5-oxo-5,7-dihydro-6 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A024 ; 3-(2-(4-hydroxy-1-(4-methoxybenzyl)piperidine-4-yl)-5-oxo-5,7-dihydro-6 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A025 ; 3-(2-(1-(3-chlorobenzyl)-4-hydroxypiperidin-4-yl)-5-oxo-5,7-dihydro-6 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A026 ; 3-(2-(1-(benzofuran-6-ylmethyl)-4-hydroxypiperidin-4-yl)-5-oxo-5,7-dihydro-6 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A027 ; 3-(2-(1-((1 H -Indazole-5-yl)methyl)-4-hydroxypiperidin-4-yl)-5-oxo-5,7-dehydro-6 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A028 ; 3-(2-(4-hydroxy-1-(pyrazolo[1,5- a ]pyridine-6-ylmethyl)piperidine-4-yl)-5-oxo-5,7-dihydro-6 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A029 ; 3-(2-(1-((2,3-dihydro-1 H -indene-2-yl)methyl)-4-hydroxypiperidine-4-yl)-5-oxo-5,7-dehydro-6 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A030 ; 3-(2-(4-hydroxy-1-(4-aminocarbonylphenylmethyl)piperidine-4-yl)-5-oxo-5,7-dihydro-6 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A031 ; 3-(2-(4-hydroxy-1-(3-aminocarbonylphenylmethyl)piperidine-4-yl)-5-oxo-5,7-dihydro-6 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A032 ; 3-(2-(1-(3-(dimethylamino)benzyl)-4-hydroxypiperidin-4-yl)-5-oxo-5,7-dehydro-6 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A033 ; 3-(2-(4-hydroxy-1-(4-(methoxymethyl)benzyl)piperidine-4-yl)-5-oxo-5,7-dihydro-6 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A034 ; 3-(2-(4-hydroxy-1-(quinoline-6-ylmethyl)piperidine-4-yl)-5-oxo-5,7-dihydro-6 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A035 ; 3-(2-(4-hydroxy-1-((1-methyl-1 H -Indazole-6-yl)methyl)piperidine-4-yl)-5-oxo-5,7-dehydro-6 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A036 ; 3-(2-(1-((1,1-deoxydotetrahydro-2 H -thiopyran-4-yl)methyl)-4-hydroxypiperidin-4-yl)-5-oxo-5,7-dehydro-6 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A037 ; 3-(2-(4-hydroxy-1-((1-phenyl-1 H -pyrazol-4-yl)methyl)piperidine-4-yl)-5-oxo-5,7-dehydro-6 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A038 ; 3-(2-(4-hydroxy-1-(4-(trifluoromethyl)benzyl)piperidine-4-yl)-5-oxo-5,7-dihydro-6 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A039 ; 4-((4-(6-(2,6-dioxopiperidin-3-yl)-5-oxo-6,7-dihydro-5 H -pyrrolo[3,4- b ]pyridine-2-yl)-4-hydroxypiperidin-1-yl)methyl)- N , N -Dimethylbenzamide A040 ; 3-(2-(1-((2,2-difluorobenzo[ d ][1,3]dioxol-5-yl)methyl)-4-hydroxypiperidin-4-yl)-5-oxo-5,7-dihydro-6 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A041 ; 3-(2-(4-hydroxy-1-(4-(trifluoromethoxy)benzyl)piperidine-4-yl)-5-oxo-5,7-dihydro-6 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A042 ; 3-(2-(1-(4-(benzyloxy)benzyl)-4-hydroxypiperidin-4-yl)-5-oxo-5,7-dihydro-6 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A043 ; 3-(2-(4-hydroxy-1-((1-methyl-1 H -Indazole-5-yl)methyl)piperidine-4-yl)-5-oxo-5,7-dehydro-6 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A044 ; 3-(2-(4-hydroxy-1-((1-methyl-1 H -pyrazol-3-yl)methyl)piperidine-4-yl)-5-oxo-5,7-dehydro-6 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A045 ; 4-((4-(6-(2,6-dioxopiperidin-3-yl)-5-oxo-6,7-dihydro-5 H -pyrrolo[3,4- b ]pyridine-2-yl)-4-hydroxypiperidin-1-yl)methyl)- N -methylbenzamide A046 ; 3-(2-(4-hydroxy-1-((1-(trifluoromethyl)-1 H -pyrazol-4-yl)methyl)piperidine-4-yl)-5-oxo-5,7-dehydro-6 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A047 ; 3-(2-(4-hydroxy-1-(4-(1-methyl-1 H -pyrazol-4-yl)benzyl)piperidine-4-yl)-5-oxo-5,7-dehydro-6 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A048 ; 3-(2-(4-hydroxy-1-((1-phenylpiperidine-4-yl)methyl)piperidine-4-yl)-5-oxo-7 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A049 ; 3-(2-(4-hydroxy-1-(4-(phenylamino)benzyl)piperidine-4-yl)-5-oxo-5,7-dihydro-6 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A050 ; 3-(2-(4-hydroxy-1-(4-hydroxypiperidin-1-yl)benzyl)piperidin-4-yl)-5-oxo-5,7-dihydro-6 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A051 ; 3-(2-(1-((1 H -pyrrolo[3,2- b ]pyridine-6-yl)methyl)-4-hydroxypiperidin-4-yl)-5-oxo-5,7-dihydro-6 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A052 ; 3-(2-(1-((2,2-dimethylbenzo[ d ][1,3]dioxol-5-yl)methyl)-4-hydroxypiperidin-4-yl)-5-oxo-5,7-dihydro-6 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A053 ; 3-(2-(1-((2,2-dimethyl-2,3-dihydrobenzofuran-6-yl)methyl)-4-hydroxypiperidin-4-yl)-5-oxo-5,7-dihydro-6 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A054 ; 3-(2-(4-hydroxy-1-(isoxazole-4-ylmethyl)piperidine-4-yl)-5-oxo-5,7-dihydro-6 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A055 ; 3-(2-(4-hydroxy-1-((tetrahydro-2 H -pyran-4-yl)methyl)piperidine-4-yl)-5-oxo-5,7-dehydro-6 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A056 ; 3-(2-(4-hydroxy-1-((1-methyl-1 H -Benzo[ d ][1,2,3]triazole-5-yl)methyl)piperidine-4-yl)-5-oxo-5,7-dihydro-6 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A057 ; 3-(2-(1-(4-((dimethylamino)methyl)benzyl)-4-hydroxypiperidin-4-yl)-5-oxo-5,7-dehydro-6 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A058 ; 3-(2-(4-hydroxy-1-(4-phenoxybenzyl)piperidine-4-yl)-5-oxo-5,7-dihydro-6 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A059 ; 3-(2-(4-hydroxy-1-(4-((tetrahydro-2 H -pyran-4-yl)oxy)benzyl)piperidin-4-yl)-5-oxo-5,7-dehydro-6 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A060 ; 3-(2-(4-hydroxy-1-(4-(4-(hydroxymethyl)piperidine-1-yl)benzyl)piperidine-4-yl)-5-oxo-5,7-dihydro-6 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A061 ; 3-(2-(4-hydroxy-1-(4-(phenoxymethyl)benzyl)piperidine-4-yl)-5-oxo-5,7-dihydro-6 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A062 ; 3-(2-(1-((1-(3-chlorophenyl)-4-piperidyl)methyl)-4-hydroxy-4-piperidyl)-5-oxo-7 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A063 ; 3-(2-(1-((1-(2-chlorophenyl)-4-piperidyl)methyl)-4-hydroxy-4-piperidyl)-5-oxo-7 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A064 ; 3-(2-(1-((1-(4-chlorophenyl)piperidine-4-yl)methyl)-4-hydroxypiperidine-4-yl)-5-oxo-5,7-dihydro-6 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A065 ; 3-(2-(4-hydroxy-1-((4-(1-methylpyrazole-3-yl)phenyl)methyl)-4-piperidyl)-5-oxo-7 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A066 ; 3-(2-(4-hydroxy-1-((4-(2-methylpyrazole-3-yl)phenyl)methyl)-4-piperidyl)-5-oxo-7 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A067 ; 3-(2-(4-hydroxy-1-((4-pyrazol-1-ylphenyl)methyl)-4-piperidyl)-5-oxo-7 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A068 ; 3-(2-(4-hydroxy-1-((1-(2-pyridyl)-4-piperidyl)methyl)-4-piperidyl)-5-oxo-7 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A069 ; 3-(2-(4-hydroxy-1-((( R )-1-phenylpiperidine-3-yl)methyl)piperidine-4-yl)-5-oxo-5,7-dihydro-6 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A070 ; 3-(2-(4-hydroxy-1-((1-(pyridine-3-yl)piperidine-4-yl)methyl)piperidine-4-yl)-5-oxo-5,7-dihydro-6 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A071 ; 3-(2-(4-hydroxy-1-((8-phenyl-8-azabicyclo[3.2.1]octane-3-yl)methyl)-4-piperidyl)-5-oxo-7 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A072 ; 3-(2-(4-hydroxy-1-((1-phenylazetidin-3-yl)methyl)piperidine-4-yl)-5-oxo-5,7-dihydro-6 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A073 ; 3-(2-(1-(4-chlorobenzoyl)-4-hydroxypiperidin-4-yl)-5-oxo-5,7-dihydro-6 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A074 ; 3-(2-(1-(3,4-dimethoxybenzyl)-4-hydroxypiperidin-4-yl)-5-oxo-5,7-dihydro-6 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A075 ; 3-(2-(4-hydroxy-1-((1-methylindole-5-yl)methyl)-4-piperidyl)-5-oxo-7 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A076 ; 3-(2-(4-hydroxy-1-((1-methylindazole-4-yl)methyl)-4-piperidyl)-5-oxo-7 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A077 ; 3-(2-(4-hydroxy-1-((4-(oxetane-3-yl)phenyl)methyl)-4-piperidyl)-5-oxo-7 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A078 ; 3-(2-(4-hydroxy-1-((3-(1-piperidyl)phenyl)methyl)-4-piperidyl)-5-oxo-7 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A079 ; 3-(2-(1-((4-(4,4-difluoro-1-piperidyl)phenyl)methyl)-4-hydroxy-4-piperidyl)-5-oxo-7 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A080 ; 3-(2-(4-hydroxy-1-(4-(piperidin-1-yl)benzyl)piperidin-4-yl)-5-oxo-5,7-dihydro-6 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A081 ; 3-(2-(4-hydroxy-1-((4-tetrahydropyran-4-ylphenyl)methyl)-4-piperidyl)-5-oxo-7 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A082 ; 3-(2-(4-hydroxy-1-(3-(tetrahydro-2 H -pyran-4-yl)benzyl)piperidin-4-yl)-5-oxo-5,7-dehydro-6 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A083 ; 3-(2-(1-((3-fluorophenyl)methyl)-4-hydroxy-4-piperidyl)-5-oxo-7 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A084 ; 3-(2-(4-hydroxy-1-((4-morpholinophenyl)methyl)-4-piperidyl)-5-oxo-7 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A085 ; 3-(2-(4-hydroxy-1-((3-morpholinophenyl)methyl)-4-piperidyl)-5-oxo-7 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A086 ; 3-(2-(4-hydroxy-1-((3-(oxetane-3-yl)phenyl)methyl)-4-piperidyl)-5-oxo-7 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A087 ; 3-(2-(4-hydroxy-1-((4-(tetrahydropyran-4-ylmethyl)phenyl)methyl)-4-piperidyl)-5-oxo-7 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A088 ; 3-(2-(1-((2-fluorophenyl)methyl)-4-hydroxy-4-piperidyl)-5-oxo-7 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A089 ; 3-(2-(4-hydroxy-1-isobutyl-4-piperidyl)-5-oxo-7 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A090 ; 3-(2-(1-((3-fluorobicyclo[1.1.1]pentane-1-yl)methyl)-4-hydroxypiperidine-4-yl)-5-oxo-5,7-dihydro-6 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A091 ; 3-(2-(4-hydroxy-1-((1-methylbenzimidazole-5-yl)methyl)-4-piperidyl)-5-oxo-7 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A092 ; 3-(2-(4-hydroxy-1-((3-methylbenzimidazole-5-yl)methyl)-4-piperidyl)-5-oxo-7 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A093 ; 3-(2-(4-hydroxy-1-((1-methylindole-6-yl)methyl)-4-piperidyl)-5-oxo-7 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A094 ; 3-(2-(4-hydroxy-1-((4-(morpholinomethyl)phenyl)methyl)-4-piperidyl)-5-oxo-7 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A095 ; 3-(2-(1-((4-fluorophenyl)methyl)-4-hydroxy-4-piperidyl)-5-oxo-7 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A096 ; (3 S )-3-((7 S )-2-(1-benzyl-4-hydroxy-4-piperidyl)-7-methyl-5-oxo-7 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A097 ; ( S )-3-(( R )-2-(4-hydroxy-1-((1-phenylpiperidine-4-yl)methyl)piperidine-4-yl)-7-methyl-5-oxo-5,7-dihydro-6 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A098 ; 3-(2-(1-(2-(3-fluorophenyl)ethyl)-4-hydroxy-4-piperidyl)-5-oxo-7 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A099 ; 3-(2-(1-(chroman-7-ylmethyl)-4-hydroxy-4-piperidyl)-5-oxo-7 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A100 ; 3-(2-(1-(chroman-6-ylmethyl)-4-hydroxypiperidin-4-yl)-5-oxo-5,7-dihydro-6 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A101 ; 3-(2-(1-((2,3-dihydrobenzofuran-6-yl)methyl)-4-hydroxypiperidin-4-yl)-5-oxo-5,7-dihydro-6 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A102 ; 3-(2-(1-(2,3-dihydrobenzofuran-5-ylmethyl)-4-hydroxy-4-piperidyl)-5-oxo-7 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A103 ; 3-(2-(1-(1,3-dihydroisobenzofuran-5-ylmethyl)-4-hydroxy-4-piperidyl)-5-oxo-7 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A104 ; 3-(2-((3 S ,4 S )-1-benzyl-3,4-dihydroxy-4-piperidyl)-5-oxo-7 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A105 ; 3-(2-((3 R ,4 R )-1-benzyl-3,4-dihydroxy-4-piperidyl)-5-oxo-7 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A106 ; 3-(2-(1-((3,4-bis(trifluoromethyl)phenyl)methyl)-4-hydroxy-4-piperidyl)-5-oxo-7 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A107 ; 3-(2-(1-((4- tert -butylphenyl)methyl)-4-hydroxy-4-piperidyl)-5-oxo-7 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A108 ; 3-(2-(1-((3- tert -butylphenyl)methyl)-4-hydroxy-4-piperidyl)-5-oxo-7 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A109 ; 3-(2-(4-hydroxy-1-((4-isopropylphenyl)methyl)-4-piperidyl)-5-oxo-7 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A110 ; 3-(2-(4-hydroxy-1-((3-isopropylphenyl)methyl)-4-piperidyl)-5-oxo-7 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A111 ; 3-(2-(1-((3-(1,1-difluoroethyl)phenyl)methyl)-4-hydroxy-4-piperidyl)-5-oxo-7 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A112 ; 3-(2-(1-((4-(1,1-difluoroethyl)phenyl)methyl)-4-hydroxy-4-piperidyl)-5-oxo-7 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A113 ; 3-(2-(1-(4-ethylbenzyl)-4-hydroxypiperidin-4-yl)-5-oxo-5,7-dihydro-6 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A114 ; 3-(2-(1-(4-chloro-3-methylbenzyl)-4-hydroxypiperidin-4-yl)-5-oxo-5,7-dihydro-6 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A115 ; 3-(2-(1-(4-((1 R ,5 S )-8-azabicyclo[3.2.1]octane-8-yl)benzyl)-4-hydroxypiperidine-4-yl)-5-oxo-5,7-dihydro-6 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A116 ; 3-(2-(1-(4-cyclobutylbenzyl)-4-hydroxypiperidin-4-yl)-5-oxo-5,7-dihydro-6 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A117 ; 3-(2-(1-(3-ethylbenzyl)-4-hydroxypiperidin-4-yl)-5-oxo-5,7-dihydro-6 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A118 ; 3-(2-(1-(4-chloro-3-fluorobenzyl)-4-hydroxypiperidin-4-yl)-5-oxo-5,7-dihydro-6 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A119 ; 3-(2-(1-(3-cyclobutylbenzyl)-4-hydroxypiperidin-4-yl)-5-oxo-5,7-dihydro-6 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A120 ; 3-(2-(1-((3-((1 R ,5 S )-8-azabicyclo[3.2.1]octane-8-yl)phenyl)methyl)-4-hydroxy-4-piperidyl)-5-oxo-7 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A121 ; 3-(2-(1-(4-cyclohexylbenzyl)-4-hydroxypiperidin-4-yl)-5-oxo-5,7-dihydro-6 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A122 ; 4-((4-(6-(( S )-2,6-dioxopiperidine-3-yl)-7-methyl-5-oxo-6,7-dihydro-5 H -pyrrolo[3,4- b ]pyridine-2-yl)-4-hydroxypiperidin-1-yl)methyl)benzonitrile A123 ; 4-((4-(( R )-6-(( S )-2,6-dioxopiperidine-3-yl)-7-methyl-5-oxo-6,7-dihydro-5 H -pyrrolo[3,4- b ]pyridine-2-yl)-4-hydroxypiperidin-1-yl)methyl)benzonitrile A124 ; 3-(2-{4-hydroxy-1-[(1 H -pyrazol-4-yl)methyl]piperidine-4-yl}-5-oxo-5 H ,6 H ,7 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A125 ; 3-(2-{4-hydroxy-1-[(1,3-oxazole-2-yl)methyl]piperidine-4-yl}-5-oxo-5 H ,6 H ,7 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A126 ; 3-(2-{4-hydroxy-1-[(1 H -1,2,4-triazole-3-yl)methyl]piperidine-4-yl}-5-oxo-5 H ,6 H ,7 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A127 ; 3-(2-{4-hydroxy-1-[(pyridine-3-yl)methyl]piperidine-4-yl}-5-oxo-5 H ,6 H ,7 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A128 ; 3-(2-{4-hydroxy-1-[(pyridine-2-yl)methyl]piperidine-4-yl}-5-oxo-5 H ,6 H ,7 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A129 ; 3-(2-{4-hydroxy-1-[(1-methyl-1 H -pyrazol-4-yl)methyl]piperidine-4-yl}-5-oxo-5 H ,6 H ,7 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A130 ; 3-(2-{4-hydroxy-1-[(1,3-thiazole-2-yl)methyl]piperidine-4-yl}-5-oxo-5 H ,6 H ,7 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A131 ; 3-(2-{4-hydroxy-1-[(piperidine-4-yl)methyl]piperidine-4-yl}-5-oxo-5 H ,6 H ,7 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A132 ; 3-(2-{4-hydroxy-1-[(oxane-2-yl)methyl]piperidine-4-yl}-5-oxo-5 H ,6 H ,7 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A133 ; 3-(2-{4-hydroxy-1-[(oxane-3-yl)methyl]piperidine-4-yl}-5-oxo-5 H ,6 H ,7 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A134 ; 3-(2-{4-hydroxy-1-[(4-hydroxyphenyl)methyl]piperidine-4-yl}-5-oxo-5 H ,6 H ,7 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A135 ; 3-{2-[1-({2-azaspiro[3.3]heptane-6-yl}methyl)-4-hydroxypiperidin-4-yl]-5-oxo-5 H ,6 H ,7 H -pyrrolo[3,4- b ]pyridine-6-yl}piperidin-2,6-dion A136 ; 3-(2-{4-hydroxy-1-[(5-methyl-1,3-thiazole-2-yl)methyl]piperidine-4-yl}-5-oxo-5 H ,6 H ,7 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A137 ; 3-[2-(4-hydroxy-1-{[(1 r ,4 r )-4-aminocyclohexyl]methyl}piperidine-4-yl)-5-oxo-5 H ,6 H ,7 H -pyrrolo[3,4- b ]pyridine-6-yl]piperidin-2,6-dione A138 ; 3-{2-[4-hydroxy-1-({5 H ,6 H ,7 H -pyrrolo[1,2- a ]imidazole-2-yl}methyl)piperidine-4-yl]-5-oxo-5 H ,6 H ,7 H -pyrrolo[3,4- b ]pyridine-6-yl}piperidin-2,6-dion A139 ; 3-(2-{4-hydroxy-1-[(1-methyl-2-oxo-1,2-dihydropyridine-4-yl)methyl]piperidine-4-yl}-5-oxo-5 H ,6 H ,7 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A140 ; 3-[2-(4-hydroxy-1-{[1-(propane-2-yl)-1 H -pyrazol-4-yl]methyl}piperidine-4-yl)-5-oxo-5 H ,6 H ,7 H -pyrrolo[3,4- b ]pyridine-6-yl]piperidin-2,6-dione A141 ; 3-{2-[4-hydroxy-1-({imidazo[1,2- a ]pyridine-2-yl}methyl)piperidine-4-yl]-5-oxo-5 H ,6 H ,7 H -pyrrolo[3,4- b ]pyridine-6-yl}piperidin-2,6-dion A142 ; 3-{2-[4-hydroxy-1-({1 H -pyrrolo[2,3- b ]pyridine-5-yl}methyl)piperidine-4-yl]-5-oxo-5 H ,6 H ,7 H -pyrrolo[3,4- b ]pyridine-6-yl}piperidin-2,6-dion A143 ; 3-(2-{1-[(1,3-benzoxazole-2-yl)methyl]-4-hydroxypiperidin-4-yl}-5-oxo-5 H ,6 H ,7 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A144 ; 3-{2-[4-hydroxy-1-({[1,2,4]triazolo[1,5- a ]pyridine-7-yl}methyl)piperidine-4-yl]-5-oxo-5 H ,6 H ,7 H -pyrrolo[3,4- b ]pyridine-6-yl}piperidin-2,6-dion A145 ; 3-(2-{1-[(2,3-dihydro-1 H -isoindole-5-yl)methyl]-4-hydroxypiperidin-4-yl}-5-oxo-5 H ,6 H ,7 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A146 ; 3-{2-[4-hydroxy-1-({4 H ,5 H ,6 H ,7 H -pyrazolo[1,5- a ]pyridine-3-yl}methyl)piperidine-4-yl]-5-oxo-5 H ,6 H ,7 H -pyrrolo[3,4- b ]pyridine-6-yl}piperidin-2,6-dion A147 ; 3-{2-[1-({4 H ,5 H ,6 H -Cyclopenta[ d ][1,3]thiazole-2-yl}methyl)-4-hydroxypiperidin-4-yl]-5-oxo-5 H ,6 H ,7 H -pyrrolo[3,4- b ]pyridine-6-yl}piperidin-2,6-dion A148 ; 3-{2-[1-({2-azaspiro[3.5]nonan-7-yl}methyl)-4-hydroxypiperidin-4-yl]-5-oxo-5 H ,6 H ,7 H -pyrrolo[3,4- b ]pyridine-6-yl}piperidin-2,6-dion A149 ; 3-(2-{1-[(1-acetylpiperidin-4-yl)methyl]-4-hydroxypiperidin-4-yl}-5-oxo-5 H ,6 H ,7 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A150 ; 3-[2-(4-hydroxy-1-{[1-(propane-2-yl)piperidine-4-yl]methyl}piperidine-4-yl)-5-oxo-5 H ,6 H ,7 H -pyrrolo[3,4- b ]pyridine-6-yl]piperidin-2,6-dione A151 ; 3-(2-{4-hydroxy-1-[(quinoline-2-yl)methyl]piperidine-4-yl}-5-oxo-5 H ,6 H ,7 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A152 ; 3-(2-{4-hydroxy-1-[(3-oxo-2,3-dihydro-1 H -isoindole-5-yl)methyl]piperidine-4-yl}-5-oxo-5 H ,6 H ,7 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A153 ; 3-[(4-{6-[2,6-dioxopiperidin-3-yl]-5-oxo-5 H ,6 H ,7 H -pyrrolo[3,4- b ]pyridine-2-yl}-4-hydroxypiperidin-1-yl)methyl]- N -methylbenzamide A154 ; 3-(2-{1-[(1,3-benzothiazole-2-yl)methyl]-4-hydroxypiperidin-4-yl}-5-oxo-5 H ,6 H ,7 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A155 ; 3-[2-(4-hydroxy-1-{[4-(2-hydroxyethoxy)phenyl]methyl}piperidine-4-yl)-5-oxo-5 H ,6 H ,7 H -pyrrolo[3,4- b ]pyridine-6-yl]piperidin-2,6-dione A156 ; 3-[2-(4-hydroxy-1-{[4-(2 H -1,2,3,4-tetrazole-5-yl)phenyl]methyl}piperidine-4-yl)-5-oxo-5 H ,6 H ,7 H -pyrrolo[3,4- b ]pyridine-6-yl]piperidin-2,6-dione A157 ; 3-(2-{4-hydroxy-1-[(3-oxo-3,4-dihydro-2 H -1,4-benzoxazine-6-yl)methyl]piperidine-4-yl}-5-oxo-5 H ,6 H ,7 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A158 ; 3-{2-[4-hydroxy-1-({4-methyl-2 H ,3 H ,4 H -Pirido[3,2- b ][1,4]oxazine-7-yl}methyl)piperidine-4-yl]-5-oxo-5 H ,6 H ,7 H -pyrrolo[3,4- b ]pyridine-6-yl}piperidin-2,6-dion A159 ; 3-{2-[1-({3-azaspiro[5.5]undecane-9-yl}methyl)-4-hydroxypiperidin-4-yl]-5-oxo-5 H ,6 H ,7 H -pyrrolo[3,4- b ]pyridine-6-yl}piperidin-2,6-dion A160 ; 4-[(4-{6-[2,6-dioxopiperidin-3-yl]-5-oxo-5 H ,6 H ,7 H -pyrrolo[3,4- b ]pyridine-2-yl}-4-hydroxypiperidin-1-yl)methyl]benzene-1-sulfonamide A161 ; 3-(2-{4-hydroxy-1-[(5-methyl-1 H -pyrazol-4-yl)methyl]piperidine-4-yl}-5-oxo-5 H ,6 H ,7 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A162 ; 3-(2-{4-hydroxy-1-[(5-methyl-1,3,4-thiadiazole-2-yl)methyl]piperidine-4-yl}-5-oxo-5 H ,6 H ,7 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A163 ; 3-[2-(4-hydroxy-1-{[1-(propane-2-yl)-1 H -pyrazol-3-yl]methyl}piperidine-4-yl)-5-oxo-5 H ,6 H ,7 H -pyrrolo[3,4- b ]pyridine-6-yl]piperidin-2,6-dione A164 ; 3-{2-[4-hydroxy-1-({1 H -pyrrolo[3,2- b ]pyridine-2-yl}methyl)piperidine-4-yl]-5-oxo-5 H ,6 H ,7 H -pyrrolo[3,4- b ]pyridine-6-yl}piperidin-2,6-dion A165 ; 3-{2-[4-hydroxy-1-({5 H ,6 H ,7 H ,8 H -Imidajo[1,2- a ]pyridine-2-yl}methyl)piperidine-4-yl]-5-oxo-5 H ,6 H ,7 H -pyrrolo[3,4- b ]pyridine-6-yl}piperidin-2,6-dion A166 ; 3-[2-(4-hydroxy-1-{[4-(piperidin-4-yloxy)phenyl]methyl}piperidin-4-yl)-5-oxo-5 H ,6 H ,7 H -pyrrolo[3,4- b ]pyridine-6-yl]piperidin-2,6-dione A167 ; 3-(2-{1-[(1-benzylpiperidin-4-yl)methyl]-4-hydroxypiperidin-4-yl}-5-oxo-5 H ,6 H ,7 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A168 ; or 3-(2-{4-hydroxy-1-[(quinoline-3-yl)methyl]piperidine-4-yl}-5-oxo-5 H ,6 H ,7 H -pyrrolo[3,4- b ]pyridine-6-yl)piperidine-2,6-dione A169 ;or its enantiomer, mixture of enantiomers, diastereomer, mixture of two or more diastereomers, tautomer, or mixture of two or more tautomers; or its pharmaceutically acceptable salt, solvate, hydrate, or prodrug. Claim 87 A pharmaceutical composition comprising a compound of any one of claims 1 to 86 or a mirror image isomer thereof, a mixture of mirror image isomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, or a mixture of two or more tautomers; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; and a pharmaceutically acceptable excipient. Claim 88 In paragraph 87, the pharmaceutical composition is a pharmaceutical composition in a single-dose form. Claim 89 In paragraph 87 or 88, the pharmaceutical composition is in the form of oral, parenteral, or intravenous administration. Claim 90 In any one of paragraphs 87 to 89, the pharmaceutical composition is a pharmaceutical composition formulated in an oral administration form. Claim 91 A pharmaceutical composition according to paragraph 90, wherein the form of oral administration is a tablet or a capsule. Claim 92 A method for treating, preventing, or alleviating one or more symptoms of a disorder or disease mediated by ARNT in a subject, comprising the step of administering a therapeutically effective amount of a compound of any one of claims 1 to 86 or a pharmaceutical composition of any one of claims 87 to 91 to a subject in need. Claim 93 In paragraph 92, the disease or disability is cancer, inflammation, or an autoimmune disorder. Claim 94 A method for treating, preventing, or alleviating one or more symptoms of a proliferative disease in a subject, comprising the step of administering a therapeutically effective amount of a compound of any one of claims 1 to 86 or a pharmaceutical composition of any one of claims 87 to 91 to a subject in need. Claim 95 In paragraph 94, the proliferative disease is cancer, method. Claim 96 A method in any one of paragraphs 92 through 95, wherein the subject is a human being. Claim 97 A method for inhibiting cell growth, comprising the step of contacting a cell with an effective amount of a compound of any one of claims 1 to 86 or a pharmaceutical composition of any one of claims 87 to 91. Claim 98 In paragraph 97, the cell is a cancerous cell, method. Claim 99 A method for inducing the degradation of ARNT, comprising the step of contacting ARNT with an effective amount of a compound of any one of claims 1 to 86 or a pharmaceutical composition of any one of claims 87 to 91. Claim 100 A method for inhibiting the activity of ARNT, comprising the step of contacting ARNT with an effective amount of a compound of any one of claims 1 to 86 or a pharmaceutical composition of any one of claims 87 to 91.
